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ABSTRACT 
 
Carrier mediated nutrient import is vital for cell and tissue homeostasis.  
Structural insights of carrier mediated transport, particularly the human glucose 
transporter GLUT1, are essential for understanding the mechanisms of human metabolic 
disease, and provide model systems for cellular processes as a whole. 
GLUT1 function and expression is characterized by a complexity unexplained by 
the current hypotheses for carrier-mediated sugar transport (9).  It is possible that the 
operational properties of GLUT1 are determined by host cell environment. A glucose 
transport-null strain of Saccharomyces cerevisiae (RE700A) was transfected with the 
p426 GPD yeast expression vector containing DNA encoding the wild-type human 
glucose transport protein (GLUT1) to characterize its functional properties.  Identical 
protein sequences generated different kinetic parameters when expressed in RE700A 
yeast, erythrocytes, and HEK293 cells. These findings support the hypothesis that red cell 
sugar transport complexity is host cell-specific. 
Cytochalasin B (CB) and forskolin (FSK) inhibit GLUT1-mediated sugar 
transport in red cells by binding at or close to the GLUT1 sugar export site. 
Paradoxically, very low concentrations of these inhibitors produce a modest stimulation 
of sugar transport (16)  This result is consistent with the hypothesis that the glucose 
transporter contains multiple, interacting, intracellular binding sites for e1 ligands CB and 
FSK. The present study tests this hypothesis directly and, by screening a library of 
cytochalasin and forskolin analogs, asks what structural features of exit site ligands 
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determine binding site affinity and cooperativity. Our findings are explained by a carrier 
that presents at least two interacting endofacial binding sites for CB or FSK. We discuss 
this result within the context of GLUT1 quaternary structure and evaluate the major 
determinants of ligand binding affinity and cooperativity.   
Cytochalasin B (CB) inhibits GLUT1 substrate transport at or near the endofacial 
sugar binding site. N-bromosuccinamide analysis combined with 3H-CB photolabeling 
implicates the region between Trp388 and Trp412 in ligand binding. Although its 
structure has been modeled(5), the specific residues comprising the sugar binding site are 
unknown. A series of alanine point mutants were made, and mutant protein 2-deoxy 
glucose transport was tested in the presence of increasing [CB].  Arg126Ala and 
Cys421Ala GLUT1 mutations altered CB affinity but were determined not to be in the e1 
site.  The Arg400Ala mutation decreased binding affinity for CB, and may comprise part 
of the e1 binding site.  Because point mutations were individually insufficient to abrogate 
CB binding, Trp388 to Trp412 chimeras were made. GLUT1/GLUT4388-412/GLUT1 and 
GLUT1/GLUT5388-412/GLUT1 chimeras showed moderately less sensitivity to CB 
inhibition of transport; these amino acids likely comprise regions determinant of CB 
binding affinity.  Furthermore GLUT1/GLUT5388-412/GLUT1 shows enhancement of 2-
DG uptake at 50nM CB, but an overall dose response indistinguishable from WT 
GLUT1.  A multisite fit of the data suggested GLUT1/GLUT5388-412/GLUT1 chimera 
possesses strong first site affinity for CB but slight negative second-site cooperativity.  
We conclude that point mutants were insufficient to abrogate CB binding and that the 
Trp388 to Trp412 sequence is necessary for CB binding affinity but is not the sole 
3 
determinant of inhibition of 2 deoxyglucose uptake by CB.  We discuss these results with 
their implications for structure-function sequence localization of the CB binding site, and 
by extension, the e1 sugar binding site.
4 
INTRODUCTION 
Glucose Transport Studies 
Glucose is the preferred energy substrate for cellular metabolism; cellular demand 
and glucose availability are of utmost importance to both unicellular and multicellular 
organisms.   Surrounded by an impermeant lipid bilayer, cells acquire glucose and other 
nutrients by utilizing integral membrane proteins, making nutrient channels and carriers 
fundamental to life.  The work described here discusses the human erythrocyte sugar 
transporter GLUT1, the first characterized sugar porter(18).  GLUT1 is expressed in all 
tissue types, is thought to be responsible for basal glucose homeostasis, and is the 
primary vehicle for transport of sugar from blood into brain as well as across other blood 
and tissue barriers.  Defects in GLUT1 or its regulation may result in epileptic-like 
seizures (19), growth defects, or embryonic inviability.  Furthermore, GLUT1 is a 
valuable model system for structural analysis of integral membrane proteins as well as 
nutrient transport.  Structural understanding of glucose transport will further our 
knowledge of carrier mediated glucose homeostasis within cells and tissues, and may 
lead to treatment of chronic metabolic disease. 
Protein Mediated Nutrient Uptake 
Cells are surrounded by an amphipathic lipid bilayer known as the plasma
5 
Figure 1.1  Crystal Structures of Membrane Transport Proteins.  
 A.  A top-down view of aquaporin, with the membrane side view of the monomer.  (10)   
B.  Top and side view of KvaP, a mammalian potassium channel.  (14)  
C.  An ABC transporter (normal to the plane of the bilayer), the crystallized catalytic 
intermediate of the maltose transport protein complex. (15)   
D.  Cytoplasmic and side view of GlpT, a Major Facilitator Superfamily bacterial sugar 
transporter.  (17)  Structures are shown in ribbon formats. 
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membrane, whose primary function is to maintain cellular homeostasis (20).  Without 
protein-mediated nutrient uptake lipid bilayers are impermeant to large, polar, or charged 
molecules including ions, cofactors, and glucose.  Water, small hydrophobic molecules, 
gases, and lipophillic drugs diffuse freely through the membrane into the cell.  Large or 
charged molecules may diffuse, but do so slowly.  Cells overcome the problem of 
excluding important metabolites and ions by utilizing integral membrane proteins which 
include channels and carriers.   Protein mediated transport is metabolite specific and is 
often fine-tuned by regulation of transporter expression or activity to meet cellular 
demands. 
Channel proteins are membrane resident and stabilize a pore normal to the lipid 
bilayer,  which provides simultaneous access to both sides of the membrane. Channels 
may be highly specific, facilitating movement of one ion, or nonspecific ‘porins’, 
permitting free water and ion access across a lipid bilayer. Channel selectivity is thought 
to be governed by pore diameter.  The crystallized channel protein Kv1.2, a voltage gated 
K+ channel (Fig 1.1B) (14), has a pore diameter of approximately 1.5Å (21), while the 
aquaporin GlpF has a pore diameter of 3.4x3.8Å at its narrowest (22).  For Kv1.2, a tight 
fit ensures dehydration of the K+ ion and subsequent transport, keeping out smaller-radius 
ions like Na+ (14, 21)  Aquaporins like GlpF (Fig 1.1A) are predominantly expressed in 
endothelial cell types requiring or mediating high rates of more permissive fluid transport 
(22, 23). A tetrameric, integral membrane protein, aquaporin functions by permitting 
water flow through a pore within each subunit lined with hydrophilic amino acids, 
permitting single-file flux to the opposite side.  Net water flow always proceeds in the 
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direction of [water]high to [water]low. 
Unlike porins, channels typically isomerize between closed, open, and 
desensitized states.  Channels transition between states in response to protein-protein 
interactions, voltage across the lipid bilayer, changes in temperature, or ligand binding 
(24). 
Three classes of carrier proteins facilitate bidirectional transport of small molecules 
across membranes: “Primary Active” carriers, facilitative carriers, and secondary active 
carriers.  “Primary Active” carriers, also known as active transporters or pumps, (see the 
maltose transporter, Fig 1.1C) mediate transport against an electrochemical gradient by 
coupling substrate transport to ATP hydrolysis (20).  Secondary active carriers are 
symporters or antiporters because net uphill transport of substrate is coupled to and 
driven by the co-transport or antiport of a second species – typically a cation such as Na+ 
or H+ – down its electrochemical gradient (Fig 1.2)(20).  Facilitative carriers like GLUT1 
catalyze both unidirectional substrate uptake and export. Since the direction of net 
substrate transport always proceeds down the electrochemical gradient, most often 
without primary active carriers transmembrane electrochemical gradients are not 
established. These gradients allow channels, secondary active carriers, and facilitative 
carriers to do useful work. 
Pathophysiology of Transport Proteins 
When fundamental channel and carrier processes are perturbed, the resulting 
disease states are chronic and debilitating.  Almost 20% of sequenced human genome
9 
Figure 1.2 Types of Secondary Active Carriers.   
 In all cases, facilitated carrier mediated transport utilizes existing substrate 
concentration gradients.  Uniporters transport a single solute (gray circles) down its 
concentration gradient.  Symporters utilize a common solute (yellow squares) to drive the 
uptake of a rarer substrate (blue triangles) against its concentration gradient.  Antiporters 
use the high concentration of a common cellular substrate to facilitate the uptake of a low 
concentration solute against its concentration gradient.
10 
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proteins are integral membrane proteins; of these, 90% are considered viable therapeutic 
drug targets for human disease (25). Moreover, the Transport Classification Database at 
UCSD listed over thirty-seven human diseases affiliated with mutant channels or carriers 
(26).   Most of these debilitating diseases are genetic, and extant therapies only treat 
symptoms.  Understanding how to ameliorate mutant function reveals important insights 
into the role of that protein within the body, and facilitates development of novel 
treatments to increase patient quality of life.  The following perturbations of integral-
membrane protein mediated cellular functions will be discussed in more detail: faulty 
chloride channels and cystic fibrosis,  the role of sugar porters and multidrug resistance 
transporters in cancer and cancer therapies,  diabetes states, both adult-onset and juvenile, 
and lastly, GLUT1 Deficiency Syndrome and the effects of insufficient glucose transport 
on cerebral function and development.  
ANION TRANSPORT AND CYSTIC FIBROSIS 
One of the most common inherited childhood diseases, cystic fibrosis is caused by 
a mutation in a protein known as the cystic fibrosis transmembrane conductance regulator 
(CTFR), a chloride ion channel.  These channels are commonly found in tissues that 
produce sweat, mucus, and other secretions.  Anion transport aids in regulating the 
osmotic balance across membranes of secretory tissues.  Without chloride secretion, 
water cannot flow to thin the mucus in the lung and other tissues, resulting in damage and 
breathing difficulties (27). While afflicted children have a life expectancy of forty years 
with surgical lung replacement, structural understanding of CTFR may lead to small 
molecule activators of the channel to ameliorate deficient function.  Mutations in CTFR 
12 
are often retained within intracellular vesicles in a manner similar to wild type GLUT4 
sequestration.  Understanding the recruitment of GLUT4 and its homologous sibling 
GLUT1 to the cell surface may suggest further therapies for cystic fibrosis. 
CANCER, SUGAR PORTERS & MULTIDRUG RESISTANCE TRANSPORTERS 
Cancerous cells grow and multiply faster than normal cells, resulting in an acutely 
increased demand for energy.  Warburg first observed in 1956 (28) that tumors have high 
rates of anaerobic glycolysis.  The level of glycolysis, typified by the high expression of 
lactate dehydrogenase, has been used as a benchmark for lymphomas, leukemias, and 
colon cancer (29).  A shift to lactate from pyruvate is thought to deprive the 
mitochondria, reducing the TCA cycle and therefore ATP output.  All of these factors 
intensify the cancer cell’s need for glycolysis, and therefore, glucose (30). 
The increased demand for glucose in cancerous cell lines as well as benign and 
malignant tumors results in up-regulation of glucose transporter expression, especially 
GLUT1 (30).  Tumor analysis has also shown glucose transporters to be up-regulated by 
hypoxia resulting from poor perfusion (31).  Similarly, tissue culture attendant hypoxia is 
thought to be a primary determinant of GLUT1 upregulation in cultured cells  (32).  
Some breast cancers also increase sugar transporter-mediated uptake in response to 
estrogen treatment, likely as a result of metabolic depletion (33).  While it is unlikely that 
increased sugar porter production is a cause or an effect of cancer, the sugar porters 
themselves remain seductive drug targets to starve tumorigenic masses. 
Multidrug Resistance (MDR) transporters are another class of integral membrane 
proteins that directly affect human anticancer strategies.  Efflux pumps such as ABCG2 
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expressed in the calnilicular membranes of the human liver, microvascular endothelium 
of the brain, and the apical surface of the small intestine epithelium drain small molecule 
chemotherapeutic delivery by facilitating rapid drug clearance (34).  It is unsurprising 
that human MDR inhibitors are fiercely sought after anticancer agents.   
DIABETES 
Diabetes is a disease of metabolism in which glucose homeostasis is disrupted; it 
has also been called the most quietly received epidemic in the US (35).  The World 
Health Organization reports that 5% of deaths worldwide are caused by type 2 diabetes; 
in the absence of medical intervention that number is expected to increase 50% in the 
next ten years (36). 
GLUT4, the insulin-sensitive glucose transporter, is a passive yet critical element 
in this disease.  Upon food intake, pancreatic beta cells release the peptide hormone 
insulin. When insulin interacts with cell surface insulin receptors in muscle and adipose, 
a signaling cascade is triggered causing the cell surface recruitment of intracellular 
GLUT4. Consequently, this results in the  reduction of blood glucose levels as well as 
strongly increased cellular sugar transport capacity in skeletal muscle and adipose tissue 
(37, 38).  There are several steps in the signaling cascade that may be perturbed and it is 
the locus of the disruption that determines what type of diabetes clinically presents.  
Diabetes may be classified as two types; Type I (Juvenile) Diabetes is usually 
genetic, involves the autoimmune destruction of insulin secreting beta cells, and begins at 
infancy.  Type II diabetes, the ‘industrialized epidemic’ (35) may involve genetic 
predisposition, but is a mature-onset disease state where skeletal muscle, adipose, and 
14 
liver tissues become insulin resistant.  This leads to systemically increased blood glucose 
levels resulting in muscle and liver damage, adult blindness, and potential limb atrophy.   
Ultimately, the pathophysiology of glucose homeostasis is an exponentially 
increasing healthcare challenge to the developed world.  Understanding glucose 
transporter structure function may introduce alternative oral strategies for regulation of 
serum glucose, obviating the need for insulin injections or other therapies for the insulin 
resistant.   
GLUT1 DEFICIENCY SYNDROME 
The human glucose transporter 1 (GLUT1) was the first glucose transporter to be 
cloned, purified, and characterized. (18, 39, 40).  GLUT1 is ubiquitously expressed and is 
the most thoroughly characterized human sugar porter.  The dense expression of GLUT1 
in the brain microvascular endothelial cells results in high capacity glucose transfer from 
the circulatory system to the brain (41). Numerous deleterious point and missense 
mutations in GLUT1 result in GLUT1 Deficiency Syndrome (GLUT1DS), an inheritable 
disease characterized by retarded brain development, reduced cranial size, and epileptic-
like seizures.  Diagnosed early, infants may be placed on a ketogenic diet (80% fat, 20% 
carbohydrates and protein) to facilitate early cerebral development and control seizures.  
On the ketogenic diet, the monocarboxylate transporters (MCTs) provides the necessary 
cellular fuel via the ketone body metabolism pathway in the brain.  GLUT1 Ds is 
typically heterozygous in clinical study, while homozygous mutant GLUT1 is thought to 
be embryonically lethal (42-44).  
GLUT1 plays a pivotal role in other neural conditions which interrupt the 
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microvascular endothelium and perturb the brain’s fuel supply.  Examples where glucose 
transport may become rate limiting include ischemia (stroke), Alzheimer’s disease, other 
forms of epilepsy, hypoxia, and brain trauma (41, 45).  Research into GLUT1 function 
and regulation offer the potential of developing therapies for these debilitating conditions.  
Ultimately, an understanding of GLUT1 structure and function may also facilitate 
engineering small molecule delivery systems for transport into damaged areas of the 
brain. 
Structural Features of Major Facilitator Superfamily Proteins 
Over 100 families of nutrient import proteins in microorganisms have been 
classified, half of which fall into two ‘superfamilies’ of structurally related transporters.  
These are the ATP Binding Cassette (ABC) superfamily, and the Major Facilitator 
Superfamily (MFS). (46)  ABC transporters are generally hetero-oligomeric in nature, 
and are considered primary active carriers with transport coupled to ATP hydrolysis.   
MFS transporters do not require ATP, may function as monomers or homo-oligomers, 
and may be passive or secondary active carriers.  
The first, largest, and most extensively studied subfamily of the MFS is the sugar 
porters.  The typical sugar porter fold includes 12 putative or confirmed transmembrane-
spanning alpha helical regions and intracellular N and C termini (Fig 1.3). Sugar porters 
are typically 400 to 800 amino acids in length, with the smaller peptides generally found 
in prokaryotes. Under normal conditions, sugar porters function via solute uniport or Na+ 
or H+-driven symport (Fig 1.2).  Given a high concentration of sugar within the cell, 
however, sugar-sugar antiport is commonly observed (46).   
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MFS Crystal Structures 
Three crystal structures of bacterial MFS proteins have been reported; the lactose 
permease LacY (3.3Å resolution), glycerol-3-phosphate transporter GlpT(3.2Å 
resolution, Fig 1D), and the oxalate transporter OxlT(6.5Å resolution (17, 47, 48)).  
These structures contain alpha-helical transmembrane (TM) domains arranged in a 
squared-off pyramid, connected by randomly coiled extramembranous loops.  Perhaps the 
most striking information from these MFS folds is that despite sequence dissimilarity, the 
helices adopt a near identical packing arrangement.  (Fig 1.3A,B)  Each structure has 
been crystallized in the e1 or cytoplasmic-facing configuration.  Helices 3, 6, and 9 are 
the shortest, and along with helix 12 are thought to be involved in structural support 
within the membrane.    The arrangement of the remaining helices suggest that they line a 
funnel-shaped, 30 Å hydrophilic cavity, with TM’s 2,5,8, and 11 on the periphery, and 
1,4,7 and 10 in the core.    A marked twofold axis of symmetry across the large 
endofacial loop supports the suggestion of a gene duplication early in the genesis of these 
proteins.  While early studies modeled sugar translocation proceeding as through a water-
filled pore or channel (49) or by wholesale rotation of the transporter, Wang, et al utilized 
kinetic evidence to support a valve-like rocking switch mechanism of sugar movement 
with translocation (50).  This is consistent with both Jardetzky’s (51) and Singer’s (52) 
model of a fixed, two site carrier discussed later in this work. 
Glucose Metabolism & the Human Glucose Transporter Family 
The biochemical reactions used to obtain cellular energy (ATP) from glucose are 
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Figure 1.3  Helix interactions in a MFS transporter.   
A.  GLUT1 sequence mapped onto a GlpT three dimensional scaffold, in the e1 
(endofacial) conformation.  The structure is shown in ribbon format and is normal to the 
plane of the bilayer.  B.  GLUT1 helix packing arrangement as observed from the cytosol, 
with the endofacial sugar vestibule facing the viewer.  Helices 3,6,9, and 12 (green) are 
the shortest and thought to provide structural stability.  Helices 1,4,7, and 10 (magenta) 
are thought to line the e1, sugar binding cavity of the protein.  Adapted from (4, 5). 
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well conserved from bacteria to humans.  Glucose metabolism occurs via two pathways - 
an anaerobic pathway and an oxidative or aerobic pathway.  Anaerobic metabolism is a 
cytosolic process which occurs primarily in tissues that need to generate energy quickly, 
such as muscles.  This process, known as glycolysis, breaks down glucose into smaller 
monosaccharides, dihydroxyacetone and glyceraldehyde, generating ATP and pyruvate.  
Anaerobic metabolism can meet sudden, stringent demands for energy, but is inefficient 
and the thermodynamic payout (in ATP) per glucose is low.  However, the buildup of 
pyruvate may be funneled into the oxidative Krebs cycle later to replenish ATP as well as 
generating amino acids and other cellular building blocks (53). 
Aerobic or oxidative metabolism involves the Krebs cycle, pentose phosphate 
shunt and use of mitochondria (53).  Compartmentalization and time make possible a 
greater amount of energy payout in the form of ATP and NADH per glucose entered into 
the system; glycolysis yields two ATP equivalents per glucose, while the mitochondrial 
path results in 38 (41, 53).  Because oxidative metabolism is more ‘profitable’ in terms of 
ATP synthesis, glucose and glucose transport remain vital throughout the human body. 
Thirteen human glucose transporters (GLUT1-12, HMIT) have been 
characterized, each with their own tissue-specific expression pattern (38).  When 
compared by sequence identity, the glucose transporters fall into three groups.  Group 1 
contains GLUT1-4, Group 2 contains GLUTs 5, 7, 9, and 11, and Group 3 comprises 
GLUTs 6, 8, 10, 12, and the myo-inositol transporter HMIT. (Table 1.1)   
Group 1 transporters are similar in that their primary function is high affinity 
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Table 1.1 
GLUT Group Gene Name Substratea Expressionb Oocyte Kmc 
GLUT1 1 SCL2A1 Glucose Erythrocytes, 
Endothelial Barrier 
Cells, Smooth 
Muscle, Cardiac 
Muscle 
5mM 
GluT2 1 SCL2A2 Glucose, 
Fructose 
Liver, Pancreatic 
Islets 
11mM 
GluT3 1 SCL2A3 Glucose Brain, Neurons 1mM 
GluT4 1 SCL2A4 Glucose Cardiac & Skeletal 
Muscle, adipocytes 
5mM 
GluT5 2 SCL2A5 Fructose Intestine, Testis, 
Kidney 
6mM 
GluT7 2 SCL2A7 ND Intestine 0.3mM 
GluT9 2 SCL2A9 Urate, 
Glucose 
Liver, Kidney 0.3mM 
GLUT11 2 SCL2A11 Glucose, 
Fructose 
Cardiac & Skeletal 
Muscle 
0.2mM 
GluT6 3 SCL2A6 Glucose Spleen, Leukocytes, 
Brain 
High Km 
GluT8 3 SCL2A8 Glucose, 
Fructose 
Testis, Blastocyst, 
Brain 
2.4mM 
GLUT10 3 SCL2A10 Glucose Liver, Pancreas 0.3mM 
GLUT12 3 SCL2A12 Glucose Placenta, Testis, 
Breast, possibly 
Cardiac Muscle  
4-5mM 
HMIT 3 SCL2A13 Inositol, H+ Brain 0.1mM 
 
Table 1.1 The Human Sugar Porter Family  
Sugar porters are arranged according to groups based on sequence similarity, with the 
porters in Group 1 discovered first(1-3).  a Where two substrates are both transported, the 
one with higher catalytic activity is listed first. b Expression listed in order of most 
concentration to least concentration within the tissue.  c The listed Km is that for oocyte-
expressed transporter uptake of D-glucose (2). 
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equilibrative transport of glucose.  GLUT1 is preferentially expressed in endothelial 
barriers such as the blood-brain barrier, as well as the surface of erythrocytes and smooth 
muscle cells, although it has low, ubiquitous expression in most tissues (38, 54).  
 GLUT2 is primarily expressed in hepatocytes, pancreatic beta cells, and absorptive 
epithelial cells in the small intestine and kidney, and may transport glucose or fructose 
(54, 55).  GLUT3 is the most prevalent sugar transporter in the brain and other nerve 
tissues, although it has basal expression in kidney, placenta, and liver (38).  GLUT4 is the 
‘insulin-sensitive’ glucose transporter present in muscle and adipocytes.  While GLUTs 
1, 2, and 3 may be regulated via altered expression or activity, insulin regulation of 
GLUT4 results in GLUT4 redistribution between cell surface and intracellular 
membranes(54).   
Group 2 transporters (5,7,9,11) are not as well characterized as those in Group 1.   
GLUT5 is highly expressed at the apical membrane in the small intestine, and is the 
major vehicle for dietary fructose uptake. It is also expressed in the brain endothelium, as 
well as in muscle and fat cells (54).  GLUT7 is expressed in small intestine and possesses 
high affinity for glucose and fructose in culture, though its physiological substrate is yet 
unknown (56). GLUT9 is a glucose transporter primarily expressed in the kidney and 
liver; interestingly, mutations in GLUT9 result in defective uric acid metabolism and 
increased sensitivity to gout (57-59).  GLUT11 transports glucose and fructose, and is 
expressed as three functionally similar alternative splicing variants (60). Unlike the 
Group 1 transporters, Group 2 transporters are only weakly inhibited by the classic 
GLUT1 inhibitor cytochalasin B.   
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Group 3 (6,8,10,12, HMIT) transporters still possess 12 putative TM regions, but 
the large extracellular loop is located between TM’s 9 and 10 rather than 1 and 2. (54) 
Each isoform has its own tissue specific expression pattern, and all transport glucose 
except HMIT.  GLUT13 or HMIT, the human 1:1 H+ myo-inositol cotransporter, is the 
last discovered gene with glucose-transport-like motifs.  HMIT is expressed primarily in 
the brain, with low-level expression in adipocytes and kidney (54, 61). 
GLUT1 Model Systems 
From expression we move on to GLUT1 model systems.  In 1952, Widdas first 
theorized that sugar transport was a saturable, protein-mediated process using sheep 
blood-placental transport as his model system (62).  Since then, erythrocytes have 
provided an ideal model system for the study of GLUT1 kinetic properties: Red cells are 
readily available by donation, are uniform in size and volume, may be lysed and resealed 
with desired contents, and GLUT1 is thought to occupy 6% of the cell surface.  
Membrane-resident erythrocyte GLUT1 may be readily purified for biochemical study. 
GLUT1 isolated from red cells is more heterogeneously glycosylated than is observed in 
other tissues.  While this impacts biochemical analysis, it is not thought to affect 
functional behavior. (63).  Nonetheless, erythrocyte GLUT1 provides a window into the 
kinetic properties of mammalian sugar flux.   
The major disadvantage of erythrocyte GLUT1 is that it is not amenable to 
mutagenic analysis.  While clinical cases of GLUT1 DS have provided some insight, they 
are resistant to systematic structural exploration.   Three model systems have been 
successfully employed to address this; Xenopus laevis oocytes, brewer’s yeast, and 
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mammalian cell lines such as 3T3L1 adipocytes, Chinese Hamster Ovary (CHO) cells, 
and Human Embryonic Kidney Cells (HEK). 
XENOPUS LAEVIS 
Mutant GLUT1 has been most commonly expressed via RNA injection in X. 
laevis oocytes (64).  Oocytes, with their consistent size and volume, provide a convenient 
vehicle for analysis of kinetic properties of mutant transporters by measuring the 
transport of radiolabelled sugars. However, oocyte expressed GLUT1 is not uniformly 
gylcosylated, is not expressed at a sufficiently high density for purification, and it does 
not self-associate into dimers and tetramers as observed in red cells (65).   This results in 
differing kinetic behavior from the human erythrocyte model, notably the lack of 
reductant sensitivity (66, 67).  In other words, sugar uptake into control erythrocytes 
without extracellular reductant (DTT-) is almost twofold greater than erythrocytes treated 
with DTT (65).  Oocyte expressed GLUT1 is unaffected by the presence of extracellular 
reductant (66, 67). 
SACCHAROMYCES CEREVISIAE 
S. cerevisiae possesses a family of HXT membrane transporters with similar 
topology to GLUT1 (68-70).  These facilitative transport proteins are thought to be 
uniformly glycosylated and therefore provide a suitable background for mutant/wild type 
study.  While large stocks of yeast may be grown, the resilience of the yeast cell wall 
often makes purification of large amounts of protein for biophysical analysis difficult 
(Levine and Robichaud, unpublished observations). However, the ease of genetic 
manipulation in S. cerevisiae’s could facilitate mutagenesis approaches to analysis of the 
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GLUT1 structure function relationship.   
MAMMALIAN CELL CULTURE 
Transient transfection of GLUT1 into Chinese Hamster Ovary (CHO) cells or 
Human Embryonic Kidney 293T (HEK 293) cells have also proved a convenient vehicle 
for studying the glucose fluxes of mutant GLUT1.  Both cell types have a very low 
concentration of endogenous glucose transporters, thereby facilitating heterologous 
overexpression of mutant transporters.  HEK 293 cells have the advantage that they retain 
erythrocyte-like glycosylation patterns on the protein (66).  Their disadvantages lie in the 
cost of culture, and a lower protein density as compared to the erythrocyte, rendering 
mutant protein purification a more expensive and complex operation. 
Structural Features of GLUT1 
Proteins may be analyzed according to primary, secondary, tertiary, and 
quaternary structure. Mueckler et al. (40) cloned the postulated human glucose 
transporter 1 (GLUT1) sequence from HepG2 hepatoma cells and confirmed that it was 
identical to the GLUT1 protein seen in erythrocytes. GLUT1 comprises 492 amino acids 
producing a transporter of molecular weight of 54,117 daltons (71).  GLUT1 sequence 
contains a single glycosylation domain at N45 (40).  Since 60% of GLUT1 amino acids 
are hydrophobic, it is unsurprising that GLUT1 is an integral membrane protein. (Fig 1.4)   
Other primary structural features of GLUT1 support the hypothesis that GLUT1 is 
an integral membrane protein typical of the Major Facilitator Superfamily (MFS) of 
nutrient importer proteins.  Hydropathy sequence analysis, glycosylation topology, and 
homology modeling suggest GLUT1 has 12 membrane-spanning alpha helices (8, 40).  
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GLUT1 has cytoplasmic N and C termini and contains a large intracellular loop between 
transmembrane (TM) domains 6 and 7, typical of MFS protein folds. The pseudo-twofold 
symmetry is thought to result from an ancient gene duplication event of the first six TMs 
(46, 72).  The termini, the large exofacial loop between TM 1 and 2, and the large 
cytoplasmic loop are thought to form the most flexible extramembranous domains of the 
protein. Mueckler et al inserted consensus glycosylation sequences into GLUT1 loops to 
confirm membrane topology (8).  This scanning glycosylation method was paired to 
assays of GLUT1 deglycosylation which confirmed the location of extracellular loops 
between TM’s 1&2, 3&4, 5&6, 7&8, 9&10, and 11&12. 
GLUT1 sequence common to sugar porters includes the endofacial RXGRR loop 
sequences (between TM2-3 and 7-8) (73). GLUT1 also has three sites with sequences 
homologous to adenylate kinase nucleotide binding domains (74), one in the central 
cytoplasmic loop at residues 225-229, another at residues 332-343 localized in 
intracellular loop 5, and the third domain comprises a Walker A ATP binding motif at 
residues 111-117, in the exofacial loop between TMs 3 and 4 (8, 40).   
GLUT1 secondary structural information is limited, as GLUT1 hydrophobicity 
and motional freedom of the long loops linking TMs result in a protein that is difficult to 
crystallize. As yet, no structure has been reported. Jung et al show using deuterium-
exchange data that 80% of GLUT1 amide protons freely exchange with an aqueous 
environment, implying significant flexibility (75). Some secondary structure has been 
deduced by biophysical methods. Fourier transform infrared spectroscopy as well 
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Figure 1.4  Hydropathy Plot of GLUT1 & Primary Sequence.   
Lipophillic intermembrane stretches initially postulated through hydrophobic analysis of 
amino acid sequence, later confirmed by Mueckler et al using inserted glycosylated 
reporters (8).  GLUT1 possesses12 transmembrane domains, an exoplasmic N-linked 
glycosylation site, and cytosolic N and C termini as well as a large endofacial loop. 
 
 
Interstitium 
COOH 
NH2- 
Fig 1.4 
27 
 
as circular dichroism measurements indicate that the secondary structure of GLUT1 is 
predominantly alpha-helical in the membrane spanning regions, and that these 
transmembrane domains are perpendicular to the membrane bilayer (73, 76, 77). Salas-
Burgos et al (5) computationally modeled the GLUT1 sequence onto the scaffold of 
crystallized GlpT and successfully minimized the structure, suggesting the GLUT1 
sequence may fit the MFS helical packing model. 
 More detailed tertiary helical packing information was determined by 
Mueckler, et. al. By combining expression of a cysteineless GLUT1 construct in X Laevis 
oocytes along with site directed mutagenesis, Mueckler et al systematically replaced each 
amino acid in a given TM domain with a cysteine. Then oocytes expressing each mutant 
were treated with p-chloromercuribenzenesulfonic acid (PCMBS), a sulfhydryl-reactive 
inhibitor of transport.  PCMBS does not penetrate the lipid bilayer well, so transport 
inhibition is thought to show that the altered amino acid has access to the aqueous 
environment.  Their results confirm that residues in TM’s 1, 2, 5, 6, 7, 8, 10, 11, and 12 
that demonstrate PCMBS-sensitive inhibition (73, 78-83).  PCMBS complexation does 
not affect glucose transport in helices 3 and 4, while 9 remains to be analyzed.  Overall, 
this method is in agreement with the MFS helix packing model (Fig 1.3) with two 
exceptions – TM 4 has aqueous access, while TM 12 does not (84). 
 GLUT1 quaternary associations in the membrane remain a topic of keen 
interest.  Monomeric GLUT1 may function as a simple uniporter (85, 86). Key to the 
multimeric hypothesis is the hypothesized presence of a intramolecular disulfide between 
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Cys 347 and 421; in the presence of reductant, red cell GLUT1 ligand binding is 
consistent with the behavior of a simple uniporter (65, 87). Glucose transport, ligand 
binding, and regulation by intracellular nucleotides also appears dependent on oligomeric 
state (65, 87-89).Furthermore, the crystallized LacY structure suggests that the diameter 
of a monomeric MFS carrier is approximately 7.5 nm at 10ºC.  The hydrodynamically 
derived diameter of octylglucoside solublized GLUT1 is approximately 15 nm at 10ºC.  
Rotary-shadowing EM of freeze-fractured erythrocyte membranes showed a protein 
diameter of ~10 nm, again consistent with a multimeric protein (11). These results 
suggest that GLUT1 forms a multimeric structure in detergent micelles and in lipid 
bilayers. 
The Simple Carrier Model 
 In 1952, WF Widdas first noted the inability of diffusion to account for sugar 
transport into sheep placenta.  He used a simplified Michaelis-Menton equation to 
simulate radiolabeled glucose fluxes and as a result of his analysis developed the simple 
carrier model (18, 62). (Fig. 1.5) 
 In the simple carrier, a monomer isomerizes between two conformations in 
the membrane. Of these, one state possesses a pocket ready to receive sugar at the 
cytosolic surface, known as the ‘e1’ or sugar exit site, and a second state with an 
interstitial binding pocket at the outside surface of the membrane called the ‘e2’ or sugar 
entry site.  Glucose import occurs when a sugar binds to e2, promoting a conformational 
change. This results in translocation of substrate across the plasma membrane, forming 
the e1 state from which the substrate is released.  Translocation-like conformational 
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changes may occur with or without a sugar present, and at any given time a protein may 
only display one sugar binding site, either e1 or e2 (63).   
 Functionally, this model may account for the observations suggesting that 
overall substrate transport in red cells is asymmetric. Assuming the simple carrier is 
correct, asymmetry is explained in the model by differing rates of empty carrier 
movement as opposed to substrate loaded translocation.  The kinetic experiments to test 
these phenomena utilize trace quantities of radiolabeled sugar, and are classified 
according to side of the membrane on which radiolabeled sugars are located as well as 
overall sugar transport direction (Fig 1.6).  Four classic erythrocyte sugar transport 
kinetic experiments will be discussed here: 1.) Equilibrium exchange, 2.) Zero-Trans 
Uptake, 3) Infinite-Cis Exit, and 4) Zero-Trans Exit.  Equilibrium exchange 
measurements take place when substrate is present in equal concentrations on both sides 
of the membrane, and measures the rate of labeled sugar entry or exit. Equilibrium 
exchange is typically measured utilizing a radiotracer that is neither metabolizable nor 
retained within the cell, such as 3-O Methyl Glucose. (3MG)  (Fig. 1.6) Equilibrium 
exchange transport at 20ºC (intracellular [D-glucose] = extracellular [D-glucose]) is 
characterized by a Km of 17 mM and a Vmax of 352 mmol L-1 min-1 (90).  In contrast, 
zero-trans uptake occurs when substrate is present only in the interstitum, and is typically 
measured by a metabolically trapped sugar such as 2-deoxy glucose (2-DG).  In 
erythrocytes at 20ºC, D-Glucose zero-trans uptake has a Km (1/affinity) of 1.6 mM and a 
Vmax (half-maximal rate) of 36 mmol*L*min-1 (90) Zero-trans efflux measures the 
outward flow of radiolabeled sugar from preloaded erythrocytes diluted into sugar-free
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Figure 1.5   The Simple Carrier Model 
 A.  Graphical representation of substrate translocation and conformational changes. 
(7)   Sugar import proceeds as follows 1) Substrate binds the e2 or exofacial binding 
pocket on a GLUT1 monomer.  2) A conformational change takes place in which the 
substrate is translocated through the membrane.  3) The e1 site forms, and the substrate 
dissociates from the transporter into the cell.    These conformational changes can take 
place with or without substrate present. 
B.  King-Altman diagram of the simple carrier model of peptide uniport   This 
model contains all of the listed states in the graphical representation. k1 and k_1 are rates 
of enzyme translocation with loaded substrate.  Empty carrier translocation rates are 
expressed as ko and k_o.  The affinity constant for substrate binding to E1 is  K1, and the 
corresponding affinity constant for E2 is K2.  From this model mathematical expressions 
can be derived to express the overall rate of sugar flux in any direction. 
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Figure 1.6  Common types of erythrocyte kinetic sugar flux measurements, with 
graphical representations of sugar flux.   
 Experimental conditions, binding affinities, and rates of reaction measured are 
listed to the right of each representation.  A.  Zero-Trans Uptake is when radiotracer 
sugar uptake in the interstitum is allowed to equilibrate with sugar-depleted cells.  After a 
fixed time, the reaction is stopped, cells are lysed, and the radiotracer is counted. B. Zero-
trans efflux is when cells preloaded with radiotracer sugar and varying concentrations of 
unlabeled sugar are diluted into media containing no sugar. C. Infinite-cis efflux 
describes an experiment in which cells are loaded with saturating concentrations of sugar 
and are resuspended in medium containing zero or increasing amounts of unlabeled 
sugar.  When net exit is monitored by light scattering this experiments reports the 
concentration of sugar that inhibits net exit by 50%. If  unidirectional exit is monitored by 
radiolabeled sugar efflux, this experiments reports that concentration of sugar that 
stimulates unidirectional exit half-maximally. Aliquots of the extracellular media are 
counted after stopping the reaction to measure the rate of sugar efflux.  D. Equilibrium 
exchange transport is measured when the concentrations of sugar in the cell and the 
extracellular medium are equal.  Unidirectional sugar fluxes are measured using 
radiotracer amounts of sugar. 
Adapted from Carruthers et al. (12) 
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medium, and at 20ºC has a Km of 4.6 mM and a Vmax of 154 mmol L-1 min-1 (91). Infinite-
cis exit measurements measure Vmax for sugar exit and the concentration of extracellular 
sugar that reduces net exit by 50%. Transport rates may be determined either by light-
scattering analysis or radiotracer sugar exit. Light-scattering infinite-cis exit of 
erythrocytes has a Km of 2.0 mM and a Vmax of 179 mmol L-1 min-1 (90). The rate of 
sugar entry as determined by zero trans uptake is almost tenfold lower than the rate of 
equilibrium exchange at the same temperature, while the rate of infinite-cis exit is only 
twofold lower than exchange.  For advocates of the simple carrier hypothesis, this 
observed transport asymmetry results from different site affinities and rates of protein 
conformational change.  Faster equilibrium exchange may be accounted for because the 
carrier bypasses a slower relaxation phase, or in this case k_1 > k_0, and k1 > k0, as seen in 
Fig 1.5.  Upon closer mathematical analysis, however, the simple carrier model breaks 
down in terms of predicting affinities and maximum transport rates. 
Carruthers (92) analyzed in detail mathematical expressions derived from the 
simple carrier (Fig. 1.5).  He found the simple carrier could successfully predict Km for 
zero trans uptake and exit (1.6 mM and 10 - 25 mM respectively).  However, the 
experimental data for glucose at 20 ºC, Km for infinite cis uptake (2 mM; saturated sugar 
uptake into cells loaded with varying [D-glucose]) is significantly lower than the simple 
carrier’s predicted values of 15 mM.  The predicted equilibrium exchange value of 8.15 
mM also underestimates the measured value of 27.2 mM (92).  These observations are 
consistent with reservations about the simple carrier model expressed by Nafatlin & 
Holman,  who proposed that the sheer density of erythrocyte GLUT1 (10% by mass, 
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(93)) creates an unstirred layer of substrate just below the cytoplasmic surface of the 
membrane. This would artificially increase the concentration of cytoplasmic glucose at 
the e1 binding site during an uptake experiment, as well as reduce the effective e1 
concentration during an exit experiment (94).  Experimental support for the unstirred 
layer hypothesis shows that net 3MG uptake displays biphasic kinetics in erythrocytes.  
This suggests rapid equilibration with an unstirred layer followed by slower diffusion into 
bulk cytosol  (95).  Given all the data, Carruthers hypothesized that extant measuring 
techniques were too slow to correctly determine binding constants. Blodgett and 
Carruthers (96), Carruthers utilized a rapid quench flow system to further resolve 3MG 
uptake (50µM, 22ºC) in red cells into three sequential phases, a rapid phase (rate constant 
k = 69s-1) thought to represent sugar sequestration within the protein, a fast phase (k = 
0.13s-1) of translocation and release, and a slow phase (k = 0.0021s-1, or .12 min-1) of 
diffusion into bulk cytosol (96).  However, even with the modifications imposed upon the 
simple carrier model by the unstirred layer hypothesis, the simple carrier remains 
inadequate to explain all the structure function data obtained, leading to the development 
of the fixed, two-site carrier. 
Alternating Conformer Model 
Carruthers et al. found that in the presence of increasing concentrations of an e2 
site inhibitor, such as maltose, the Ki (inhibitor affinity constant) for an e1 site inhibitor 
increases in a saturable manner that is quite inconsistent with the competitive inhibition 
predicted by the simple carrier model (97). The reverse situation was also true; increasing
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Figure 1.7  Graphical representation of substrate translocation and conformational 
changes within an alternating conformer or fixed site carrier model.  
 A.  There are four possible conformational changes in dimer translocation:  empty 
dimer, dimer with one substrate transporting inward, dimer with one substrate 
transporting outward, and dimer with two substrates traveling simultaneously in opposite 
directions.  E represents the dimer with its left subunit facing the outside of the cell, while 
F represents its functional equivalent after both monomers have exchanged orientation.   
 B. King-Altman Diagram of the fixed two site carrier model of obligate, antiparallel 
dimer transport.  Rates of translocation are indicated by small case k constants, while 
binding affinities are shown as uppercase K constants.  Any motion implied by a small k 
constant crosses the lipid bilayer, while any arrow with a large K constant indicates a 
substrate binding event.  Empty dimer is E, in the top left corner of the inner square.  
Fully complexed dimer is S1ES2, in the bottom right corner of the outer square. 
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concentrations of an e1 inhibitor, such as cytochalasin B, increased Ki for maltose in a 
hyperbolic manner (97).  The simple carrier model predicts that an exofacial inhibitor at 
e2 should reduce the concentration of e1 sites available for endofacial inhibitor at site 1, 
and vice versa. However, the simple carrier model cannot account for the observed 
allosteric communication between e1 and e2 sites.  Hamill et al. went on to show that low 
concentrations of extracellular maltose increase the rate of 3-OMG import (7). These 
observations argue for the presence of at least two coordinating exofacial e2 sites. 
Similarly, Cloherty et al (16) demonstrate that low concentrations of cytochalasin B or 
forskolin stimulate sugar uptake, which argues for the presence of at least two 
coordinating endofacial e1 sites.   If we assume that each GLUT1 protein alternately 
presents e2 and e1 sites, and that maltose and cytochalasin B bind at e2 and e1 sites 
respectively, together these findings argue that tetrameric GLUT1 is the minimal 
membrane complex that may accommodate the data. 
Further evidence for tetramer subunit-subunit interactions comes from 
mononucleoside adenosine triphosphate (ATP) interactions with the transporter.  At its 
simplest, the cytosolic side of GLUT1 e1 monomer presents at least one ATP binding 
site, which when occupied by ATP promotes sugar transport asymmetry.  However, when 
red cells become ATP depleted, are artificially acidified, or excess AMP is present, this 
sugar transport asymmetry is lost.  Vmax for sugar exit is increased, Km for exit is reduced, 
and both Km and Vmax for sugar uptake are increased (88, 89, 93, 98, 99).  The net effect 
is increased total glucose transport capacity at physiological glucose (5-10 mM).   
ATP binding to GLUT1 is cooperative. While binding of the first ATP molecule 
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is a low affinity event (Kd(app)=250 µM), the second ATP molecule binds with 15-fold 
greater affinity (Kd(app)=15µM, (89)), suggesting communication between sites.  Upon 
reconstitution into pH 6 proteoliposomes, GLUT1 displays only high affinity binding for 
ATP and loses ATP-modulation of transport as well as cooperative function(88, 99).  
Under conditions of low pH, all four subunits expose an ATP-binding site and, 
paradoxically, they become insensitive to ATP (89). This underscores the importance of 
conformational change to cooperative binding. 
The simplest explanation for the observed cooperative binding of ligands is the 
obligate, functionally antiparallel association of two sugar uniporters.  The fixed, two site 
model (Fig 1.6A) posits that the glucose transporter is a homo-oligomer, typically a 
dimer or tetramer, with equal numbers of e1 and e2 sites facing opposite sides of the 
membrane.  Binding of a sugar in the substrate-binding pocket of one subunit results in a 
coordinated conformational change in which the entire oligomer switches its functional 
orientation, whether or not other subunits contain substrate (63).   Thus a tetramer 
comprising e1.e2.e1.eS2 becomes e2.e1.e2.eS1.  Subunit-subunit contacts provide an 
intuitive model for the cooperativity seen between substrate binding sites. These affinity 
constants are represented in the King-Altman diagram in Fig 1.6 as uppercase 
dissociation constants, with isomerization rates represented as lower case constants (63, 
92). 
Small Molecule Modulators of GLUT1 Function 
 Due to the utility and availability of the human erythrocyte glucose transporter in 
erythrocytes, the properties of many sugars and ligand modulators have been extensively 
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characterized  (Tables 1.2, 1.3 and 1.4) GLUT1 transports the sugars D-glucose, 2-deoxy 
glucose, galactose, sorbose, dehydroascorbic acid, and 3-O-methyl glucose.  (Table 1.2)   
GLUT1 behavior is modulated by sugars in three ways; 1) sugars compete for binding at 
the same site (cis competition), 2) Binding of sugars allosterically modulates sugar 
binding at different sites at the same surface of the membrane (cis-allostery), and 3) 
binding of sugar at the surface of the membrane allosterically modulates sugar binding at 
the opposite side of the membrane (trans-allostery) (97).   
 What comprises a transportable sugar?  To further elucidate determinants of sugar 
binding to the e2 site, Munday, et al studied the hydrogen bonding preferences of the 
exofacial sugar binding pocket by measuring the ability of substituted sugars to inhibit L-
sorbose uptake. (Table 1.4)  Munday et al deduced key structural requirements for 
glucose transport asymmetry:  they concluded that the hydroxyl group at carbon 1 and 
carbon 3 of glucose were hydrogen bond acceptors, while the hydroxyl at carbon 4 was a 
hydrogen bond donor.  Spatial requirements around carbon 2 are considered tight, since 
2-O-Methyl Glucose binds with low affinity. Glucose-6-phosphate poorly inhibits L-
sorbose uptake, suggesting that a strongly hydrophobic region surrounds the area that 
interacts with glucose at carbon position 6 (Fig 1.7)(6, 111). 
 The most extensive and varied research into other GLUT1 ligands has been done by 
Naftalin et al, analyzing ligands such as testosterones, estrogens, and green tea cathechins 
to fathom the complex interregulatory effects of hormones and drugs on this ubiquitously 
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Table 1.2 
 
 
Table 1.2  Transportable Sugars and their Kinetic Properties in Erythrocytes.  
a Properties of the transporter directly measured by the experimental analysis.  b Affinity 
in mM.  c Rate expressed as (mmol*L)/min. 
 
 
Sugar Measurement Actiona Kmb Vmaxc Ref 
D-Glucose 
20C 
ZT Uptake Km e2 
Vmax Influx 
1.6 36 (90) 
 IC Exit Km e1, 
Vmax efflux 
2.0 179 (90) 
 Eq Exch Km, Vmax 
exchange 
17 352 (90) 
D-Galactose 
20C 
ZT Uptake Km e2 
Vmax Influx 
31.8 28.6 (63) 
 IC Exit Km e1, 
Vmax efflux 
19.2 - (63) 
 Eq Exch Km, Vmax 
exchange 
138 432 (63) 
DHA 
20C 
ZT Uptake Km e2 
Vmax Influx 
3.5 4.8 (100) 
D-Glucose 
0-4C 
ZT Uptake Km e2 
Vmax Influx 
0.2 0.21 (90) 
 IC Exit Km e1, 
Vmax efflux 
0.39 8.6 (101) 
 Eq Exch Km, Vmax 
exchange 
25 30 (101) 
3MG 
0-4C 
ZT Uptake Km e2 
Vmax Influx 
0.38 0.18 (12) 
 ZT Exit Km e1, 
Vmax efflux 
4.35 1.62 (12) 
 Eq Exch Km, Vmax 
exchange 
22.6 9.17 (12) 
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Table 1.3 
Inhibitor Site Ki (inh) T Inhibits / Measured Ref 
Cytochalasin B e1 0.1 µM 22C 14C CB to Ghosts (102) 
 e1 0.35 µM 21C IC D Glucose Efflux (103) 
 e1 0.26 µM 21C D Glucose Eq Exch (103) 
 e1 0.46 µM 25 C IC D Glucose Efflux (104) 
+ATP e1 0.76 µM 25 C IC D Glucose Efflux (104) 
      
Phloretin e2 10 µM 37C ZT D Glucose Upt (105) 
 e2 0.37 µM 25 C IC D Glucose Efflux (104) 
 e2 0.48 µM 21 C ZT D Glucose Upt (106) 
      
Forskolin e1 7.5µM 21C ZT 3MG Uptake (107) 
      
p-butyl phenol e2 660 µM 37C ZT D Glucose Upt (105) 
Phloretic Acid e2 1.42 mM 37C ZT D Glucose Upt (105) 
Phlorpropophenone e2 142 µM 37C ZT D Glucose Upt (105) 
Phloroglucinaldehyde e2 5 mM 37C ZT D Glucose Upt (105) 
Naringenin e2 142 µM 37C ZT D Glucose Upt (105) 
Hexestrol e2 14.2 µM 37C ZT D Glucose Upt (105) 
Stilbestrol e2 6.25 µM 37C ZT D Glucose Upt (105) 
Dienestrol e2 66 µM 37C ZT D Glucose Upt (105) 
      
      
Tamoxifen e1 0.76 µM 25 C IC D Glucose Efflux (104) 
Oestradiol e1 4.71 µM 25 C IC D Glucose Efflux (104) 
Genistein e1 4.2 µM 25 C IC D Glucose Efflux (104) 
      
Quercetin e2 16 µM 37 C ZT 3MG Uptake (108) 
 e2 1.04 µM 21 C ZT D Glucose Upt (106) 
      
Myricetin e2 33.5 µM 37 C ZT 3MG Uptake (108) 
Catechin-gallate e2 90 µM 37 C ZT 3MG Uptake (108) 
AzitriFluoroethylbenzoyl bismannose e2 338 µM 360 µM 
0 C 
20 C D-Galactose Binding (109) 
      
Phenobarbital e2* 0.91 mM 21 C ZT D Glucose Upt (110) 
Aniracetam e2* 1.05 nM 21 C ZT D Glucose Upt (110) 
Benigride e2* 10.2 µM 21 C ZT D Glucose Upt (110) 
Montirelin e2* 45.7 µM 21 C ZT D Glucose Upt (110) 
Sunifferam e2* 26 µM 21 C ZT D Glucose Upt (110) 
Levriacetam e2* 3.19 mM 21 C ZT D Glucose Upt (110) 
Galanin Peptide e2* 19.6 µM 21 C ZT D Glucose Upt (110) 
L-Pyroglutamic Acid e2* 13.8 mM 21 C ZT D Glucose Upt (110) 
Methamphetamine e2* 118 µM 21 C ZT D Glucose Upt (110) 
Diazepam e2* 50 µM 21 C ZT D Glucose Upt (110) 
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Inhibitor Site Ki (inh) T Inhibits / Measured Ref 
Thiamylal e2* 0.22 mM 21 C ZT D Glucose Upt (110) 
Melatonin e2* 155 µM 21 C ZT D Glucose Upt (110) 
      
Testosterone e2 39.2 µM 21 C ZT D Glucose Upt (106) 
Andostrenedione e2 29.6 µM 21 C ZT D Glucose Upt (106) 
5 Andostenediol e2 50 µM 21 C ZT D Glucose Upt (106) 
Androsterone e2 44 µM 21 C ZT D Glucose Upt (106) 
Epianderosterone e2 33 µM 21 C ZT D Glucose Upt (106) 
Etiocholanone e2 1.25 µM 21 C ZT D Glucose Upt (106) 
Dehydroepiandrosterone  
3 acetate e2 4.8 µM 21 C ZT D Glucose Upt (106) 
Dehydroepiandrosterone  
Sulfate e2 189.1 µM 21 C ZT D Glucose Upt (106) 
Flutamide e2 73.4 µM 21 C ZT D Glucose Upt (106) 
Green Tea Extract (Whole) e2 1.31 µM 21 C ZT D Glucose Upt (106) 
Epigallochatechin 3-gallate e2 0.97 µM 21 C ZT D Glucose Upt (106) 
Epichatechin e2 1.74 µM 21 C ZT D Glucose Upt (106) 
Epichatechin 3-gallate e2 0.14 µM 21 C ZT D Glucose Upt (106) 
Epigallochatechin e2 111 µM 21 C ZT D Glucose Upt (106) 
 
Table 1.3  Summary of Ligand Interactions With GLUT1.   
All experiments  were made in erythrocytes, and are inhibition of D-Glucose 
transport by GLUT1 except where noted. 
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#Ca Sugar Name Transportable Site Ki L-Sorboseb 
1 D-Glucose Y Both 7.6  
1 1-Deoxy D Glucose Y Both 76  
2 2-Deoxy D Glucose Y Both 3.2  
2 2-O-Methyl D Glucose Y Both 119  
2 D-Mannose N E2 36  
3 3-Deoxy D Glucose Y Both 71.5  
3 3-O-Methy D Glucose Y Both 12 
3 D-Allose N E2 N.D.c 
4 D-Galactose Y Both 85 
4 Maltose N E2 19 
4 Cellobiose N E2 51 
4 Lactose N E2 >250  
6 6-Deoxy D-Glucose Y Both 6.7  
6 Glucose 6-Phosphate N E2 N.D.c 
5 D-Xylose Y Both 69  
5 D-Galactose Y Both 85 
 
Table 1.4  Summary of the inhibition of L-Sorbose uptake into erythrocytes by modified 
Sugars(6).  
a Carbon  position on the glucose molecule that has been modified, as compared to D-
Glucose.  b All Ki constants are in mM.  c No detectable inhibition of uptake.  
Table 1.4 
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Figure 1.8  Rendition of exofacial sugar binding site taken from Munday, et al. (6) 
  The first four carbons of the D-Glucose molecule pictured are numbered.  It is 
postulated that  D-Glucose slides through the transporter in the pyranose ring form, 
emerging in the same orientation at the other side.  The membrane protein surface has 
been sketched in to approximate the results from L-sorbose inhibition data. 
 
 
 
1 
2 
3 
4 
Fig 1.8 
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expressed protein (104, 106, 110, 112).  The results of these studies are summarized in 
Table 1.3.  However, the most widely studied small molecule modulators of sugar 
transport are discussed here in more depth: cytochalasin B, forskolin, phloretin, and ATP.  
CYTOCHALASIN B 
Cytochalasin B (CB) is a cell-permeable fungal toxin which also inhibits glucose 
transport by interacting with the e1 conformation of GLUT1.  This ligand binds with an 
approximate erythrocyte Kd of 0.1µM (102, 104, 113).  Other cellular activities include 
the strong inhibition of actin polymerization, restriction of cellular movements, as well as 
inhibition of cytokinesis (114).   
Documented interactions of CB inhibition of GLUT1 include the following.  1) A 
common clinical missense case of GLUT1DS arising by point mutation at position R126 
(H, E, L, K, C) results in decreased CB affinity (115). 2) Cytochalasin B at low 
concentrations (5nM) is a mild stimulator of sugar uptake by GLUT1 (88). This behavior 
in conjunction with maltose stimulation of glucose uptake refutes the simple carrier 
hypothesis as mentioned above (97).  3) Mutation of W387 and W412 separately 
decreases CB photolabeling of GLUT1, and together eliminates labeling by CB (44, 116, 
117).  4) Salas-Burgos et al mapped one endofacial cytochalasin B binding site on their 
homology-modeled GLUT1 structure, suggesting involvement of residues L85, N88, 
R89, R92, K225, Q250, M251, and R400 (5).  5) Holman and Rees uv-photolabeled 
GLUT1 with a radiolabeled cytochalasin B, then digested labeled transporter with 
chymotrypsin.  The smallest 3H-CB photocrosslinked fragment found on the gel 
corresponded to GLUT1 residues 388-412, indicating that the GLUT1 endofacial sugar 
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binding site lies within or adjacent to that sequence. (13)  
FORSKOLIN 
Forskolin (FSK) is a cell-permeable diterpenoid that competitively inhibits 
glucose transport at the e1 site with a Ki(app) of 7.5µM for inhibition of  red cell transport.  
FSK is also a high-affinity inhibitor of GLUT4 mediated sugar transport in cardiac and 
skeletal muscle. (107, 118).  Forskolin acts as an activator of adenylyl cyclase, and sees 
broad use in cell culture as a stimulator of cyclic adenosine monophosphate production 
(119, 120).  Further documented interactions of FSK with GLUT1 include 1) IAPS 
forskolin has also been used to photolabel GLUT1; like CB, its photolabeling site is near 
W388 (121, 122).  2) Salas-Burgos et al docked forskolin to their homology modeled 
GLUT1 structure at two sites: the exofacial residues are N34, K38, W65, S285 and P306 
while the endofacial residues are F81, V83, G84, G138, G398, and R400 (5). 
PHLORETIN 
Phloretin is the aglucon (sugarless form) of phlorizin, a compound originally 
known to induce glycosuria(123), and later shown to inhibit glucose transport in 
erythrocytes with a KI of 10µM at 37ºC  (105, 124).  Phloretin is a competitive, 
temperature dependent inhibitor of the e2 site of both Group 1 and Group 2 human sugar 
porters. (104, 106, 125).  It also blocks L-type Ca2+ channels, and may activate Ca2+-
activated K+ channels in amphibian myelinated nerve fibers. (114)  Salas-Burgos et al 
mapped two phloretin binding sites on their GlpT homology modeled version of GLUT1: 
an exofacial binding site at residues N34, W65 and S285, and an endofacial one at S80, 
F81, L85, G183, R400, and G398 (5).  
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ADENOSINE TRIPHOSPHATE 
GLUT1 is an ATP binding protein that does not engage in ATP hydrolysis. 
GLUT1-ATP interactions appear to regulate GLUT1 function to meet the metabolic 
needs of the cell.  As mentioned previously, if ATP dips below normal physiological 
levels, GLUT1 transport asymmetry is lost. (88, 89, 93, 98, 99, 126-131) It is tempting to 
speculate that this system evolved to permit tissues in which glycolysis is used for fast 
energy metabolism in order to respond rapidly to metabolic stress.   
Several lines of evidence point to the cooperativity of ATP binding.  Binding is 
cooperative as measured by fluorescence quenching with at least two binding sites per 
oligomer.  (88) ATP binding is known to induce significant conformational changes 
when bound to GLUT1, for covalent labeling of GLUT1 lysine residues by NHS esters, 
GLUT1-sensitivity to trypsin and IgG binding to Loop 7 or the C terminus are inhibited 
when GLUT1 is exposed to saturating ATP.  (89, 99)  Proteolytic digestion followed by 
mass spectrometric analysis confirms global conformational changes of GLUT1 by ATP.  
Briefly, sulfo-NHS-biotin, a lysine-reactive reagent, was reacted with GLUT1 ± ATP, 
digested, and protected lysines determined by MALDI-TOF analysis.  Loop 6-7 lysines 
225, 229,  and 230 are not protected, but labeling of lysines 244, 255, and 256 are 
inhibited by the presence of ATP.  Substitution of GLUT4 loop 6-7 sequence greatly 
reduced ATP inhibition of c-terminal IgG binding, although two of three sensitive lysines 
remained present.  Taken together, this suggests loop 6-7 lysines do not play a direct role 
in ATP regulation of glucose transport, though they possess an altered conformation in 
response to ATP binding. (132)  It is possible the strong cooperativity shown in ATP 
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binding serves to fine-tune the regulation of GLUT1 function. 
Overall Conclusions and Research Purpose 
Protein-mediated sugar transport is vital for cellular growth. Dissecting and 
delineating transporter structure/function relationships is imperative to understand of 
GLUT1 function in vivo,  essential to efforts to develop small molecules that target 
specific transporters for inhibition (or activation) and is fundamental to efforts aimed at 
understanding the molecular basis of carrier-mediated transport. Remaining gaps in our 
understanding addressed in this thesis include how cellular context affects function, as 
well as characterization of the e1 binding site from a ligand binding or mutagenic 
perspective. 
GLUT1 has been studied in different tissues and in varied heterologous 
expression systems and is characterized by a complexity that is unexplained by the 
available hypotheses for carrier-mediated sugar transport (9). It is possible that the 
operational properties of GLUT1 are determined by host cell environment. A glucose 
transport-null strain of Saccharomyces cerevisiae (RE700A) was transfected with 
GLUT1.  Its growth on glucose media, selectivity, and sugar transport kinetics were 
characterized. Unlike erythrocyte transport, the Km(app) for RE700A-resident GLUT1 2-
deoxy- D-glucose uptake equals Ki(app) for 2-deoxy-D-glucose inhibition of 3-O-
methylglucose uptake. Unidirectional sugar uptake in RE700A-GLUT1 is neither 
inhibited by reductant nor stimulated by intracellular sugar. Net uptake of subsaturating 
3-O-methylglucose by RE700A-GLUT1- HA-H6 is a first-order process. These findings 
support the hypothesis that the observed red cell sugar transport complexity is host cell-
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specific. 
Cytochalasin B (CB) and forskolin (FSK) inhibit GLUT1-mediated sugar 
transport in red cells by binding at or close to the GLUT1 sugar export site. 
Paradoxically, very low concentrations of these inhibitors produce a modest stimulation 
of sugar transport (16)  This result is consistent with the hypothesis that the glucose 
transporter contains multiple, interacting, intracellular binding sites for e1 ligands CB and 
FSK. By screening a library of cytochalasin and forskolin analogs, asks what structural 
features of exit site ligands determine binding site affinity and cooperativity. Some 
forskolin derivatives and cytochalasins inhibit equilibrium [3H]-CB binding to red cell 
membranes depleted of peripheral proteins. Others produce a modest stimulation of [3H]-
CB binding when introduced at low concentrations, but inhibit binding as their 
concentration is increased. Yet other analogs modestly stimulate [3H]-CB binding at all 
inhibitor concentrations applied. These findings are best explained by a carrier that 
presents at least two interacting endofacial binding sites for CB or FSK. We discuss this 
result within the context of GLUT1 quaternary structure and evaluate the major 
determinants of ligand binding affinity and cooperativity.   
As mentioned above, cytochalasin B (CB) inhibits GLUT1 substrate transport at 
or near the endofacial sugar binding site. N-bromosuccinamide digestion combined with 
3H-CB photolabeling implicates the region between Trp388 and Trp412 in ligand 
binding. Although its structure has been modeled(5), the specific residues which 
comprise the sugar binding site are unknown. A series of alanine point mutants were 
made and characterized for CB inhibition of 2DOG uptake.  Expression was verified by 
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Western blot and surface localization by immunofluorescence.   GLUT1Phe88Ala, 
GLUT1Arg92Ala and  GLUT1Trp412Ala mutants were weakly expressed, while 
GLUT1Ser80Ala did not express at the membrane.  The ranking of 2-DG uptake by 
construct was GLUT1Arg126Ala > GLUT1Cys421Ala >  GLUT1Arg400Ala as 
compared to untagged GLUT1 expressed in HEK cells. The CB inhibition of 2-DG 
uptake of the constructs GLUT1Arg126Ala, GLUT1Cys421Ala , and GLUT1Arg400Ala 
were not statistically different from that of c-myc tagged GLUT1.  Since point mutations 
proved insufficient to abrogate CB binding, chimeras of GLUT1 Trp388 to Trp 412 
sequence were exchanged with the equivalent GLUT4 and GLUT5 sequence.  
GLUT1/GLUT4/GLUT1 was a point mutation (Iso404Met) whose 2-DG uptake had a 
similar CB sensitivity profile to untagged GLUT1.  GLUT1/GLUT5/GLUT1 shows 
enhancement of 2-DG uptake at 50nM CB but its overall CB dose response is 
indistinguishable from WT GLUT1.  We conclude the W388 to W412 sequence is 
necessary for CB photolabeling, but not inhibition of 2 deoxyglucose uptake by CB.  We 
discuss these results with their implications for structure-function sequence localization 
of the CB binding site, and by extension, the e1 sugar binding site. 
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CHAPTER II 
 
PROPERTIES OF THE HUMAN ERYTHROCYTE 
GLUCOSE TRANSPORT PROTEIN ARE 
DETERMINED BY CELLULAR CONTEXT 
 
 
This chapter was published in the journal Biochemistry in 2005, and can be found using 
the following reference: 
 
Levine, K. B., Robichaud, T. K., Hamill, S., Sultzman, L. A., and Carruthers, A. (2005) 
Properties of the human erythrocyte glucose transport protein are determined by cellular 
context, Biochemistry 44, 5606-5616. 
 
Data presented in this chapter found in Tables 2.1 and 2.2, as well as Figures 2.5 B and C 
were contributed to by myself, Trista K Robichaud; the remaining work was a 
collaboration with Kara B Levine, Ph.D. based upon original observations by Lisa 
Sultzman, Ph.D.  
 
This work was supported by NIH grant DK 44888
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ABSTRACT 
Human erythrocyte hexose transfer is mediated by the glucose transport protein 
GLUT1 and is characterized by a complexity that is unexplained by available hypotheses 
for carrier-mediated sugar transport (Cloherty, E. K., Heard, K. S. and Carruthers, A. 
(1996), Biochemistry, 35, 10411-10421). The current study examines the possibility that 
the functional properties of the transport protein are determined by the host cell. A 
glucose transport-null strain of S. cerevisiae (RE700A) was transfected with the p426 
GPD yeast expression vector containing DNA encoding wild-type human glucose 
transport protein (GLUT1), mutant GLUT1 (GLUT13338A3) or carboxy-terminal 
hemagglutinin-polyHis-tagged GLUT1 (GLUT1-HA-H6). GLUT1 and GLUT1-HA-H6 
are expressed at the yeast cell membrane and restore 2-deoxy-D-glucose, 3-O-
methylglucose, and D-glucose transport capacity to RE700A. GLUT1-HA-H6 confers 
GLUT1-specific sugar transport characteristics to transfected RE700A including 
inhibition by cytochalasin B and high affinity transport of the nonmetabolized sugar 3-O-
methylglucose. GLUT1338A3 – an engineered GLUT1 mutant that cannot catalyze transport in 
mammalian cells – is expressed but does not restore RE700A sugar uptake capacity. In contrast to 
sugar transport in human red cells, Km(app) for uptake of a primary sugar by RE700A-
GLUT1-HA-H6 is very close to Ki(app) for inhibition of import of a second sugar by the 
primary sugar (e.g. Km(app) for 2-deoxy-D-glucose uptake = Ki(app) for 2-deoxy-D-glucose 
inhibition of 3-O-methylglucose uptake). Unlike transport in human red cells or in human 
embryonic kidney cells transfected with GLUT1-HA-H6, RE700A-GLUT1-HA-H6 sugar 
uptake is not inhibited by reductant and is not stimulated by intracellular sugar. The time-
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course of net sugar uptake at subsaturating 3-O-methylglucose concentrations is 
monophasic in RE700A-GLUT1-HA-H6. These findings support the hypothesis that red 
cell sugar transport complexity is host cell specific. 
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THE ABBREVIATIONS USED ARE: GLUTs, glucose transporters, GLUT1; human 
erythrocyte glucose transporter; 2DOG, 2-deoxy-D-glucose; C-Ab, rabbit polyclonal 
antiserum raised against a synthetic peptide comprised of GLUT1 residues 480-492; CB, 
cytochalasin B; 3MG, 3-O-methyl-D-glucopyranoside; DTT, dithiothreitol; EDTA, 
ethylenediaminetetraacetic acid; FOA, 5-fluoroorotic acid; HA-Ab, mouse monoclonal 
antibody directed against the hemagglutinin sequence LYPYNVPNYA; HEPES, (N–[2–
Hydroxyethyl]piperazine–N'–[2–ethanesulfonic acid]); RBC, red blood cell; SDS-PAGE, 
sodium dodecyl sulfate -polyacrylamide gel electrophoresis ;Tris–HCl, 
tris(hydroxymethyl)aminomethane hydrochloride; Dpmp1p, dolichol phosphate mannose 
synthase. 
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INTRODUCTION 
The facilitated diffusion of glucose across cell membranes is mediated by a family 
of integral membrane proteins named Glucose Transporters (1GluTs). Twelve mammalian 
glucose transport proteins have been identified, differing in primary structure, tissue 
distribution and substrate specificity (1). GLUT1, the human erythrocyte glucose 
transport protein, mediates sugar transport in red blood cells, in endothelial cells lining the 
vasculature and contributes to basal glucose transport in adipose and cardiac muscle (40, 
133-135). Membrane-associated GLUT1 is multimeric (65, 87) and cytoplasmic ATP 
interacts directly and cooperatively with GLUT1 to modify transporter affinity for 
substrate and net sugar flux through the transport complex (93, 136, 137). 
Red cells are uniquely suited to steady-state sugar transport determinations 
because they provide a geometrically uniform population of cells in which to measure 
sugar fluxes. The human red blood cell is also a particularly rich source of GLUT1, with 
the transporter representing 6% or more of total erythrocyte integral membrane proteins. 
Erythrocyte GLUT1is not directly amenable to mutagenesis and in situ expression. 
Manipulation of GLUT1-mediated sugar transport through mutagenesis, has required the 
development of heterologous expression systems for mutant GLUT1 expression. GLUT1 
has been successfully expressed in mammalian cells (CHOK1(65), Cos-7 and HEK293 
(99)), Xenopus oocytes (138) and in insect cells(139). None of these systems has achieved 
an efficiency of protein expression that yields sufficient GLUT1 to facilitate detailed 
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biochemical analysis. Only the oocyte presents a relatively uniform cell geometry and 
thereby permits detailed kinetic analysis of GLUT1-mediated sugar transport. 
Previous heterologous expression studies have suggested that S. cerevisiae can 
express a relatively homogeneously glycosylated form of human GLUT1(140). Yeast, a 
eukaryotic organism, contains a superfamily of sugar transporters (35 genes) that includes 
maltose, inositol, and glycerophosphoinositol transport proteins(68). S. cerevisiae 
contains a subfamily of 18 hexose transporters (HXT 1-17 and galactose permease 
(Gal2)) which, like the GLUTs, catalyze the facilitated diffusion of sugars across cell 
membranes(141). Sequence alignment indicates that the HXT proteins are similar to 
GLUT1, containing 12 putative transmembrane domains and intracellular amino and 
carboxyl termini (70). Yeast may, therefore, present  a suitable expression system in 
which to produce wild type and mutant recombinant human red blood cell glucose 
transport proteins.  
Deletion of S. cerevisiae HXT 1-7 produces a strain of yeast (RE700A) that is 
unable to grow on glucose media (142). This suggests that HXT 1-7 are the major hexose 
transporters in S. cerevisiae. Wieczorke et al (141) have suggested that a minimum of 20 
hexose transporter genes (hxt 1-17, Gal2, maltose permeases Y9DL247w, YJR160c) must 
be eliminated in S. cerevisiae order to produce a yeast strain completely lacking in sugar 
transport capacity. However, in contrast to RE700A, the yeast strain used in their study 
(CEN.PK2-1C) appears to possess a greater capacity for respiration and consequently, 
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may be able to grow by utilizing residual levels of sugar present in the cells (143). The 
galactose permease (Gal2), which is a member of the hexose transporter family, has also 
been shown to transport glucose. Although it remains in the RE700A strain, Gal2 is 
tightly controlled by the presence of galactose and is inhibited by high intracellular 
glucose(144). Expression of the maltose permeases (YDL247w, YJR160c) which may 
modulate glucose transport in S. cerevisiae, is also repressed by glucose (145). 
The present study characterizes human GLUT1 expression in S. cerevisiae using 
RE700A - the HXT 1-7 null yeast strain. RE700A transfected with exogenous, human 
GLUT1 is selectable by its ability to grow on, and transport glucose. Expressed GLUT1 
interacts with human GLUT1-directed C-terminal antisera, co-localizes with yeast plasma 
membrane markers, displays a functional stereochemistry similar to erythrocyte-resident 
GLUT1 and is inhibited by inhibitors of GLUT1-specific sugar transport. This 
heterologous expression system may provide a rapid screening vehicle for mutant 
GLUT1 proteins. Significant kinetic differences between sugar transport in GLUT1 
expressing human red cells and RE700A cells suggest that the complexity of human 
erythrocyte sugar transport (9) may be cell context-specific. 
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MATERIALS & METHODS 
MATERIALS  
[14C]-D-Glucose, [14C]-3-0-methyl-glucose, and [3H]-2-deoxy-glucose were 
purchased from Dupont NEN (Wilmington, DE). Complete protease inhibitor tablets 
were purchased from Roche (Mannheim, Germany). Supersignal ECL reagents were 
obtained from Pierce (Rockford, Il). Centricon concentrators were acquired from 
Millipore (Bedford, MA). SCM-URA dropout mix was purchased from Bufferad 
(Newark, NJ). Nitrocellulose and Immobilon-P were obtained from Fisher Scientific, 
(Pittsburg, PA). 
RED CELLS  
De-identified, washed red blood cells and whole blood stored in CPDII AS-1 
preservative solution were obtained from Biological Specialties Corporation (Colmar, 
PA). Red cells were isolated by repeated wash/centrifugation cycles in ice-cold saline. 
One volume of whole blood was mixed with 3 or more volumes of saline and centrifuged 
at 10,000 x g for 5 minutes at room temperature. Serum and the buffy coat were aspirated 
and the wash/centrifugation cycle repeated until the supernatant was clear and the buffy 
coat was no longer visible. Cells were resuspended in 20 volumes of saline and were 
incubated for 30 minutes at 37 ˚C in order to deplete intracellular sugar levels. 
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HEK923T CELLS  
HEK cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS , 100 units/mL penicillin, and 100 µg/mL streptomycin in a 
37 ˚C humidified 5% CO2 incubator. 
ANTISERA  
A peptide corresponding to GLUT1 residues 480-492 was synthesized by the 
University of Massachusetts Medical School Peptide Synthesis facility. This peptide 
was conjugated to keyhole limpet hemocyanin using a kit purchased from Pierce. Rabbit 
antisera (C-Ab) against this GLUT1 peptide were obtained from Animal Pharm Services 
Inc (Healdsburg, CA). Anti-GLUT1 antisera reacting exclusively with extracellular 
epitopes of GLUT1 (∂-Ab) were prepared as described previously (146). Goat anti rabbit 
IgG horseradish peroxide was purchased from Biorad (Hercules, CA). Anti-yeast dolichol 
phosphate mannose synthase (Dpm1p) antiserum was obtained from Molecular Probes 
(Eugene, OR). 
SOLUTIONS  
Phosphate-buffered saline (PBS) contained 140 mM NaCl, 10 mM Na2HPO4, 3.4 
mM KCl, 1.84 mM KH2PO4 (pH 7.3), and 5 mM EDTA. 2X Spheroplasting buffer 
contained 2.8 M sorbitol, 0.1 M potassium phosphate buffer (pH 7.4), and 10 mM 
NaN3. Membrane buffer was composed of 0.8 M sorbitol, 1 mM EDTA, and 25mM 
HEPES). Sample buffer (2X) contained 0.125M Tris-HCl, (pH 6.8), 4% SDS, 20% 
glycerol, and 50 mM DTT. Phosphate Buffer (PB) pH 6.5 included 0.329 mM KH2PO4. 
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Buffer A consisted of 300 mM NaCl, 10 mM imidazole, 20% Glycerol, and 50 mM 
NaH2PO4. 
REAGENTS  
Restriction enzymes were purchased from New England Biolabs. The glucose 
transport null strain of S. cerevisiae, RE700A, was generously provided by Dr. M. 
Johnston (University of Washington, St. Louis). p426 and p416 yeast expression vectors, 
as described in(89), were provided by Dr. C. Hirschberg (Boston University, the 
Goldman School of Dentistry, Department of Molecular and Cell Biology). 
GENETIC ENGINEERING  
A 1.7 kbp fragment of GLUT1 cDNA was subcloned into BamH1 site of the high 
copy number yeast expression vector p426. Removal of the 5’-untranslated region of the 
GLUT1 sequence was accomplished by using PCR to insert a unique Spe1 restriction site 
3 bps prior to the GLUT1 start codon. This construct was subcloned into the Spe1-
BamH1 restriction site of the p426 yeast expression vector. The triple alanine GLUT1 
mutant, GLUT1338A3 in which GLUT1 residues 338, 339 and 340 were each replaced 
with alanine, was engineered using the Stratagene Quickchangetm Site Directed 
Mutagenesis Kit and confirmed by sequence analysis.  
TRANSFECTION OF RE700A WITH GLUT1  
Stable expression of GLUT1 in yeast was accomplished using RE700A, a strain of 
S. cerevisiae in which 7 of 20 hexose transporters are disrupted (142). This results in a 
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yeast strain incapable of using glucose as a primary carbon source and subsequently 
unable to grow on glucose media. Briefly, cells were prepared for electroporation using 
the following protocol. RE700A (250 mL) grown to an OD600 of 1.3-1.5 in YP-maltose 
were pelleted by spinning at 1,500 x g for 5 min at 4 oC. Following two washes in ice cold 
sterile water (250 mL followed by 125 mL), the cells were washed in 20 mL of ice cold 
1M sorbitol than resuspended in 1 mL of 1M sorbitol. A portion of the cell slurry (80-
100µL) was mixed with 5-20µg of DNA, equilibrated on ice for 10-20 minutes, then 
transferred to a pre-chilled 0.2 cm electroporation cuvette. The yeast were pulsed at 1.5 
kV, 25 µF, and 200 Ohms. Immediately, 1mL of ice cold sorbitol was added to the 
cuvette and the cells were plated onto SCM-URA maltose selective media. Growth was 
observed after 2-4 days at 30 ˚C. 
TRANSIENT EXPRESSION OF GLUT1 IN HEK CELLS  
GLUT1-HA-H6 was subcloned into the BamH1 site of the pcDNA3.1+ 
mammalian expression vector as described previously (147). Sub confluent HEK923T 
cells were transfected with GLUT1-HA-H6 cDNA using the Fugene 6 transfection 
reagent system. Following transfection, cells were maintained in DMEM for 24 hours, at 
which time, 0.72 mM G418 (Geneticin) was added to the media and the cells were 
allowed to continue growing for an additional 48 hours. 
MEMBRANE ISOLATION 
Yeast grown to late log phase were washed in an equal volume of cold 10 mM 
NaN3 and resuspended in 20 mL each of 10 mM NaN3 and 2X spheroplasting buffer. 
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Zymolase 20T was added (25mg/15mL) and the suspension was incubated at 30 ˚C for 1-
2 hours. Successful cell wall removal was monitored by measuring yeast optical density 
periodically throughout the incubation period. Yeast were centrifuged at 3000 x g for 10 
min and the pellet was resuspended in a small volume of membrane buffer containing 
protease inhibitors. Yeast were lysed by repetitive pipetting and were then diluted to 
100mL by addition of membrane buffer plus protease inhibitors. Lysed cells were spun at 
3,000 x g for 10 minutes to isolate the P1 fraction; at 8,000 x g for 20 minutes to pellet the 
P2 Fraction, and at 100,000 x g for 30 minutes to sediment the plasma membrane 
containing P3 fraction. Membranes were resuspended in membrane buffer with protease 
inhibitors and stored at -70 oC until use. 
To harvest HEK923T cell membranes, 6 culture plates of cells (150 mm) were 
washed twice with PBS + 5 mM EDTA, than scraped into 20 mL of lysis buffer mixed 
with 1 mM PMSF. Membranes were prepared according to (148). Briefly, cells were 
homogenized for five minutes with a Fisher Dyna-Mix, then spun at 5000 x g for 10 
minutes at 4 ˚C. The supernatant was decanted and centrifuged at 100,000 x g for 1 hour 
to pellet crude membrane fractions. Membranes were resuspended in 300 µL Buffer A 
with 1mM PMSF and frozen at –70ºC until use. 
RENOGRAFIN DENSITY GRADIENTS   
Crude yeast membranes were resolved on Renografin gradients as previously 
described in (149). Briefly, the P3 fractions isolated from RE700A and RE700A-GLUT1-
HA-H6 were combined with an equal volume of Renografin-76. The Renografin gradient 
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was constructed on top of 0.8mL of sample (38% Renografin) by sequentially layering 
0.8 mL of 34, 30, 26, and 22% Renografin-76 diluted in 50 mM Tris-HCl pH 7.4. 
Gradients were centrifuged in a 50.1Ti rotor at 40,000 rpm for 20 hours at 4 oC. Samples 
were isolated from the top down in aliquots of 500 µL, and stored at -70 ˚C until use. 
Fractions containing GLUT1, the yeast endoplasmic reticulum marker OST, and the yeast 
plasma membrane marker Ste1p were determined by Western Blotting.  
POLYACRYLAMIDE GEL ELECTROPHORESIS AND WESTERN BLOTTING  
Proteins were resolved on 10% polyacrylamide gels as described previously in 
(150). Recombinant human GLUT1, Dpm1p, and Ste1p were detected by Western Blot 
analysis. Peptides separated by SDS-PAGE were transferred electrophoretically to 
nitrocellulose membranes, which were subsequently blocked for 1 hour in PBS-T (PBS + 
0.1% tween detergent) with 20% Carnation nonfat dry milk. Following four washes of 5 
minutes in PBS-T, membranes were incubated for 1 hour in primary antibody. C-Ab was 
diluted 1:10,000 in 3% nonfat dry milk/PBS-T, anti Dpm1p was diluted 4µg/ml in 3% 
nonfat dry milk/PBS-T, and anti-Ste1p was diluted 1:2000 in 3% nonfat dry milk/PBS-T. 
Following four wash cycles to remove primary antibody, membranes were exposed for 45 
minutes to secondary antibody (goat anti-rabbit IgG or goat anti mouse IgG) diluted 
1:5000 in PBS-T containing 3% nonfat dry milk. Detection of antigen-antibody 
complexes was achieved by chemiluminescence using Pierce Supersignal ECL reagents.  
65 
      
Sugar Transport Measurements 
ZERO-TRANS UPTAKE   
RE700A and RE700A-GLUT1 (wild type and mutant 338) were grown to an 
OD600 of 0.6 in YP-maltose and SCM-URA-maltose respectively. 50 mL of culture was 
centrifuged at 5,000 x g, then washed twice in phosphate buffer (PB). Samples were 
resuspended in 1 mL of PB. 100 µL aliquots of cells at room temperature were exposed to 
4 volumes of room temperature PBS containing [3H] D-glucose. Uptake of 100µM D-
glucose was measured at 5 minute intervals then 10 volumes of ice cold PBS were added 
to the samples to stop the reaction. The yeast suspension was sedimented by 
centrifugation (14,000 x g for 30sec), the supernatant was aspirated, and the 
wash/centrifugation/aspiration cycle was repeated. The resulting pellet was extracted in 
500µL of 3% perchloric acid. The acid extract was centrifuged, and duplicate samples of 
the clear supernatant were counted. Time zero uptake points were prepared by addition 
of ice cold PBS to cell suspensions prior to addition of medium containing sugar and 
radiolabel. Cell suspensions were immediately processed. Radioactivity associated with 
yeast suspensions at time zero was subtracted from the activity associated with cell 
suspensions following the uptake period. Uptake assays were performed using solutions 
and tubes pre-equilibrated to 20 oC. 
2-Deoxy-D-glucose (2DOG) uptake in yeast was carried out as described D-
glucose uptake. 100µL aliquots of cells at room temperature were exposed to 2 volumes 
of room temperature PBS containing [3H]2-deoxy-D-glucose. Uptake of 100µM 2DOG 
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was measured at 2 minute intervals, and quenched by addition of 10 volumes of ice cold 
PBS buffer containing 50mM maltose.  
Zero-trans sugar uptake experiments in intact human red blood cells were made at 
4 ˚C (to slow transport and thereby permit accurate determinations of transport) as 
described previously (9). Briefly, sugar-free cells or erythrocyte ghosts (at ice 
temperature) were exposed to 5 volumes of saline (ice temperature) containing variable 
concentrations of unlabeled sugar plus labeled sugar. Uptake was permitted to proceed 
over intervals of 30sec then 50 volumes (relative to cell volume) of stopper solution (PBS 
containing 10µM CB and 100µM phloretin) were added to the cell suspension. Cells 
were sedimented by centrifugation (14,000 x g for 30 sec), washed once in stopper, 
collected by centrifugation and extracted in 500µL 3% perchloric acid. The acid extract 
was centrifuged and duplicate samples of the clear supernatant fluid were counted. Zero-
time uptake points were prepared by addition of stopper to cells prior to addition of 
medium containing sugar and radiolabel. Cells were immediately processed. Radioactivity 
associated with cells at zero-time was subtracted from the activity associated with cells 
following the uptake period. Uptake assays were performed using solutions and tubes 
pre-equilibrated to 4 ˚C. Triplicate or quadruplicate samples were processed at each time 
point. Cell counts were obtained from a calibration curve relating red cell absorbance at 
417nm to cell numbers (obtained using a hemocytometer). 
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Michaelis Menten parameters for sugar uptake by recombinant human GLUT1 
expressed in yeast were calculated by measuring the concentration dependence of 2DOG 
transport (100µM to 100mM 2DOG). 3MG inhibition of 2DOG transport in wild-type 
yeast and RE700A-GLUT1 was analyzed by measuring 2DOG uptake (100µM) in the 
presence or absence of increasing concentrations (100µM - 100mM) of 3MG.  
ELISA   
Purified, human erythrocyte GLUT1, and yeast membranes (isolated from 
RE700A +/- GLUT1 HA 6His) were attached to ELISA dishes by incubation at 37˚C for 
18-24 hours. Following absorption of proteins to the microtiter plates, each well was 
washed 3 times with phosphate buffer (PB) and then incubated for 90 minutes at 37˚C 
with 250µL of 3% BSA in PB. GLUT1 was detected with rabbit antisera raised against a 
synthetic carboxyl-terminal peptide of the human red blood cell glucose transport protein 
(C-Ab) diluted 1:20,000 with 1% BSA in PB. The reporter molecule for rabbit IgG was 
goat anti-rabbit IgG peroxidase diluted 1:5000 with 1% BSA in PB. Bio-Rad peroxidase 
substrate kits were employed. Detection of product was determined by absorbance at 
410nm using a Dynatech MR 700 plate reader. Nonspecific IgG binding was determined 
by processing wells lacking glucose transport protein.
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Figure 2.1  GLUT1-HA-H6 expression in S. cerevisiae.   
RE700Acells were transfected with HA-H6-tagged wild-type GLUT1 (GLUT1-
HA-H6), with mutant GLUT1 (GLUT1338-A3), with an empty vector (p426 GPD), or 
without a vector (RE700A) and plated on SCM-URA maltose (A) or SCM-URA glucose 
(B). Plates were photographed after 3 days. (C) RE700A-GLUT1-HA-H6 grown on 
SCM-URA maltose. (D) RE700A-GLUT1-HA-H6 streaked onto 5-FOA-containing 
media. (E) RE700A-GLUT1-HA-H6 restreaked post-5-FOA exposure (3 days) onto YP-
maltose. (F) RE700AGLUT1-HA-H6 restreaked post-5-FOA exposure (3 days) onto 
YPdextrose. (G) RE700A-GLUT1-HA-H6 restreaked post-5-FOA exposure (3 days) onto 
SCM-URA dextrose.
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Figure 2.2 Human Expression of human GLUT1 in S. cerevisiae.  
 A Western blot using GLUT1 carboxyl-terminal IgGs (C-Ab) of GLUT1 expressed 
in RE700A. Membranes were isolated by differential centrifugation, resolved by 10% 
SDS PAGE, and transferred to nitrocellulose for western blotting. Lanes 2-7 each contain 
35 µg total membrane protein. Lane 1 contains 1µg of purified erythrocyte GLUT1. Two 
fractions were obtained upon yeast lysis: The F2 fraction (lanes 2 and 3) was collected as 
the low speed (8,000 x g) pellet. The F3 membrane fraction (lanes 4,5 , 6 and 7) was 
obtained as the high speed (100,000 x g) pellet. Lane 2 contains membranes from the 
RE700A hxt-null mutant.  Lane 3 contains membranes from -5'UTR-GLUT1-transfected 
RE700A; Lane 4 contains membranes from the RE700A hxt-null mutant; Lane 5 contains 
membranes from -5'UTR-GLUT1-transfected RE700A. Lane 6 contains membranes from 
RE700A transfected with GLUT1 containing the 5’UTR. Lane 7 contains membranes 
from -5'UTR-GLUT1-transfected RE700A. Lanes 6 & 7 were obtained from a separate 
gel. The migration and mass of molecular weight markers is shown to the left of Lane 1.  
 B Western blot using GLUT1 carboxyl-terminal IgGs (C-Ab) of GLUT1 expressed 
in RE700A. Membranes were isolated by differential centrifugation, resolved by 10% 
SDS PAGE, and transferred to nitrocellulose for western blotting. Lanes 2-4 each contain 
35 µg F3 fraction membrane protein. Lane 1 contains 0.25µg of purified erythrocyte 
GLUT1. Lanes 2, 3 and 4 contain membranes from RE700A-5’UTR-GLUT1-HA-H6 
grown on glucose (lane 2), maltose (early passage, Lane 3) or maltose (late passage, Lane 
4). The migration and mass of molecular weight markers is shown to the left of Lane 1. 
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FOA INDUCED VECTOR DROP-OUT  
Clones of RE700A-GLUT1-HA-H6 that have lost the URA3 based p426-GPD 
plasmid were selected by plating on media containing 5-fluoroorotic acid (5-FOA; 0.1% 
for 2-3 days).  
RESULTS 
The disruption of seven of 20 hexose transporter genes in S. cerevisiae results in a 
strain of yeast (RE700A) that is capable of growing on maltose (a disaccharide imported 
by maltose-H+ symport then hydrolyzed to yield 2 glucose molecules), but incapable of 
growth on glucose (142).  
RE700A were transfected with epitope-tagged GLUT1 cloned into the BamH1 
site of the yeast expression vector p426 GPD and subsequently plated onto selective 
media containing maltose (SCM-URA maltose), and later glucose only (SCM-URA 
glucose). Transfection with either empty vector (p426 GPD), or p426-GLUT1-HA-H6 
results in growth on maltose. Only p426-GLUT1-HA-H6-containing yeast grow on 
glucose (Figure 2.1). In the absence of vector, RE700A fails to grow (Figure 2.1). 
RE700A was also transfected with the GLUT1338-3A mutant (residues 338, 339 and 340 
each replaced with alanine). Mammalian cells (Cos-7) transiently transfected with 
GLUT1338-3A exhibit sugar transport rates indistinguishable from untransfected control 
cells, yet GFP-tagged GLUT1338-3A is expressed at high levels at the plasma membrane 
suggesting that hGLUT1338-3A is targeted correctly but is catalytically impaired (147). 
Figure 2.1 demonstrates that RE700A-GLUT1338-3A grows on maltose, but lacks the 
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Figure 2.3 Sugar transport by RE700A expressing or lacking hGLUT1-HA-H6. 
 A. D-glucose transport in RE700A transfected with GLUT1 DNA containing the 
5'UTR. D-glucose uptake was measured in transfected (▲) and untransfected () cells. 
Ordinate: mol sugar imported per 109 cells; Abscissa: time in minutes. Each point 
represents the mean of 4 or more separate determinations.  
 B. 3MG uptake in RE700A transfected with GLUT1 DNA lacking the 5'UTR. 3-O-
methyglucose uptake (100 µM sugar) was measured in nontransfected () and 
transfected () cells. Ordinate: mol sugar imported per 109 cells; Abscissa: time in 
seconds. Each point represents the mean of 4 or more separate determinations. 
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ability to survive on glucose. This result is consistent with previous observations in 
mammalian cells suggesting that GLUT1 mutant GLUT1338-3A lacks the capacity to 
transport D-glucose.  
To determine that the RE700A-GLUT1-HA-H6 phenotype (growth on glucose) 
results directly from the GLUT1-HA-H6 sequence carried on the p426 GPD vector, cells 
containing p426 GLUT1-HA-H6 were plated onto media containing 5-fluoroorotic acid 
(FOA). FOA is toxic to yeast expressing the URA-3 gene.  This selection thus identifies 
clones that have lost their URA-3 containing plasmid (p426 GLUT1-HA-H6). Following 
exposure to FOA, growth of RE700A GLUT1 was observed on YP maltose, but not on 
YP glucose, SCM-URA maltose or SCM-URA glucose (Figure 2.2) suggesting that the 
yeast have lost both the GLUT1 containing vector (p426 GLUT1-HA-H6) and the 
capacity to survive on glucose.  
hGLUT1 Expression in RE700A 
Yeast transfected with epitope-tagged GLUT1 were screened for protein 
expression by immunoblot and sugar transport analyses. Initial attempts at RE700A 
transfection resulted in yeast with slow growth rates (doubling time > 8 hr on glucose 
medium) and undetectable GLUT1 expression by Western analysis of total yeast 
membranes (lane 6, Figure 2.2A). In an effort to increase human GLUT1 expression, we 
re-engineered the transporter construct by deleting the mammalian 5’ untranslated region 
(5’ UTR). A unique Spe1 site 3 base pairs 5’ to the GLUT1 start codon was introduced 
by PCR. Excision, using Spe1 and BamH1, permits ligation of the resulting 1.5 kbp 
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fragment of epitope-tagged GLUT1 (–5’UTR-GLUT1-HA-H6) into the Spe1/BamH1 
restriction site of the p426 GPD expression vector. RE700A was transfected with p426-
5’UTR-GLUT1-HA-H6 and plated as described previously. These yeast grow more 
rapidly on glucose medium (doubling time ≈ 2 hours).  C-Ab immunoblot analysis of 
yeast membranes indicates the presence of a 50-55 kDa C-Ab reactive protein in 
RE700A-5’UTR-GLUT1-HA-H6 (Figure 2.2A, Lanes 3,5) which is absent in 
untransfected cells (Figure 2.2A, Lanes 2,4). Thus removal of the 5'UTR appears to 
increase GLUT1 expression in RE700A. Densitometric analysis suggests that 
recombinant GLUT1 (present in both the F2 (8,000 x g) and F3 (100,000 x g) membrane 
fractions of RE700A-5’UTR-GLUT1-HA-H6 approaches 1% of total protein. It is also 
apparent that GLUT1 expressed in yeast is characterized by a relatively narrow 
electrophoretic mobility. In contrast, purified human red blood GLUT1 is 
heterogeneously glycosylated and is resolved as a broader smear (Figure 2.2A, lane 1). C-
Ab reactive peptides of relatively low Mr (21-29 kDa) are detected in the F3 fraction of 
RE700A  GLUT1-5’UTR (Figure 2.2A, Lane 5) suggesting that proteolytic fragments of 
GLUT1 or truncated versions of the transporter may also be present. GLUT1-HA-H6 
expression is unaffected by growth medium  (Figure 2.2B). 
Net uptake at 24ºC of 100µM [3H]-D-glucose by RE700A-5’UTR-GLUT1-HA-
H6 is 12-fold greater than uptake in nontransfected RE700A (Figure 2.3A). Uptake of 
[14C]3-O-methylglucose (3MG, a transported but nonmetabolizable sugar) is 10.5-fold 
greater in RE700A-5’UTR-GLUT1-HA-H6 than in RE700A (Figure 2.3B).  
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Sites of hGLUT1 expression in RE700A 
Renografin gradient separation of cellular membrane compartments was used to 
identify the cellular location of recombinant GLUT1-HA-H6 expression in RE700A. 
Membrane fractions from yeast with and without -5’UTR-GLUT1-HA-H6 were layered 
under a gradient of renografin-76. Samples were centrifuged for 20 hours at 40,000 rpm 
to allow proteins to migrate to regions of equivalent buoyant density. Fractions were then 
isolated in order of increasing density, and were immunoblotted by using GLUT1 C-Ab 
and antibodies directed against yeast plasma membrane (Ste1p) and endoplasmic 
reticulum (OST1p or Dpm1p) markers. Figure 2.4 indicates that the largest fraction of -
5’UTR-GLUT1-HA-H6 in transfected RE700A co-fractionates with the yeast plasma 
membrane marker Ste1p. Very little of the expressed transporter is detected in the less 
dense, ER-dominated (OST1p or Dpm1p) membrane fractions.
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Figure 2.4 Renografin gradient centrifugation of yeast membranes. 
 F3 fractions isolated from RE700A and RE700A-GLUT1 were combined with an 
equal volume of Renografin-76. The Renografin gradient was constructed over 0.8 mL of 
sample (38% Renografin) by sequentially layering 0.8 mL of 34, 30, 26, and 22% 
Renografin-76 diluted in 50 mM Tris-HCl pH 7.4. Gradients were centrifuged in a 50.1Ti 
rotor at 40,000 rpm for 20 hours at 4ºC. Samples were isolated from the top down in 
aliquots of 500 µL, and stored at -70oC until use. Fractions containing GLUT1 (), the 
yeast endoplasmic reticulum marker OST (), and the yeast plasma membrane marker 
Ste1p () were determined by Western Blotting. Ordinate: fraction of total GLUT1, 
OST or Ste1p in each sample. Abscissa: fraction number (samples closest to the top of 
the gradient have the greater numbers). The distribution of OST and Ste1p are unchanged 
by GLUT1 expression (nontransfected RE700A yeast give identical results for OST and 
Ste1p; not shown). 
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Figure 2.5 Yeast and Erythrocyte 2DG Uptake 
A) Concentration dependence of 2-deoxy-D-glucose uptake and inhibition of D-glucose 
uptake by RE700A-5′UTR-GLUT1- HA-H6. Left ordinate: 2DG uptake [nmol/109 
cells/min ()]. Right ordinate: uptake of 100 µM D-glucose [pmol/109 cells/min ()]. 
Abscissa: [2DOG] (mM). Each point represents the mean of at least four separate 
determinations in triplicate. The curve drawn through the 2DOG uptake data points () 
was computed by nonlinear regression assuming simple Michaelis-Menten sugar uptake 
kinetics and takes the form V ) Vmax[2DG]/[Km(app) + [2DOG]], where V is the rate of 
uptake at any [2DOG], Vmax is the maximum rate of sugar uptake obtained at a saturating 
[2DOG], and Km(app) is that [2DOG] that results in uptake of 0.5Vmax. The curve has the 
following constants: Vmax = 2.35 ± 0.09 nmol/(109 cells)-1 min-1; Km(app) = 2.9 ± 0.4 mM 
2DOG; R2 = 0.985). The curve drawn through the D-Glucose uptake data points () was 
computed by nonlinear regression assuming simple Michaelis-Menten competitive 
inhibition of D-Glucose uptake by 2DOG and takes the form V = Vo - Vi[2DOG]/[Ki(app) 
+ [2DOG]], where Vo is the rate of D-Glucose uptake in the absence of 2DOG, Vi is the 
extent of inhibition produced at a saturating [2DOG], and Ki(app) is that [2DOG] that 
results in 50% of the maximum inhibition of D-Glucose uptake. The curve has the 
following constants: Vo = 72.9 ± 4.5 pmol (109 cells)-1 min-1; Vi = 64.2 ± 5.0 pmol (109 
cells)-1 min-1; Ki(app) = 2.1 ± 0.6 mM 2DOG; R2 = 0.983.  
 
(B) Concentration dependence of CCB inhibition of 2DOG uptake by RE700A-5′UTR-
GLUT1-HA-H6 and baker’s yeast. Left ordinate: 2DOG uptake in RE700A-GLUT1-HA-
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H6 [mol/109 cells/min ()]. Right ordinate: 2DOG uptake in baker’s yeast [mol/109 
cells/min ()]. Abscissa: [CB] (nM). Each point represents the mean of four triplicate 
determinations of 2DOG uptake at 100 µM sugar. The curve drawn through the RE700A-
GLUT1-HA-H6 data points was computed by nonlinear regression assuming simple 
Michaelis-Menten inhibition of sugar uptake and takes the form V = Vo - Vi[CB]/[Ki(app) 
+ [CB]], where V is the rate of uptake at any [CB], Vo is the rate of uptake in the absence 
of CB, Vi is the maximum decrease in sugar uptake produced by a saturating [CB], and 
Ki(app) is that [CB] that inhibits uptake by 50% of Vi. The curve has the following 
constants: Vo = (6.99 ± 0.24) × 10-11 mol (109 cells)-1 min-1; Vi = (3.68 ± 0.27) × 10-11 
mol (109 cells)-1 min-1; Ki(app) = 142 ± 42 nM CB; R2 = 0.969.  
 
(C) Inhibition of 2DOG uptake in RE700A-GLUT1-HA-H6 and in baker’s yeast by 
cytochalasin B. Ordinate: moles of 2-deoxy-D-glucose imported by 109 cells. Left 
ordinate: uptake in nontransfected RE700A ( and ) or in RE700A-GLUT1-HA-H6 
(▲ and ). Right ordinate: uptake in baker’s yeast ( and ). Abscissa: time in 
seconds. 2DOG uptake was assessed at 100 µM sugar in the presence (, , and ▲) or 
absence (,, and ) of cytochalasin B. RE700A- 5′UTR-GLUT1-HA-H6 cells were 
exposed to 10 µM CB, while wild-type S. cerevisiae cells were exposed to 100 µM CB. 
Cells received CCB 10 min prior to 2DOG uptake initiation. The curves drawn through 
the points were computed by nonlinear regression assuming uptake is described by the 
expression 2DOGt = 2DOG∞(1 - e-kt), where 2DOGt is the amount of 2DOG associated 
with the cells at time t, 2DOG∞ is the amount of 2DOG associated with the cells at 
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equilibrium, and k is the first-order rate constant describing the rate of 2DOG uptake. The 
following constants were obtained: 2DOG∞ = 2.5 ± 0.2 nmol/109 cells, k = 0.007 ± 0.001 
s-1, and R2 = 0.999 for baker’s yeast; 2DOG∞ = 4.3 ± 0.4 nmol/109 cells, k = 0.0048 ± 
0.001 s-1, and R2 = 0.975 for baker’s yeast and CB; 2DOG∞ = 2.1 ± 0.2 nmol/109 cells, k 
= 0.00076 ± 0.00033 s-1, and R2 = 0.992 for RE700A-GLUT1-HA-H6; 2DOG∞ = 2.1 ± 
0.3 nmol/109 cells, k = 0.00025 ± 0.00001 sec-1, and R2 = 0.985 for RE700A-GLUT1-
HA-H6 and CB; 2DOG∞ = 2.1 nmol/109 cells, k = (4.1 ± 0.4) × 10-5 s-1, and R2 = 0.835 
for RE700A; and 2DOG∞ = 2.1 nmol/109 cells, k = (4.2 ± 0.5) 10-5 s-1, and R2 = 0.770 for 
RE700A and CB. With RE700A cells, 2DOG∞ was assumed to be identical to RE700A-
GLUT1-HA-H6. 
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Fig 2.5 
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Table 2.1 Specificity of GluT1-mediated sugar transport 
 
  aRE700A-GluT1-HA-H6 awt S. 
cerevisiae 
bHuman erythrocytes 
Sugar Temp 
(ºC) 
Km(app)  
mM 
cVmax dKi(app) dKi(app) Km(app)  
mM 
cVmax dKi(app
) 
2DOG 4     0.59 ± 
0.27 
19.14 ± 
2.64 
1.4 ± 
0.4 
 24 2.89 ± 
0.42 
2.35 ± 
0.09 
2.05 ± 
0.57 
5e 1.8 ± 
0.2f 
 3.2g 
3MG 4     0.38 ± 
0.13 
11.9 ± 
1.32 
1.9 ± 
0.3 
 24   10.1 ± 
4.2 
64.4 ±  
3.8 
4.6 ± 
0.3g 
 13g 
     250e 3.1 ± 
0.8h 
  
      2i   
      15-23j   
CB 4       126 ± 
16 
 24   142 ± 42 > 10,000   110k 
 
a Sugar uptake was measured in wild-type (wt) and GluT1-HA-H6-transfected RE700A 
yeast at 20ºC. b Sugar uptake in red cells was measured at 4ºC. Km(app) is that 
concentration at which uptake is  0.5 Vmax. cVmax is the maximal rate of sugar uptake in 
nmol*109cells*min. dKi(app)  is that concentration of sugar (mM) or cytochalasin B (nM) 
that reduces sugar uptake by 50% of the maximal inhibition. In experiments where 2DOG 
was the inhibitory sugar, uptake of 66µM D-glucose was measured. In experiments 
where 3MG or CB were the inhibitors, uptake of 66µM 2DOG was measured. e From ref 
(151). f From ref (152). g From ref (6). h From ref (153). i From ref (154). j From refs 
(155) and (96). k (156) 
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Figure 2.6 Lack of hGluT1-HA-H6-mediated trans-acceleration in RE700A. 
A)  Ordinate: mol 2-deoxy-D-glucose imported by 109 cells per min. Abscissa: 
Intracellular [3MG] in mM. 2DOG uptake (100µM) was measured in RE700A-5'UTR-
GluT1-HA-H6 () that had been pre-loaded for 1 hr with 0, 10, 20 or 40 mM 3MG. The 
rate of 2DOG uptake was then measured over a 5 minute interval. Results are shown as 
mean ± SEM of at least 3 separate determinations made in triplicate. The straight line 
drawn through the data points was computed by linear regression. The rectangular 
hyperbolae illustrate the fold stimulation and the [3MG] dependence of transport 
stimulation that is expected (9) if transport were measured in human red cells at 4ºC 
(solid line) or at 20ºC (dotted line).  
B)  Transacceleration is observed in HEK cells expressing GluT1-HA-H6. Ordinate: rate 
of 2DOG uptake in mol per µg cell protein per minute. Abscissa: experimental condition. 
100µM 2DOG uptake was measured in control (HEK) or 3MG (40 mM) loaded HEK 
cells (HEK+3MGi) or in HEK cells transiently transfected with GluT1-HA-H6 and 
preloaded with 0 (HEK-GluT1-HA-H6) or 40mM 3MG (HEK-GluT1-HA-H6+3MGi). 
These results represent the mean ± SEM of three separate measurements. Uptake in 
nontransfected HEK cells (1.62 pmol/µg protein/min) was subtracted from the data. 
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Fig 2.6 
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Table 2.2 Effect of DTT on sugar uptake by human red cells and RE700A. 
 
 2DG Uptakea   
Cell Type controlb DTTb CBc nd pe 
RE700A-GluT1-HA-H6f 98.2 ± 2.6 144.0 ±11.6 42 ±  6 5 0.264 
HEK293g 3.91 ± 0.21 3.61 ± 0.12 0.04 ± 0.003 4 0.153 
HEK293+GluT1-HA-H6g 5.94 ± 0.16 4.63 ± 0.11 0.04 ± 0.01 4 0.002 
GluT1-HA-H6 uptakeg,h 0.20 ± 0.02 0.13 ± 0.01  4 0.013 
 
a 2DOG uptake at 100 µM sugar was assessed in RE700A-GLUT1-HA-H6 cells and 
control (HEK293) or GLUT1-HA-H6-transfected HEK cells (HEK293+GLUT1-HA-
H6). b 2DOG uptake was assessed at 20 °C following a 30 min pre-incubation at 30 °C in 
the absence (control) or presence (DTT) of 20 mM DTT at pH 7.4. c 2DOG uptake by 
HEK cells (control and transfected) is inhibited by >90% by 20 µM CB. d Number of 
separate measurements made in duplicate. e Probability that there is no difference 
between control and DTT conditions in each experiment calculated using the Student’s t-
test. This two-tailed test assumes that paired samples have equal variance. f Uptake is 
expressed as picomoles per 109 cells per minute and is shown as mean ± standard error of 
the mean. g Uptake was assessed as picomoles per microgram per minute and is shown as 
mean ± standard error of the mean. h GLUT1-HA-H6-specific 2DG was calculated as the 
difference between uptake in transfected versus nontransfected HEK293 cells. 
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Characterization of sugar transport in RE700A GLUT1  
The concentration dependence of 2DOG uptake by RE700A-5’UTR-GLUT1-
HA-H6 at 24 ºC shows saturation kinetics with Michaelis and velocity constants of 
Km(app) = 2.64 ± 0.40 mM and Vmax = 2.25 ± 0.08 nmol/min/109 cells respectively (Table 
2.1; Figure 2.6A). 2DOG transport rates in wild type yeast are at least 10-fold greater 
than in GLUT1-transfected RE700A (Fig 2.6B). 2DOG-inhibition of D-glucose uptake 
by RE700A-5’UTR-GLUT1-HA-H6 at 24 ˚C is characterized by Ki(app) = 1.75 ± 0.75 
mM (Table 2.1). Ki(app) for 2DOG-inhibition of D-glucose uptake by human red cells is 
1.4 ± 0.4mM while Km(app) for 2DOG uptake by red cells is 0.59 ± 0.17mM (Table 2.1). 
3MG inhibition of 2DOG uptake by RE700A-5’UTR-GLUT1-HA-His6 (Figure 
2.5B) is characterized by a Ki(app) of 10.1 ± 4.2mM. In contrast, Ki(app) for 3MG 
inhibition of 2DOG uptake by wild type S. cerevisiae is 64.4 ± 3.8 mM (Table 2.1). 
Cytochalasin B, an inhibitor of human red blood cell sugar transport, also inhibits 2DOG 
uptake by RE700A-5’UTR-GLUT1-HA-H6 with Ki(app) = 60 ± 17nM (Figure 2.5C). 
Maximum inhibition of unidirectional uptake is 58%.  The remaining uptake is similar to 
that observed in the presence of saturating concentrations of 3MG or D-glucose 
suggesting a non-mediated or leakage pathway. 2DOG uptake in wild-type S. cerevisiae 
is unaffected by 100 µM CB (Figure 2.5B). 
Human red cell unidirectional sugar import is inhibited 5-fold by extracellular 
reductant (65) and is stimulated by 10 - 100-fold by intracellular sugar (96, 155, 157, 
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158). 2DOG uptake by RE700A-5’UTR-GLUT1-HA-H6 is not inhibited by DTT 
exposure (10mM, 30min at 30ºC; Table 2.2). Unidirectional uptake of 100µM 3MG by 
RE700A-5’UTR-GLUT1-HA-H6 is unaffected by preloading cells with 10, 20 or 40 mM 
unlabeled 3MG (Fig 2.6A). Introduction of the carboxy-terminal HA-H6 tag to GLUT1 
could influence (positively or negatively) the ability of the GLUT1 cytoplasmic C-
terminal domain to interact with other cytoplasmic regions of GLUT1. This, in turn, 
could influence GLUT1-mediated sugar transport. We therefore expressed GLUT1-HA-
H6 in human embryonic kidney cells (HEK923T) and determined whether reductant or 
intracellular sugar influences sugar transport in these cells. GLUT1-HA-H6 catalyzes 
DTT-inhibitable 2DOG uptake in HEK cells (Table 2.2) where intracellular 3MG 
stimulates GLUT1-HA-H6-mediated 2DOG unidirectional uptake (Figure 2.6B). 
Uptake of the non-metabolizable sugar, 3MG, by human red cells is characterized 
by multi-phasic import kinetics(93, 101, 159, 160). 3MG uptake by RE700A-5’UTR-
GLUT1-HA-H6 is a simple, exponential process (Figure 2.5A). 
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DISCUSSION 
Sugar transport in S. cerevisiae 
The S. cerevisiae genome contains seventeen hexose transporter genes (Hxt1-11, 
Hxt13-17, Gal2) and three maltose transporter homologs (Agt1, Mph2, Mph3) each of 
which can catalyze hexose transport (141). A recent analysis suggests that it is necessary 
to disrupt all 20 of these genes in order to prevent growth on glucose media (141). The 
present study confirms earlier observations that a yeast strain (RE700A) lacking Hxt1-7 
is unable to grow on glucose as the sole carbon source (142, 161, 162). We further 
demonstrate that introduction of human GLUT1 into RE700A restores the ability of the 
organism to utilize glucose as an energy source.  
GLUT1 is directly involved in promoting glucose transport in transfected 
RE700A cells since subsequent exposure to 5-FOA selects for cells that have lost the 
URA-3 containing plasmid and results in clones capable of growth on YP-maltose but not 
on YP-dextrose or SCM-URA dextrose. Sugar transport measurements also indicate that 
FOA-treated yeast have lost the ability to import 2-deoxy-D-glucose. This suggests that 
the selected RE700AGLUT1 clones have lost both the GLUT1 containing vector and the 
ability to use glucose as a carbon source. 
One explanation for this result could be that RE700A responds to transfection 
with human GLUT1 by inducing the expression or activation of an endogenous yeast 
hexose transport protein. Ozcan et al. (162) have shown that two hxt-like genes in S. 
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cerevisiae (rgt2 and snf3) are not transporters but rather are glucose sensors that control 
expression of several members of the hxt family of genes. Furthermore, Wieczorke et al. 
(141) demonstrate that deletion of snf3 in the background of the 20 hexose transporter 
gene deletion, partially restores growth on hexoses suggesting the existence of even more 
yeast proteins that are capable of transporting hexoses. Thus recombinant GLUT1 may 
act in S. cerevisiae as a glucose sensor, introducing a signal for transcriptional induction of 
previously inactive or inhibited sugar carriers. 
This seems unlikely for several reasons. 1) Glucose transport by wild-type yeast 
(grown under conditions required for GLUT1 expression in RE700A) is characterized by 
a lack of sensitivity to the sugar transport inhibitor cytochalasin B (see here and (163)). 
Expression of the cytochalasin B-sensitive, human GLUT1 gene confers acute CB 
sensitivity to RE700A sugar transport. Thus if GLUT1 expression induces the 
expression of an unrecognized sugar transporter, this transporter must differ from other 
yeast hexose transporters in being CB-inhibitable. This inhibitory action of CB on sugar 
transport is unlikely to result from inhibition of transcriptional activation by GLUT1 
because the actions of the inhibitor on transport are acute (fully observable within 10 
minutes of addition). 2) Wild-type yeast shows only very low affinity (Ki(app) = 65mM) 
for the nonmetabolized but transported sugar 3-O-methylglucose while human GLUT1 
and RE700A yeast expressing GLUT1HAHis6 are characterized by 6-fold greater affinity 
for the sugar (see (24) and here). 3) The transport-deficient GLUT1 mutant GLUT1338A3 
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does not catalyze sugar transport when expressed in mammalian cells or in RE700A. 4) 
Identical results have been obtained with GLUT1i  using the yeast strain employed by 
Wieczorke et al.  (141) in which all 20 hexose transporter genes are eliminated. Thus if 
GLUT1 serves as a transcriptional activator, it must induce the expression of as yet 
unrecognized glucose transporters. We conclude, therefore, that human GLUT1 directly 
catalyzes glucose, 2-deoxy-D-glucose and 3-O-methylglucose transport when expressed 
in yeast. 
Previous studies have suggested that GLUT1 expression is limited to the 
endoplasmic reticulum in yeast (140, 164). The present study not only shows that 
GLUT1 expression increases sugar import by RE700A, but that expressed GLUT1 co-
migrates with yeast plasma membrane and endoplasmic reticulum markers upon 
membrane fractionation by Renografin gradient density centrifugation. Similar results have 
been described by Wieczorke et al. (165). However, in this case, GLUT1 was expressed 
at the cell surface but was either inactive or misfolded (165). These workers demonstrated 
that GLUT1-mediated transport could be activated in one of two ways. 1) By 
mutagenesis of a cluster of amino acids (human GLUT1 residues 63, 67, 68 and 69) in 
putative transmembrane domain two. 2) By selection of a ∆hxt strain containing a 
genomic mutation (fgy1-1) that now permits GLUT1 function. In the present study, 
sequence analysis of the p426GPD-GLUT1-HA-H6 vector isolated from transfected 
RE700A and amplified in E. coli indicates that the GLUT1-encoding sequence is 
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unaltered. We conclude that the use of the yeast expression vector p426 GPD and 
elimination of the hGLUT1 5’UTR results in sufficiently robust expression of GLUT1 to 
saturate any ER-sequestering mechanism and thereby permit leakage to the yeast plasma 
membrane. Furthermore, high expression of GLUT1 either saturates the mechanism 
(fgy1-1) that suppresses GLUT1 transport function or the RE700A yeast strain also 
contains the fgy1-1 genomic mutation proposed in (165) and thus permits full function of 
human GLUT1 when expressed at the yeast plasma membrane. 
Properties of GLUT1 in S. cerevisiae and human red cells 
Sugar transport in RE700A cells expressing hGLUT1 is a saturable process. 
Equilibrium exchange 2DOG import is characterized by Km(app) = 2.6±0.4mM and Vmax = 
2.3 nmol/min/109 cells. 2DOG uptake is competitively inhibited by 3MG (Ki(app) = 
10mM) and 2DOG and D-glucose uptake compete for sugar uptake (2DOG Ki(app) = 
1.75±0.75mM). This measure of the apparent affinity of hGLUT1 for 2DOG compares 
with Ki(app) for 2DOG inhibition of glucose entry in human red cells at 4 ˚C of 1.4 mM 
and with Km(app) for 2DOG uptake by red cells at 4 ˚C of 0.6 mM. Ki(app) for 2DOG 
inhibition of sorbose entry in human red cells at 22˚C is 7 mM (24) 
These observations in yeast illuminate a long-standing problem in the field of 
human erythrocyte sugar transport. The Michaelis parameters for D-glucose and 3MG 
uptake by human red cells are 1.6 mM and 5 mM respectively (63). However, Ki(app) for 
glucose and 3MG inhibition of L-sorbose uptake by human red cells are 7 mM and 14 
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mM respectively (6). These discrepancies between half-saturation constants for transport 
and transport inhibition have led some to suggest that sugar transport measurements in 
human red cells are technically flawed owing to: 1) complications arising from interactions 
of transported sugar with intracellular sugar binding species and/or, 2) the extremely high 
sugar transport capacity of red cells which makes accurate estimates of initial rates of 
transport difficult to attain  (9, 157, 166, 167). Support for this hypothesis is available 
from recent measurements of 3MG transport by human red cells at 22 ˚C made using a 
rapid quench device that permits msec resolution of transport. These studies indicate 
Km(app) for net 3MG uptake by red cells is 15 - 25mM (101, 160). 
The transport properties of RE700-5’UTR-GLUT1-HA-H6 differ from those of 
human red blood cells in several important ways. These include: 1) Km(app) for net 
transport of sugar is indistinguishable from Ki(app) for sugar-inhibition of transport of a 
second sugar. 2) Sugar uptake is unaffected by extracellular reductant. 3) Net sugar uptake 
at subsaturating [3MG] is a simple mono-exponential process (τ = 400sec). 4) CB-
inhibition of sugar uptake shows simple, saturable (Michaelis) inhibition. In human red 
cells, Ki(app) for sugar inhibition of uptake of a second sugar is normally greater than 
Km(app) for net uptake of the sugar (summarized in (24)). Net sugar uptake in erythrocytes 
is inhibited by 50% by reductant (65, 93). 3MG uptake by human red cells is multiphasic 
consisting of sequential, rapid (τ = 44msec), fast (τ =12sec) and slow (τ =1400 sec) 
phases at room temperature (160). Inhibition of erythrocyte sugar transport by CB is 
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characterized by complex cooperative kinetics at subsaturating [CB] where net sugar 
uptake can be subject to a paradoxical stimulation by inhibitor (16). These differences are 
significant and suggest that the functional properties of human GLUT1 may be 
determined by cellular environment. 
Properties of GLUT1 in other cells 
The possibility that transporter phenotype could be determined by cellular 
environment is not unexpected. GLUT1-mediated sugar transport in human red cells is 
asymmetric (Vmax and Km(app) for net sugar exit > Vmax and Km(app) for net sugar entry), is 
characterized by trans-acceleration (intracellular sugar stimulates unidirectional uptake of 
radiolabeled sugar;(158)) and is inhibited by extracellular reductant (65). GLUT1-
mediated sugar transport in rabbit red cells and metabolically depleted avian erythrocytes 
is symmetric, does not display trans-acceleration (98, 168-170)  but is inhibited (in avian 
red cells) by reductant (98, 169). These differences could be explained by subtle 
differences between the primary structures of human and avian GLUT1 (85% identical) 
or rabbit GLUT1 (97% identical to human). Rat erythrocyte GLUT1 is kinetically 
symmetric and has been reported to lack (171) or to display (172, 173) accelerated 
exchange transport. Rat GLUT1 is 98% identical to human GLUT1. Human GLUT1 
expressed in Xenopus oocytes displays transacceleration (174) but is not inhibited by 
extracellular reductant(65). Primary sequence differences cannot account for the disparate 
behavior of human GLUT1 in yeast, Xenopus oocytes and human red cells. The absence 
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of transacceleration in RE700A-GLUT1-HA-H6 (Figure 2.7A) is unrelated to the 
introduction of a modified GLUT1 carboxy-terminal region because the same construct 
catalyzes transacceleration when expressed in HEK cells (Figure 2.7B). 
Accelerated exchange and kinetic asymmetry are not obligate properties of carrier-
mediated sugar transport. For example, rat GluT4 – the insulin-sensitive sugar transporter 
(1) – shares 65% identity and 83% similarity with GLUT1 but is kinetically symmetric 
and does not display accelerated exchange (175). Passive sugar transport in giant axons of 
Loligo forbesi is asymmetric but shows trans-inhibition(176). Passive sugar transport in 
isolated, striated muscle cells of Balanus nubilis is symmetric and lacks trans-
acceleration or inhibition (177). Human erythrocyte sugar transport in red cell ghosts 
lacking ATP at 4 ºC is symmetric (versus asymmetric in the presence of ATP) but 
continues to display accelerated exchange (129). At 37ºC, ATP-containing red cells lose 
kinetic asymmetry and trans-acceleration . Trans-acceleration is also lost in rat red cells 
at 40ºC(172). These observations indicate that cytoplasmic factors and temperature 
profoundly influence GLUT1 phenotype.  
A model of GLUT1-mediated transport 
We have proposed that human GLUT1 forms a reductant-sensitive GLUT1 
homotetramer in the red cell membrane (65). When reduced, the transporter complex 
dissociates into GLUT1 dimers. Tetrameric GLUT1 interacts allosterically with 
cytoplasmic ATP(88, 99, 147). This interaction promotes conformational changes in 
GLUT1 cytoplasmic domains (136) leading to formation of a “cytoplasmic cage” that 
encloses the exit site of the translocation pathway and introduces a noncatalytic sugar 
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binding site within the cage thus delaying release of sugar into cytosol(93). Reductant 
causes dissociation of tetrameric GLUT1, loss of GLUT1 ATP binding capacity (99) and 
loss of the “cytoplasmic cage”. In the absence of ATP, the “cytoplasmic cage” is relaxed, 
the noncatalytic sugar binding site is lost and transport asymmetry (which is proposed to 
result from substrate recycling within the cage) is reduced (93, 101, 160). We therefore 
propose that RE700A-GLUT1-HA-H6 exists predominantly as a “reduced” GLUT1 
homodimer. However, it should be noted that while the so-called “cage-hypothesis” can 
account for ATP- and reductant-sensitivity of GLUT1 sugar transport asymmetry, it does 
not account for the lack of human GLUT1-sensitivity to reductant in Xenopus oocytes 
and S. cerevisiae  - tissues where GLUT1 displays transacceleration and no trans-
acceleration respectively. 
The RE700A GLUT1 heterologous expression system may provide a useful 
model for systematic analysis of environmental factors and GLUT1 primary structural 
details that influence GLUT1-mediated sugar transport. It may also prove useful in the 
development of genetic and pharmacodynamic screens for molecules that modulate 
GLUT1 activity. RE700A expresses hGLUT1 at a level approximately 10-fold lower than 
that observed in human red blood cells. RE700A may, therefore, also serve a rich source 
of recombinant hGLUT1.  
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1The abbreviations used are: GLUT1 - Human Glucose Transporter Type 1 
(SCL2A), GLUT1DS - GLUT1 Deficiency Syndrome, CA - Cytochalasin A, CB - 
Cytochalasin B, CC - Cytochalasin C, CD - Cytochalasin D, CE - Cytochalasin E, CH - 
Cytochalasin H, CJ - Cytochalasin J,  e1 - endofacial sugar binding site, e2 - exofacial 
sugar binding site, 3MG - 3-O-Methyl Glucose, FSK - Forskolin, 1,6DiA-FSK - 1,6 Di 
Acetyl Forskolin, 6A-FSK - 6 Acetyl Forskolin, 7FPPNEA-FSK - 7-{2-[3-(4-
Fluorophenyl)propanamido]-N-ethyl-7-aminocarbonyl} Forskolin, 7DeA-FSK - 7 
Deacetyl Forskolin, 7-FPA-FSK - 7-(4-Fluorophenyl)acyl Forskolin, 1DeO-FSK - 1 
Deoxy-Forskolin, 9DeO-FSK - 9 Deoxy Forskolin, 7FA-FSK - 7-Fluoroacetyl Forskolin, 
1A-FSK - 1 Acetyl Forskolin, 14,15DiH-FSK - 14, 15 Dihydro Forskolin, 7FPP-FSK - 7-
[3-(4-Fluorophenyl)propionyl] forskolin, 6A,7DeA-FSK - 6 Acetyl, 7 DeAcetyl 
Forskolin.
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ABSTRACT 
Cytochalasin B (CB) and forskolin (FSK) inhibit GLUT1-mediated sugar 
transport in red cells by binding at or close to the GLUT1 sugar export site. 
Paradoxically, very low concentrations of these inhibitors produce a modest stimulation 
of sugar transport (Cloherty, E. K., Levine, K. B., & Carruthers, A. (2001). The red blood 
cell glucose transporter presents multiple, nucleotide-sensitive sugar exit sites. 
Biochemistry, 40(51), 15549-15561). This result is consistent with the hypothesis that the 
glucose transporter contains multiple, interacting, intracellular binding sites for CB and 
FSK. The present study tests this hypothesis directly and, by screening a library of 
cytochalasin and forskolin analogues, asks what structural features of exit site ligands 
determine binding site affinity and cooperativity. Like CB, FSK competitively inhibits 
exchange 3-O-methylglucose transport (sugar uptake in cells containing intracellular 
sugar) but non-competitively inhibits sugar uptake into cells lacking sugar. This refutes 
the hypothesis that FSK binds at the sugar import site in addition to the sugar export site. 
Some forskolin derivatives and cytochalasins inhibit equilibrium [3H]-CB binding to red 
cell membranes depleted of peripheral proteins. Others produce a modest stimulation of 
[3H]-CB binding when introduced at low concentrations but inhibit binding as their 
concentration is increased. Yet other analogs modestly stimulate [3H]-CB binding at all 
inhibitor concentrations applied. These findings are explained by a carrier that presents at 
least two interacting endofacial binding sites for CB or FSK. We discuss this result 
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within the context of GLUT1 quaternary structure and evaluate the major determinants of 
ligand binding affinity and cooperativity. 
       
102 
INTRODUCTION 
Cellular exchange of nutrients, ions and metabolites proceeds via membrane-
spanning proteins called channels and carriers (24).  The Major Facilitator Superfamily of 
carriers is responsible for the largest portion of nutrient transport in cells (46) and among 
these carriers, the sugar porter sub-family is one of the oldest and largest family 
classifications. 
Sugar porters catalyze both cellular sugar import and export but net sugar 
transport always proceeds from high to low sugar concentration. The first human sugar 
transporter to be isolated was the erythrocyte membrane protein GLUT1 (133, 178).  
GLUT1 is primarily expressed in the cardiovascular system and astrocytes and mediates 
glucose transport across blood-tissue barriers (179). Any one of several mutations in 
GLUT1 results in GLUT1 Deficiency Syndrome (GLUT1DS) in which reduced glucose 
transport into the brain leads to developmental defects and seizures (43). 
Hydropathy analysis, scanning glycosylation mutagenesis and proteolytic 
digestion studies confirm that GLUT1 (a 55 kDa protein) contains twelve alpha-helical 
transmembrane domains (73).  Each GLUT1 polypeptide is thought to function as a 
simple carrier (85), presenting either a sugar uptake or a sugar exit site at any given 
moment.  However, the simple carrier model does not explain the complex behavior of 
GLUT1 in human red cells (9) where the association of GLUT1 monomers into 
cooperative oligomers promotes an obligate, functionally antiparallel arrangement of 
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subunits such that any given GLUT1 complex displays uptake and efflux sites 
simultaneously (158). 
Scanning cysteine mutagenesis analysis (80) suggests that the GLUT1 sugar 
uptake site involves portions of alpha-helical, transmembrane spanning regions 1, 5, 7, 8 
and 11.  Peptide mapping studies of affinity labeled GLUT1 suggest that the exit site 
contains a subdomain of membrane spanning regions 10 and 11 (13). However, specific 
GLUT1 residues contacting glucose in GLUT1 import (e2) and export (e1) 
conformations are unknown.   
The present study characterizes the GLUT1 export conformation by analysis of 
inhibitor binding to the GLUT1 exit site.  Comprehensive analysis of GLUT1 interaction 
with a library of inhibitors may reveal details of the complementary relationship between 
ligand and binding pocket structures.  We selected GLUT1 endofacial site inhibitors and 
their derivatives for this analysis. Cytochalasin B (CB) is a cell-permeable alkaloid that 
disrupts actin filaments and inhibits glucose transport (180).  Forskolin (FSK) is a cell-
permeable diterpenoid that inhibits GLUT1 and activates adenylate cyclase (107). Both 
CB and FSK are thought to bind to the endofacial orientation of GLUT1 where they act 
as noncompetitive inhibitors of erythrocyte glucose uptake and competitive inhibitors of 
exit ((17, 97 , 107) and this work).  These e1 inhibitors have also been docked to an 
homology-based, theoretical GLUT1 structure where they are proposed to bind to 
cytoplasmic domains of the carrier (5). Our findings confirm that export-site inhibitors 
inhibit ligand binding by two mechanisms - direct competition and cooperative inhibition 
- and provide new insights into the molecular determinants of each type of inhibition. 
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MATERIALS AND METHODS 
SOLUTIONS:  
Kaline consisted of 150 mM KCl, 5 mM MgCl2, 5 mM EGTA, 5mM HEPES, pH 
7.4. Lysis buffer contained 10 mM Tris-HCl, 2mM EDTA, pH 8.0. Stripping solution 
contained 2 mM EDTA, 15.4 mM NaOH, pH 12. Sugar-stop solution consisted of ice-
cold Kaline containing 20 µM CB and 200 µM phloretin. 
MATERIALS:  
[3H]-3-O-methylglucose, [3H]-cytochalasin B, and [3H]-forskolin were purchased 
from Sigma Chemicals. Human blood was purchased from Biological Specialties 
Cooperation. Other reagents were purchased from Sigma Chemicals.  
RED CELLS:  
Red cells were isolated from whole human blood by centrifugation as described 
previously(9). 
RED CELL MEMBRANES:  
Red cell membranes depleted of peripheral membrane proteins (including the 
cytochalasin B binding protein actin) were prepared as described in (93). 
3-O-METHYLGLUCOSE UPTAKE:  
Zero trans 3MG uptake (3MG uptake into cells lacking intracellular sugar) and 
equilibrium exchange 3MG sugar uptake (unidirectional [3H]-3MG uptake in cells where 
intracellular [3MG] = extracellular [3MG]) were measured at 4 ºC as described 
previously ((9); (131)). 
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FORSKOLIN OR CYTOCHALASIN B INHIBITION OF 3MG TRANSPORT  
3MG uptake was measured as described above in the absence and presence of 
cytochalasin B, forskolin or their derivatives. Inhibitor concentrations ranged from 10-9 -
10-4 M using ethanol or dimethylsulfoxide as carriers. Carrier concentration never 
exceeded 0.1% (vol:vol) and is without effect on sugar transport rates. Cells were pre-
incubated with inhibitor of 15 minutes on ice before starting uptake measurements. When 
transport inhibition was profound (> 75%), the uptake interval was extended to permit 
more accurate determinations of uptake.  
LIGAND BINDING COMPETITION ASSAY    
Stripped ghosts (peripheral protein-depleted membranes) were diluted to 2 mg/ml 
in 50 mM Tris medium, pH 7.4 at 4ºC.  Ligand binding assay solutions comprised Tris 
medium plus 50 nM unlabeled CB, 1 µCi/ml [3H]-CB plus a range of inhibitor (I) 
concentrations (0 - 100 µM). Some ligand binding assays substituted 50 nM forskolin and 
1 µCi/ml [3H]-forskolin for cytochalasin B. Binding assays were as described previously 
(96).  Membranes (50 µL) and ligand binding solutions (50 µL) were mixed in a micro 
centrifuge tube and, following 15 minutes of inversion at 4ºC, two 10 µL aliquots were 
sampled (Total dpms).  The tubes were centrifuged at 14,000 rpm for 5 minutes, and two 
10 µL aliquots of the supernatant were sampled (Free dpms).  ‘Bound’ dpms were 
calculated as the difference between ‘total’ and ‘free’ dpms. Each inhibitor concentration 
was tested three times in triplicate. 
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LIGAND BINDING TO GLUT1 - THEORY 
 Equilibrium cytochalasin B and forskolin binding to GLUT1 display non-
Michaelis kinetics at low ligand concentrations ((16); (7)).   The simplest model that 
accounts for this behavior (see Scheme 1) assumes that the glucose transporter complex 
presents two interacting binding sites for e1 ligands. This could be explained either by 
two sites on one transport protein or two interacting transport proteins each with one site. 
When presented with a binary mixture of ligands (e.g. radio-ligand plus inhibitor I), the 
transporter, e, may form several liganded states: e (unliganded transporter), 2(I. e), 
2(L.e), 2(I.e.L), L.e.L and I.e.I.  
Inhibition Scheme 3.1 
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Cooperative interactions between binding sites (positive or negative 
cooperativity) may depend on whether the first and second ligands to bind are identical or 
different. For example, the ligand CB might enhance binding of the remaining site for CB 
(α < 1; positive homo-cooperativity) but reduce the affinity of the remaining site for 
inhibitor I (β > 1; negative hetero-cooperativity). 
Ligand (L) binding to GLUT1 in the presence of a competing e1 inhibitor I is 
described by: 
where Bmax = 0.5[GLUT1] and Kd(app) is given by: 
and where KL, KI, α, β and γ are shown in scheme 1. In a typical experiment, the ratio of 
bound : free ligand is measured as a function of competing e1 inhibitor I. The ratio of 
inhibited : control binding (b'/b) is thus obtained as:
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This analysis assumes that all binding and dissociation steps are rapid with respect 
to the time of measurement and that free and bound ligand achieve true equilibrium. 
These assumptions are most likely satisfied because cytochalasin B binding to GLUT1 
occurs with a time constant of 1 sec at 4ºC ((158); (181)) whereas binding was measured 
over a period of 15 minutes (> 1,000 half-lives).This model allows for several possible 
effects of  inhibitor (I) on ligand (L) binding. 
1 Binding is not cooperative. When binding of L and I at any single site is 
mutually exclusive and lacks hetero-cooperativity (β = 1; Figure 3.1, curve a), the 
inhibitor I will serve as a simple competitive inhibitor of L binding. 
2 Binding is negatively cooperative. When binding of L and I at any single 
site is mutually exclusive and displays negative hetero-cooperativity (β > 1; Figure 3.1, 
curve b), the inhibitor I will appear to serve as a simple competitive inhibitor of L 
binding although the inhibition dose response is shifted to the left. 
3 Binding is positively cooperative. When binding of L and I at any single 
site is mutually exclusive but displays positive hetero-cooperativity between sites (β < 1; 
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Figure 3.1, curve c), the inhibitor I will enhance L binding at low [I] where I and L bind 
at adjacent sites. When [I] is increased further such that I and L compete for binding to 
the same site, L binding is inhibited. 
4 Zero hetero-cooperativity and positive or negative homo-cooperativity. 
When binding of L and I at any single site is mutually exclusive but displays zero hetero-
cooperativity but positive homo-cooperativity (i.e. β = 1 and γ <1; Figure 3.1, curve d), 
the inhibitor I will inhibit L binding more effectively (the inhibition curve is left-shifted). 
If the inhibitor I displays negative homo-cooperativity, I will be a less effective inhibitor 
and maximum inhibition will be reduced (i.e. β = 1 and γ >1; Figure 3.1, curve e). 
5 Positive hetero-cooperativity and positive or negative homo-
cooperativity. When binding of L and I at any single site is mutually exclusive but 
displays positive-hetero-cooperativity and positive homo-cooperativity (i.e. β << 1 and γ 
<<1; Figure 1, curve f), the inhibitor I will enhance L binding at low [I] and inhibit 
binding at greater [I]. If the inhibitor I displays negative homo-cooperativity (γ >>1) but 
strong positive hetero-cooperativity (β << 1), I will enhance ligand binding at all [I] 
(Figure 3.1, curve g). 
Ligand binding was calculated as the ratio ligand bound in the presence of 
inhibitor (b’) to ligand bound in the absence of inhibitor (b). b’/b was plotted against [I] 
(see Figure 1) and binding was analyzed using eqn 3 and the method of least squares 
using the software programs Kaleidagraph (v 4.03, Synergy Software) or ProFit (v 6.13, 
Quantum Soft). When cytochalasin B inhibition of [3H]-cytochalasin B binding (or 
forskolin inhibition of [3H]- forskolin) was measured, the analysis simplifies considerably 
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because α = β = γ and KL = Ki. Thus the homo-inhibition experiment allow the 
unambiguous calculation of KL and α for cytochalasin B and forskolin (Table 3.1). These 
values may then be substituted directly into eqn 3 leaving only 3 parameters to solve for 
in hetero-inhibition experiments: β, γ and Ki.
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Figure 3.1 Simulations of effects of inhibitors on cytochalasin B binding to GLUT1 
when each transporter complex contains two interacting binding sites .  
Ordinate: CB binding in the presence of an inhibitor/CB binding in the absence of 
inhibitor (calculated using equation 3).  Abscissa: inhibitor concentration in µM (note the 
log scale). Seven (a-g) scenarios were simulated. In each instance KL for CB binding, Ki 
for inhibitor binding and α (cooperativity between CB binding sites when only the CB is 
present) were set at 0.25 µM, 1 µM and 1 respectively. The curves show: a, β = γ = 1; b β 
=10, γ = 1; c β = 0.1, γ = 1; d β = 1, γ = 0.1; e β = 1, γ = 10; f β = γ = 0.1; g β = 0.1, γ = 
100. 
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Figure 3.2 Erythrocyte sugar transport inhibition by forskolin.   
 Panels A & B, Ordinate: initial rate of 3MG uptake (mmol/L cell water/min). 
Abscissa: [3MG] mM. Results are shown as mean ± SEM of at least 3 experiments made 
in quadruplicate. Uptake was measured in the absence (○) and presence (●) of 2 µM 
FSK. Curves drawn through the points were computed by nonlinear regression assuming 
that 3MG uptake follows simple Michaelis-Menten kinetics. A Zero-trans 3MG uptake 
(cells lack intracellular sugar). Control: Kmapp = 1.51 ± 0.22 mM;  Vmax = 0.114 ± 0.009 
mM/L/min; R2 = 0.995. FSK: Kmapp = 1.09 ± 0.15 mM; Vmax = 0.055 ± 0.004 mM/L/min., 
R2 = 0.994. B Equilibrium-exchange 3MG uptake (intracellular [sugar]= extracellular 
[sugar]). Control: Kmapp = 17.8 ± 4.7 mM; Vmax = 6.5 ± 0.7 mM/L/min, R2 = 0.981. FSK: 
Kmapp = 48.5 ± 7.3 mM; Vmax = 8.3 ± 0.7 mM/L/min, R2 = 0.997. 
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RESULTS 
Cytochalasin B is a competitive inhibitor of equilibrium exchange transport in 
erythrocytes (156) and a noncompetitive inhibitor of net sugar uptake into red cells 
lacking sugar (97). Equilibrium exchange transport is a condition in which intra- and 
extracellular [sugar] are identical and unidirectional fluxes are monitored through use of 
tracer sugar.  Competitive inhibition by cytochalasin B indicates that extra- or 
intracellular sugar compete with cytochalasin B for binding to the transporter. 
Noncompetitive inhibition of uptake into cells lacking sugar indicates the absence of 
competition between extracellular sugar and inhibitor at the uptake site. This aggregate 
behavior is characteristic of an inhibitor that binds at (or whose binding site is mutually 
exclusive with) the sugar export site ((97)). 
Forskolin is a competitive inhibitor of cytochalasin B binding to the human 
erythrocyte sugar transporter (182) suggesting that forskolin, like cytochalasin B binds at 
or close to the transporter sugar export site. In support of this hypothesis, we observe that 
forskolin acts as a noncompetitive inhibitor of net sugar uptake (Figure 3.2A) and as a 
competitive inhibitor of exchange sugar uptake (Figure 3.2B) in human erythrocytes. 
Forskolin reduces Vmax for sugar uptake by sugar-depleted cells but increases Km(app) for 
equilibrium exchange transport. Assuming noncompetitive and competitive inhibition of 
3MG zero-trans and equilibrium exchange transport respectively, Ki(app) for FSK inhibition 
of net and exchange transport are 1.9 ± 0.4 µM and 1.2 ± 0.6 µM respectively. 
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Figure 3.3 A Modulation of [3H]-CB binding to red cell membranes by forskolin and its 
derivatives.   
Ordinate: The ratio CB binding in the presence of forskolin to CB binding in the absence 
of forskolin. Abscissa: [forskolin], µM (note the log scale). Results are shown as mean of 
at least 3 separate measurements made in quadruplicate. Standard errors about the mean 
are ≤ 10% of the averaged data. CB binding was measured at 50 nM [3H]-CB. Results are 
shown for inhibition by FSK (○), 7DAFSK (●) and 1DOFSK (∆). Curves drawn through 
the points were computed by nonlinear regression using equation 3.  Based on CB 
inhibition of [3H]-CB, Kl and α were set at 0.25 ± 0.03 µM and 0.52 ± 0.26 respectively. 
The results are: FSK, Ki = 2.13 ± 0.45 µM, β = 0.48 ± 0.05, γ = 1.13 ± 0.26, R2 = 0.979. 
7DeA-FSK, Ki = 0.07 ± 0.01 µM, β = 0.36 ± 0.01, γ = ∞, R2 = 0.86. 1DO-FSK, Ki = 0.20 
± 0.10 µM, β = 0.34 ± 0.01, γ = 58 ± 29, R2 = 0.975. B Modulation of [3H]-FSK binding 
to red cell membranes by unlabeled forskolin.  Ordinate: The ratio [3H]-FSK binding in 
the presence of forskolin to [3H]-FSK binding in the absence of forskolin. Abscissa: 
[forskolin], µM (note the log scale). Results are shown as mean ± SEM of 3 separate 
measurements made in quadruplicate. [3H]-FSK binding was measured at 50 nM [3H]-
FSK. The curve drawn through the points was computed by nonlinear regression using 
equation 3. The results are:, Ki = KL = 2.13 ± 0.45 µM and α = β = γ = 0.88 ± 0.31, R2 = 
0.939. 
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We screened the ability of forskolin and its derivatives to displace cytochalasin B 
from GLUT1 by measuring forskolin inhibition of equilibrium 3H-cytochalasin B binding 
to red cell  membranes depleted of peripheral membrane proteins.  Cytochalasin B 
binding to peripheral membrane protein-depleted human red cell membranes, is 
competitively displaced by D-glucose and other GLUT1 substrates and is quantitatively 
accounted for by ligand binding to GLUT1 ((183); (86)).  
Forskolin and its derivatives modify cytochalasin B (50 nM) binding to GLUT1 in 
several interesting ways (Figure 3.3).  Some forskolins (see Figure 3.3A and Table 3.1) 
appear to function as simple inhibitors of cytochalasin B binding in which inhibition is a 
saturable function in [forskolin]. Other forskolins (see Figure 3.3A and Table 3.1) first 
enhance then inhibit cytochalasin B binding as the concentration of the inhibitor is raised. 
Yet other inhibitor analogs simply increase cytochalasin B binding (see Figure 3.3A and 
Table 3.1) while others appear to be without effect. 
These behaviors are predicted by a simple binding model (Scheme 1) in which each 
transporter complex presents two cytochalasin B or forskolin binding sites that interact in 
ways that are dependent upon the nature of the bound ligands. For example, if binding of 
a forskolin derivative at the first site increases the affinity of the second site for 
cytochalasin B or the forskolin derivative, cytochalasin B binding may be enhanced at 
low [forskolin] then inhibited as [forskolin] is raised and competes more effectively with 
cytochalasin B for binding at the second site. Other permutations are possible (see 
Scheme 1 and Figure 3.1) and, according to the model, the net effect of any [forskolin] on 
cytochalasin B binding is determined by 5 parameters: KL (Kd for cytochalasin B 
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binding), Ki (Kd for forskolin derivative binding), α (a cooperativity factor indicating how 
cytochalasin B binding at the first site impacts Kd(app) for cytochalasin B binding at the 
second site), β (a cooperativity factor indicating how cytochalasin B binding at the first  
site impacts Kd(app) for forskolin binding at the second site and vice versa) and γ (a 
cooperativity factor indicating how forskolin binding at the first site impacts Kd(app) for 
forskolin binding at the second site). In homo-inhibition studies where, for example, the 
radioligand and unlabeled competing ligand are the same species (e.g. cytochalasin B or 
forskolin), KL = Ki and α = β = γ thereby simplifying analysis of experimental data to the 
resolution of two affinity parameters -  KL and α. These values may then be explicitly 
inserted into binding equation 3 thereby reducing the challenge of non-linear curve fitting 
of forskolin-modulation of cytochalasin B binding (hetero-inhibition) to the resolution of 
3 parameters - Ki, β and γ. 
Tests for internal consistency mandate that studies of unlabeled forskolin 
inhibition of [3H]-forskolin binding to GLUT1 (forskolin homo-inhibition) provide 
values for  KL and α (2.12 ± 0.35 µM and 0.88 ± 0.31 respectively, see Figure 3.3B) that 
that are indistinguishable from Ki and γ (2.13 ± 0.45 µM and 1.13 ± 0.26 respectively) 
obtained in studies of forskolin-modulation of [3H]-cytochalasin B binding (hetero-
inhibition). 
Table 3.1 summarizes the results of hetero-inhibition studies in which the effects 
of a wide range of forskolin analogues on [3H]-cytochalasin B binding were measured. 
Figure 3.4 and Table 3.1 summarize the results of similar studies in which the effects of a 
number of cytochalasin analogues on [3H]-cytochalasin B binding were measured. 
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Table 3.1 Modulation of  3H cytochalasin B binding to red cell membranes by 
cytochalasins and forskolins - summary of findings.  
The results of analyses such as those in Figures 3 and 4 are summarized for the 
cytochalasins and the forskolins. The concentration of radioligand ([3H]-CB) was 50 nM 
in all experiments. aThe concentration of unlabeled competing ligand was varied from 0 
to 100 µM. Analysis of binding inhibition was carried out as described in Figures 2 and 3 
using equation 3.  bKi (µM) represents the affinity of unoccupied GLUT1 for ligand. cGº 
was calculated as RT ln(1/Ki). d∆∆Gº was calculated as the change in ∆Gº using the 
lowest Ki for cytochalasins or foskolins as the baseline. e,f,gAnalysis according to 
equation 3 also permits computation of the cooperativity parameters β and γ and yields a 
correlation coefficient R2. hTypes of inhibition are: Michaelis like inhibition (curves a & 
e, Figure 3.1); stimulation followed by inhibition (curves c & f, Figure 3.1);  high and 
low affinity inhibition (curve d, Figure 3.1); stimulation (curve g, Figure 3.1) and no 
effect. iThese types of inhibition are related to the product β*γ. . jKL (µM) and kα for CB 
binding were computed in studies of CB inhibition of [3H]-CB binding and assume that α 
= β = γ.  lWhile γ parameters are ligand dependent, β parameters appear to be invariant 
and are averaged for the cytochalasins and forskolins (mean ± SEM). mNo effect on 
binding was observed. In all experiments, at least three complete dose responses were 
performed with each data point in triplicate and averaged at each concentration to 
perform the final analysis.  Ligand structures shown in Tables 3.2 and 3.3. 
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Table 3.1 – Modulation of GLUT1 Cytochalasin B binding by cytochalasins and forskolins 
aLigand bKI µM 
cΔG 
kcal/mol 
dΔΔG 
kcal/mol 
eβ fγ gR2 
hInh. 
Sche
me 
iβ*γ 
         
CB 0.25 ± 0.03 -8.37 0.00 0.52 ± 0.26 0.52 ± 0.26 0.995 f 0.4 
CD 111.7 ± 14.8 -5.01 3.36 1.00 ± 0.12 0.67 0.906 f 0.7 
CH 2.08 ± 0.39 -7.20 1.17 0.34 ± 0.03 7.1 ± 0.55 0.946 f 2.4 
CJ 1.37 ± 3.11 -7.43 0.94 0.55 ± 0.13 41.4 ± 66.3 0.927 c 22.8 
CE 0.53 ± 0.31 -7.95 0.41 0.47 ± 0.04 363 ± 44 0.823 c 170.6 
CA 1.44 ± 0.88 -7.40 0.96 0.35 ± 0.12 93.365 0.999 f 31627.8 
CC 1.87 ± 1.11 -7.26 1.11 0.34 ± 0.08 ∞ 0.915 g ∞ 
         
CB jKL µM 0.25 ± 0.03  lmean 0.510     
CB kα 0.52 ± 0.03   ± 0.088     
         
FSK 2.13 ± 0.45 -7.19 2.73 0.48 ± 0.05 1.13 ± 0.26 0.979 f 0.5 
14,15 DiH-FSK 1.27 ± 0.03 -7.47 2.44 0.467 ± 0.031 4.49 ± 0.68 0.969 f 2.1 
1A-FSK 0.99 ± 0.31 -7.61 2.31 0.32 ± 0.18 21 ± 7 0.850 f 6.7 
9DeO-FSK 0.269 ± 0.25 -8.33 1.59 0.37 ± 0.01 127 ± 119 0.852 f 10.8 
7FA-FSK 0.651 ± 0.45 -7.84 2.08 0.375 ± 0.012 29.2 ± 1.9 0.972 f 11.0 
1DeO-FSK 0.20 ± 0.10 -8.49 1.43 0.34 ± 0.01 58 ± 29 0.975 f 19.7 
6A-FSK 0.015 ± 0.021 -9.92 0 0.36 ± 0.01 555 ± 27 0.994 c 199.8 
1,6DiA-FSK 0.018 ± 0.58 -9.82 0.10 0.38 ± 0.01 621 ± 46 0.976 c 236.0 
7FPA-FSK 0.109 ± 0.35 -8.82 1.09 0.43 ± 0.01 1230 ± 404 0.823 c 528.9 
7FPPNEA-FSK 0.02 ± 0.04 -9.76 0.16 0.33 ± 0.01 36858 ± 83397 0.748 g 12073.1 
7DeA-FSK 0.07 ± 0.10 -9.07 0.85 0.36 ± 0.01 ∞ 0.860 g ∞ 
6A,7DeA-FSK NAm   NA NA NA c  
7FPP-FSK NA   NA NA NA e  
         
   lmean 0.378     
    ± 0.016     
Table 3.1  
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Figure 3.4 Modulation of cytochalasin B binding to red cell membranes by 
cytochalasins.   
Ordinate: The ratio CB binding in the presence of forskolin to CB binding in the absence 
of cytochalasins. Abscissa: [cytochalasin], µM (note the log scale). Results are shown as 
mean of at least 3 separate measurements made in quadruplicate. Standard errors about 
the mean are ≤ 10% of the averaged data. CB binding was measured at 50 nM [3H]-CB. 
Results are shown for inhibition by CB (○), CC (●) and CH (∆). Curves drawn through 
the points were computed by nonlinear regression using equation 3.  The results are: CB, 
Ki = KL = 0.25 ± 0.03 µM and α = β = γ = 0.52 ± 0.26, R2 = 0.995. CC, Ki = 1.87 ± 0.11 
µM, β = 0.34 ± 0.06, γ = ∞, R2 = 0.915. CH, Ki = 2.08 ± 0.39 µM, β = 0.34 ± 0.03, γ = 
7.1 ± 0.55, R2 = 0.946. 
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DISCUSSION 
GLUT1 LIGANDS & TETRAMERIC COOPERATIVITY 
The human type 1 glucose transporter (GLUT1) is inhibited by diverse natural 
compounds. Methylxanthines and ATP act as mixed-type inhibitors of sugar exit 
reducing Vmax and increasing Km(app) (98, 184, 185). Cytochalasins and forskolins increase 
Km(app) for exchange transport and reduce Vmax for net entry (see here and (97, 107, 156)). 
Tyrosine kinase inhibitors are competitive inhibitors of sugar import (186) and the 
androgens and catechins reduce Vmax for exit and increase Km(app) for uptake (106). These 
observations are consistent with the hypothesis that cytochalasins and forskolins bind at 
or close to the sugar export site and that the tyrosine kinase inhibitors, androgens and 
catechins bind at or close to the sugar import site (106). Methylxanthines and ATP appear 
to modulate transport by acting at a site(s) distinct from import and exit sites. 
Recent studies have revealed an unexpected complexity in transport inhibition by 
import and export site inhibitors. When presented at very low concentrations, the import 
site inhibitor maltose or the exit site inhibitors cytochalasin B (CB) or forskolin (FSK) 
modestly stimulate sugar import in human red blood cells (7, 16). As inhibitor 
concentration is increased, sugar import stimulation is replaced by transport inhibition. 
The simplest explanation for this behavior is that the sugar transporter contains 2 
interaction sites for import site inhibitors and two sites for export site inhibitors. When 
one import or export interaction site is occupied by inhibitor, the transporter is converted 
into a high affinity, high capacity sugar transporter that catalyzes greater net transport (7). 
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As the concentration of inhibitor is increased further, the second import or export site is 
occupied and transport is fully inhibited. 
This behavior is consistent with the structural and functional properties of 
GLUT1.  Each GLUT1 protein functions as a sugar transport pathway by isomerizing 
rapidly between two states - e2, exposing an exofacial, sugar import site and e1, exposing 
an endofacial, sugar export site(8). Overall behavior, however, is determined by 
transporter quaternary structure. Red cell GLUT1 is a dimer of GLUT1 dimers (65). Each 
dimer always contains one subunit presenting the e2 state and one subunit presenting the 
e1 state (12). CB binding to the e1 subunit of any dimer inhibits transport through each 
subunit of the occupied dimer but stimulates transport through the neighboring 
unoccupied dimer. As the concentration of cytochalasin B is increased, an e1 subunit 
within the neighboring unoccupied dimer becomes complexed with cytochalasin B and 
transport via both dimers is inhibited (7, 16). The goals of the present study were to 
understand the structural features of cytochalasin B and forskolin that determine ligand 
binding affinity and dimer-dimer cooperativity. 
CYTOCHALASIN AND FORSKOLIN DERIVATIVE ANALYSIS  
The cytochalasins (Table 3.2) share a common rigid bicyclic isoindoline core 
fused to a macrocycle. CB shows the greatest affinity for GLUT1 (Kd(app) = 0.25 µM), and 
an auto-inhibition profile consistent with scheme f in Fig 3.1. Dehydration of the 
macrocycle hydroxyl group to form cytochalasin A (CA) maps to scheme g, and results 
in a 6-fold loss of affinity for GLUT1 (∆∆Gº = 1 kcal/mol). This group may serve as a 
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Table 3.2 Cytochalasin derivative structures.  
KL and γ are also shown (taken from Table 3.1) to facilitate comparison. 
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Table 3.3 Forskolin derivative structures.  
KL and γ are also shown (taken from Table 3.1) to facilitate comparison. 
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hydrogen bond donor. Shortening the macrocycle by three carbon atoms reduces GLUT1 
affinity for ligands by 5- to 8-fold (cytochalasins C, H and J; ∆∆Gº = 0.9 - 1.2 kcal/mol). 
This may result from the loss of van der Waal’s interactions or from the resultant mis-
location of the macrocycle hydroxyl group within the binding site. Addition of an acetyl 
group to the macrocycle ketone does not affect ligand binding (CC and CH versus CA). 
Addition of a carbonyl at position 5 of a shortened macrocycle is without effect on 
binding affinity (compare CJ and CC). However, subsequent methyl substitution at 
position 5 of the bicyclic isoindoline reduces binding affinity by 55-fold (compare CD 
and CC; ∆∆Gº = 2.25 kcal/mol). This suggests that the cytochalasin binding pocket can 
tolerate reduced molecular motion at each position but not at both. 
The forskolins (FSK; Table 3.3) are a family of labdane diterpenes known 
primarily for their activation of adenylyl cyclase (187). FSK derivatives containing acetyl 
groups at positions 6 and 7 show greatest affinity for GLUT1. Substitution of both groups 
with hydroxyl groups results in a 3-fold loss in FSK binding affinity (∆∆Gº = 0.9 
kcal/mol). Deacylation at position 7 results in the complete loss of FSK binding affinity 
whereas loss of the acyl group at position 6 (to form the parent molecule FSK) results in 
a 500-fold loss of affinity (∆∆Gº = 3.6 kcal/mol). Deacylation at position 6 is partially 
mitigated by introduction of an acetyl group at position 1 (10-fold recovery in affinity), 
by removal of hydroxyl groups at positions 1 (50-fold recovery of affinity) or 9 (30-fold 
recovery of affinity) or, by conversion of the acetaldehyde to a formyl fluoride (16-fold 
recovery). FSK binding tolerates hydroxyl, acetyl, formyl fluoride, fluorophenylacetyl 
and fluorophenyl propanamidoethylcarbamic group additions at position 7. 
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Cytochalasins and forskolins show a similar cooperativity parameter (ß = 0.44 ± 
0.05) for binding to the second site when the first site is occupied by CB. This positive 
hetero-cooperativity means that forskolin or cytochalasin occupancy of the first site 
increases the affinity of the second site cytochalasin B by two-fold and vice versa. CB-
inhibition of radiolabeled CB binding also displays positive cooperativity (α = 0.5 ± 0.3, 
Fig 3.1 scheme f) whereas forskolin inhibition of radiolabeled forskolin binding is not 
cooperative (α = 0.9 ± 0.3, Fig 3.1 scheme d). This suggests that β - the cooperativity 
factor describing binding site interactions when different ligands bind at sites 1 and 2 - is 
determined by the ligand whose binding is experimentally measured (in this case the 
radioligand). This is consistent with the observation that the cooperativity parameter γ - 
describing the effect of occupancy of the first site by unlabeled inhibitor on unlabeled 
inhibitor binding to the second site - is determined by the nature of the unlabeled 
inhibitor. 
Cytochalasin D, while displaying only poor affinity for GLUT1, shows the same 
homo-cooperativity (γ = 0.7, scheme f) for binding to GLUT1 as does CB (γ = 0.52 ± 
0.26, scheme f). Cytochalasin C differs from CD only at position 5 of the bicyclic 
isoindoline but has a homo-cooperativity γ parameter of infinity. This means that CD 
cannot bind at the second site when the first site is occupied by CD. Dehydration of the 
CB macrocycle hydroxyl group to form CA results in 180,000-fold increase in γ 
suggesting that loss of a hydrogen bond donor at this position promotes negative 
cooperativity between sites (Fig 3.1, scheme g). Addition of an acetyl group to the 
macrocycle ketone is without great effect on γ. 
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Addition of a single acyl group to forskolin at positions 1 or 6 or extension of the 
acyl group at position 7 significantly increase γ. Simultaneous additions of acyl groups at 
positions 1 and 6 have neither additive nor synergistic effects on γ, and both map to 
cooperativity scheme f in Fig 3.1.  Elimination of hydroxyl groups at positions 1 or 9 
(schemes f, Fig 3.1) or elimination of the acyl group at position 7 (scheme e, Fig 3.1) 
greatly increase γ.  γ  and Ki(app) appear to be inversely related. 
CURRENT VS. CLASSIC CYTOCHALASIN STUDIES 
Previous studies have examined cytochalasin and forskolin inhibition of sugar 
transport and cytochalasin B binding in human red cells (107, 121, 182, 188) and 
forskolin inhibition of energized D-galactose transport by the GalP sugar-H+ symport 
protein of Escherichia coli (189). The present study differs from previous studies in that 
our analysis of inhibition of ligand binding to GLUT1 allows for two interacting ligand 
binding sites. 
In their study of cytochalasin inhibition of [3H]-cytochalasin B binding to GLUT1 
in red cell membranes (188) Rampal and coworkers revealed that only CA and CB inhibit 
CB binding with high affinity. The remaining cytochalasins (CC through CH) were 
extremely low affinity inhibitors (Ki(app) > 100 µM). While this result appears to contradict 
our observations, closer inspection reveals that Ki(app) for occupation of the second ligand 
binding site by cytochalasin analogs (provided in our study as the product γKi), 
corresponds to Ki(app) observed by Rampal et al (188). For example, CE inhibition of CB 
binding is characterized by β, γ and Ki parameters of 0.47 ± 0.04, 363 ± 44 and 0.53 ± 
0.31 µM respectively. This means that CB binding is inhibited by ≤ 5% over the CE 
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concentration range 0 to 0.5 µM then by an additional 6% over the CE concentration 
range 1 to 25 µM. Analysis assuming a single ligand binding site would result in Ki(app) of 
222 ± 76 µM. Rampal et al report that Ki(app) ≥ 100 µM. As with our previous studies 
showing that low concentrations of “inhibitors” can produce a paradoxical stimulation of 
transport (7, 16), the key to these observations is the use of inhibitor concentrations that 
span Kd(app) by ± 2 log units. 
CLASSIC VS. COOPERATIVE ANALYSIS 
When considering cooperativity, the ‘gold standard’ measure in the literature is 
the application of the Hill equation, derived by A.V. Hill to model the binding of oxygen 
to hemoglobin (190).  While many variants on the Hill equation are utilized to measure 
binding site interactions, this analysis is not useful to the current study for the following 
reasons.  1) The Hill equation does not allow for appreciable concentrations of binding 
intermediates in competitive analysis, 2) is it not intended to measure competition 
analysis between ligands of varying natures, and 3) the Hill equation was designed with 
the assumption of strong positive cooperativity between ligand sites as in the hemoglobin 
model; negative cooperativity reduces the Hill coefficient to a minimum of 1(191).  The 
model derived from Scheme 1 allows for analysis of positive and negative homo- and 
hetero- cooperativity, which closely reflects observed stimulatory and inhibitory binding 
behavior seen in our dose-response data. 
LIGAND BINDING SITE NUMBER AND POTENTIAL LOCATIONS 
GLUT1 three-dimensional structure has been modeled using the crystal structure 
of GlpT (an E. Coli MFS protein) as an homology template and human glucose-6-
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phosphate translocase as an “evolutionary template” to correct for missing residue 
assignments in the homology-based analysis (5). The resulting structure has been docked 
with a variety of GLUT1 ligands (cytochalasin B, forskolin, glucose, galactose, mannose, 
quecertin and phloretin) to reveal potential substrate binding sites (5, 112). 
Salas-Burgos et al. suggest that GLUT1 presents two binding sites (exofacial and 
endofacial) for forskolin, phloretin and glucose but only one endofacial site for 
cytochalasin B. (5)An exofacial phloretin and glucose binding site is consistent with the 
observed competition between substrate and phloretin during sugar uptake. However, 
forskolin is a noncompetitive inhibitor of sugar uptake (see here and (107)), hence the red 
cell sugar import site and the putative exofacial site are not functionally analogous 
because docking analysis predicts that glucose and forskolin compete for binding. 
Forskolin is proposed to make H-bond acceptor contacts with the GLUT1 endofacial site 
via hydroxyl or carbonyl groups at forskolin positions 6, 9 and 11. Contrary to this 
suggestion, elimination of the hydroxyl group at position 9 is observed to enhance the 
affinity of ligand binding but also increases homo-negative-cooperativity (γ) by 130-fold. 
Deviations between experimental and modeled behavior are not unexpected. A recent 
study demonstrates that the use of homology-based threading to model LacY and GlpT 
structures results in the correct overall transporter architecture but incorrect alignment of 
key residues within active sites (192). 
CB is proposed to dock with GLUT1 at a single site comprising portions of 
GLUT1 cytoplasmic loops 2, 6 and 10 (5). The available experiment data suggest that CB 
interacts with GLUT1 transmembrane helices 10 and 11 and loop 10 (13, 116, 163). 
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Photo activation of CB complexed with loop 2 of one subunit could react covalently with 
loop 10 of the same subunit or with loop 10 of an adjacent subunit provided that loops 2 
and 10 approach within approximately 1.6 nm. The lone hydroxyl group on the CB 
macrocycle is postulated to form a hydrogen bond with the backbone carbonyl of leucine 
85 (5). This is consistent with our observation that macrocycle shortening or dehydration 
of the macrocycle OH results in a significant loss of binding affinity. Reduced binding 
affinity may cause the ligand to extend its molecular envelope into the cytochalasin 
binding pocket of an adjacent subunit thereby inhibiting ligand binding at the second site 
(negative cooperativity; Figure 3.5 A-B)
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Figure 3.5 Model of Cooperative Inhibition Interactions. 
Panel A shows a GLUT1 tetramer (see (11)) viewed from the interstitium. Two subunits 
(blue) are shown in the e2 conformation each presenting an import site and two subunits 
(a and b) are shown in the e1 conformation (their sugar binding sites are not visible 
because they are exposed to the cytoplasm). Panel B shows the e1 subunits a and b 
viewed normal to the bilayer and each sectioned directly through its catalytic center.  
According to Salas-Burgos et al (5), the cytochalasin binding site is located close to TM3. 
These subunits are oriented such that TM 3 on subunit a faces TM3 on subunit b (subunit 
b is rotated 180º relative to subunit a about the central axis of the tetramer). If the 
molecular envelope of cytochalasin bound to subunit a overlaps with that of cytochalasin 
bound to subunit b, this could account for strong negative cooperativity as observed, for 
example, with CA. Holman and Rees (13) suggest that the CB binding site lies closer to 
TMs 10 and 11 which would require that the opposite half of each GLUT1 molecule 
(TMs 9 and 12 most likely) form the oligomerization interface. Panel C hypothesizes that 
ligand interaction with subunit a promotes a conformational change in both subunits 
which, in this instance enhances the affinity of subunit b for ligand. 
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 Fig 3.5 
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CHAPTER IV 
 
MUTAGENIC AND CHIMERIC ANALYSIS OF 
LIGAND BINDING DETERMINANTS AT THE 
GLUT1 ENDOFACIAL BINDING SITE  
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ABSTRACT 
Cytochalasin B (CB) inhibits GLUT1 substrate transport by binding at or near the 
endofacial sugar binding site. N-bromosuccinamide analysis combined with 3H-CB 
photolabeling implicates the region between Trp388 and Trp412 in ligand binding (13). 
Although the GLUT1 structure has been modeled(5), the specific residues comprising the 
sugar binding site are unknown.  Constructs of mutant, exofacially myc tagged GLUT1 
were expressed in HEK293 cells to test residues for effective CB inhibition of 2 deoxy 
glucose uptake (2-DG).  A series of alanine point mutants were made at residues 
implicated by docking studies to be involved in cytochalasin B binding: Ser80, Arg400,  
and a double mutant Phe88,Arg92 (5).  In addition, alanine substitutions were made at the 
proposed CB photolabeling site Trp412 (117), and at sites where missense GLUT1 DS 
point mutants are observed - Arg126 and Cys421 (44, 193).  Expression was verified by 
Western blot and surface localization by immunofluorescence.   Phe88, Arg92 and 
Trp412 alanine mutants only weakly expressed, while Ser80 does not express at the 
membrane.  The ranking of 2-DG uptake by construct is GLUT1Arg126Ala > 
GLUT1Arg200Ala > GLUT1Cys421Ala as compared to myc tagged GLUT1 expressed 
in HEK cells. CB inhibition of 2-DG uptake by GLUT1Arg126Ala and 
GLUT1Cys421Ala is significantly different (α=0.05) to inhibition of myc tagged GLUT1 
mediated sugar uptake. GLUTArg400Ala also shows a moderate decrease in affinity for 
CB, suggesting its involvement in CB binding. In addition, GLUT1 chimeras were made 
by exchanging the sequence Trp388-Trp412 with the corresponding region of either 
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GLUT4 or GLUT5.  GLUT5 shows very low affinity for CB.  GLUT1/GLUT4388-
412/GLUT1 is a point mutation (Ile404Met) which shows statistically reduced  sensitivity 
to CB inhibition. The GLUT1/GLUT5388-412/GLUT1 chimera shows enhanced 2-DG 
uptake at 50nM CB but normal inhibition by higher concentrations of CB. We conclude 
that point mutants in this region are insufficient to abrogate CB binding, that the Trp388 
to Trp412 sequence is necessary for CB photolabeling and binding affinity, but is not the 
major determinant of high affinity inhibition of 2 deoxyglucose uptake by CB.
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INTRODUCTION 
The structural mechanisms of integral membrane protein mediated nutrient 
transport are unknown. Two superfamilies of nutrient transport proteins or carriers 
mediate cellular import and export of metabolites: the ATP Binding Cassette (ABC) 
superfamily comprised of primary active carriers, and the Major Facilitator Superfamily 
(MFS) containing primary and secondary active, single-polypeptide, integral membrane 
carriers.   The oldest and largest subfamily of the MFS is the sugar porter family.  To date 
thirteen hexose transporters (GLUT1-12, HMIT) have been characterized in humans, 
each of which exhibits its own tissue distribution and unique catalytic properties.   These 
thirteen porters may be further subdivided by sequence similarity into three groups.  
Group 1 (1-4) transporters primarily mediate glucose flux, were the first sugar porters 
discovered, and are the best characterized to date. GLUT2 expressed in liver, pancreas, 
and the intestine transports glucose with low affinity, while GLUT1 expressed in 
erythrocytes, endothelial and smooth muscle cells, GLUT3 expressed in neurons and 
GLUT4 expressed in adipocytes and skeletal muscle cells transport glucose with high 
affinity. Group 1 transporters are inhibited by phloretin, forskolin, and cytochalasin B. 
Since carcinomas typically up regulate GLUT1 and glycolysis, chemical inhibition of 
carrier-mediated sugar may be instrumental in starving tumorigenic masses. 
Group 2 GLUTs (5,7,9,11)  and Group 3 GLUTs (6,8,10,12,HMIT) are less well 
studied. Group 2 porters primarily transport fructose. GLUT5 and GLUT7 are expressed 
in the intestine, and GLUT9 and GLUT11 are expressed in the kidney, liver, heart, and 
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pancreas. Group 3 porters have an enlarged exofacial loop between transmembrane 
helices 10 and 11 and transport glucose or fructose. The exception is HMIT, a neuronal 
H+/myo inositol symporter highly expressed in the brain.  Neither Group 2 nor Group 3 
sugar porters are inhibited by cytochalasin B.  This inhibitor is hypothesized to compete 
for sugar efflux by binding at the endofacial (e1) sugar binding site of the Group 1 
primary glucose transporters.  
Human GLUT1 has been extensively characterized; it comprises twelve 
transmembrane-spanning alpha helices (TMs)(73), is heterogeneously glycosylated at N-
45 (40), presents both N- and C- termini to the cytosol, and TMs 6 and 7 are linked by a 
large intracellular loop.  Each GLUT1 molecule is a functional sugar uniporter(85), and is 
thought to present only one sugar binding site, endofacial or exofacial, at any point in 
time (7, 16). GLUT1 self-associates in lipid bilayers as dimers or tetramers (65, 87). 
Kinetic analyses have suggested that the functional arrangement of subunits provides an 
obligate, antiparallel arrangement of binding sites such that the GLUT1 tetramer presents 
two endofacial and two exofacial binding sites at all times(98, 158).  Salas-Burgos et al 
threaded the GLUT1 sequence through the GlpT folding scaffold providing a convenient 
model for hypothesis testing (5).  Docking analysis of this structure and cytochalasin B 
(CB) suggests that CB binds near the edge of the endofacial sugar binding vestibule. 
Moreover, CB can photo-crosslink specifically to GLUT1 under UV light.  Holman and 
Rees used  n-bromosuccinamide proteolysis in combination with radiolabeled CB and 
peptide mapping to determine the smallest fragment of GLUT1 bound to CB.  This 
fragment is between W387 and W412 of GLUT1, in TM’s 10 and 11 (13).  Mutation of 
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tryptophan residues flanking the CB-labeled peptide abrogates CB photolabeling (117, 
122). 
CB competes for glucose efflux and may directly interact with the e1 sugar 
binding site (180 , 194).  Point mutations in GLUT1 result in a heritable heterozygous 
disease known as GLUT1 deficiency syndrome (GLUT1DS), characterized by growth 
defects, mental retardation, and epileptic-like seizures (19).  A few clinical cases of 
GLUT1DS present with reduced sensitivity to CB inhibition, readily testable via 
erythrocyte uptake of radiotracer glucose (42, 44). Some of these point mutants, such as 
C421(195) or R126(193), may be within the e1 binding site. Systematic exploration of 
these sequences may target domains important in endofacial sugar binding. 
GLUT5 shares approximately 50% sequence similarity with GLUT1 (2, 196) and 
is proposed to resemble GLUT1 in its helical packing arrangement. Although transport of 
high fructose concentrations (≥1mM) in GLUT5-expressing oocytes is not inhibited by 
CB (197, 198), GLUT5-mediated transport of low concentrations (~100µM) of 
radiolabeled glucose (199) or fructose (this work) is inhibited by CB but with greatly 
increased KI(App).  This suggests a strategy for isolating determinants of CB binding to 
Group 1 transporters – the construction of Group 1 – Group 2 chimeras.  Inukai et al 
expressed chimeras of GLUT1 and GLUT5 in X. laevis oocytes, and found the second 
half of GLUT1 (i.e. TM’s 7-12) is crucial to glucose transport and CB photolabeling 
(200).  
The aim of this work is to further deduce the location of the e1 binding site in 
GLUT1 by analysis of GLUT1 mutant sensitivity to inhibition by CB.  To this end we 
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express point mutants and W388-W412 chimeras in HEK293 cells, and determine CB’s 
ability to inhibit 2-deoxyglucose uptake. 
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MATERIALS & METHODS 
REAGENTS 
Unless otherwise stated, all tissue culture medium and reagents, including 
Dubelco’s Modified Eagle Medium (DMEM) ± glucose, trypsin, and1X sterile PBS, were 
purchased from Gibco.  Tissue culture dishes obtained from Nunc.  Fetal Bovine Serum 
was obtained from Hyclone.  Lipofectamine and Herculase were purchased from 
Invitrogen.  PCR primers were ordered from Integrated DNA Technologies (IDT), and 
restriction endonucleases, phosphorylases, and ligases purchased from New England 
Biolabs (NEB). 3H 2 deoxy glucose (3H 2-DG), Cytochalasin B and all other salts and 
nonradioactive reagents were purchased from the Sigma Chemical Company.  
VectashieldTM immunofluorescence mounting agent was purchased from Vector Labs.  
BioMol C-myc primary antibody was purchased from BioMol, and secondary antibodies 
goat anti rabbit HRP, and goat anti mouse HRP from BioRad, while secondary goat-anti-
mouse FITC was from Caltag Laboratories.  Protease Inhibitor Cocktail tablets (-EDTA) 
were obtained from Roche.  Competent cells used were either XL-1 Blue Supercompetent 
Cells from Stratagene, or lab-grown strains of DH5α treated with the Zymo Z-Competent 
Cells kit. 
SOLUTIONS 
 Unless stated otherwise, all buffers used were GIBCO sterile phosphate 
buffered saline supplemented with 5mM MgCl2 pH 7.4  (PBS).  
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 3H 2DG Uptake  Radioactive uptake solution is 100 µM 2-deoxy glucose 
supplemented with 3H 2-DG in PBS, or 100µM fructose supplemented with C14 labeled 
fructose.  Radiolabel was typically added to 2 µCi/mL uptake.  ‘Stop’ medium is 100 µM 
CB and 100µM phloretin in PBS.  Assays in which increasing doses of CB were added to 
the uptake medium also included an identical concentration of cytochalasin in both the 
pre-uptake and radiolabeled uptake solution.  CB solutions were all diluted from a 
parental stock solution containing a maximum of 10% DMSO or ethanol; dose solutions 
were normalized to contain 0.1% ethanol or DMSO.  Triton lysis solution contains PBS + 
5mM MgCl2 pH 7.4 treated with 0.5% Triton and 10X Roche Protease Inhibitor Cocktail. 
Immunofluorescence Solutions  A stock solution of 5% gelatin in PBS was made, 
and diluted into PBS for 1% block solution, or diluted to 0.5% and mixed with 1:350 
BioMol C-Myc Antibody or 1:900 Caltag Goat Anti-Rabbit antibody.  4% 
paraformaldehyde made in PBS. 
HEK CELL MAINTENANCE 
 HEK-293 cell stocks were grown using 10cm Nunc tissue culture dishes.  
Medium was GIBCO High Glucose DMEM, supplemented with 10% fetal bovine serum 
and 1x GIBCO penicillin/streptomycin.  (D10) Cell confluence before splitting was 
visually judged using a light microscope; cells were considered 50% confluent when the 
area covered by cells was equal to that yet uncolonized.  90% confluent stock plates were 
typically split using a 1 minute incubation with Trypsin 1X (GIBCO), followed by 
aspiration.  The dishes were gently knocked against each other, after which the cells were 
easily washed free with D10.    Cells were separated by resuspension using a 200µL 
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plastic tip placed over a 10 mL sterile pipet; the media was pipetted up and down a 
minimum of three times against the tissue culture dish to dislodge and separate cells.  
Stock plates were typically split 1:5 mother: daughter, and would usually grow to 90% 
confluence within five days.  After passage 22, cells were discarded and stock parental 
cells would be thawed. 
HEK CELL FREEZING 
 Low passage number (<5) cells were split as above and grown to almost 
100% confluence, typically in units of 10 plates.  These cells were trypsinized, suspended 
in media, pelleted in a 4ºC centrifuge, and resuspended in antibiotic free media 
supplemented with 10% DMSO to a volume of 1mL/10cm dish.  500 µL were aliquoted 
into cryo-vials and stored in liquid nitrogen. 
HEK CELL TRANSFECTION 
Hemocytometer counted HEK cells were seeded at a density of one million cells 
per well of a 12 well Nunc tissue culture multi-dish (approximately 2.9 x 105 cells/cm3) 
and grown overnight at 37ºC (up to 16 hrs) to 70-80% confluence.  HEK cells were 
transiently transfected using Invitrogen’s Lipofectamine 2000 reagent in accordance with 
the package directions.  Briefly, 1.6 µg of DNA was diluted in 100 µL serum-free tissue 
culture media, and 4 µL of Lipofectamine was diluted into an equal volume of media.  
After five minutes at 21ºC, these working reagents were combined and incubated for a 
minimum of 30 minutes at ambient temperature.  During the reagent incubation, the 
media covering the cells was changed from D10 to 37ºC High Glucose DMEM with 10% 
Fetal Bovine Serum lacking antibiotic.  After the media change, 200 µL of working 
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reagent were gently pipetted into each well.  The transfected cells were grown for a 
further 36-48 hours before being used for experiments, expression timeframe initially 
determined by Western Blot with C-terminal GluT1 Ab. (Fig 4.3) 
WESTERN BLOTTING 
Western Blot analyses were made using c-myc primary mouse antibody (1:700) 
or GLUT1 c-terminal rabbit antibody (1:5000) as described here (66). 
IMMUNOFLUORESCENCE FOR SURFACE EXPRESSION VERIFICATION 
Unless stated differently, all incubations were at room temperature (22ºC).  Round 
glass cover slips were sterilized by washing with neat ethanol followed by irradiation 
under UV light for 10 minutes, cover slips were then placed one/well in a Nunc 6 well 
dish.  HEK cells were seeded at a density of 1x106 cells per well, and transfected with 4.0 
µg of DNA and 10µL of Lipofectamine.  After 36-48 hours post transfection, plates were 
washed with PBS, covered with fresh 4% paraformaldehyde, and incubated on a rocker 
for 20 minutes. Wells designated to have permeable cells were rinsed with PBS once and 
covered with 0.5% Triton for 5 minutes with agitation.  Plates were washed at least 3X w/ 
PBS, and blocked for 30 minutes using 1% gelatin.  Cells were then covered with BioMol 
C-myc primary antibody SA-294, at 1:350 dilution in 0.5% gelatin, incubated for 1 hour, 
then rinsed 4x5min with PBS.  Cells were covered with goat anti-mouse antibody (1:900) 
in 0.5% gelatin, wrapped in aluminum foil, incubated for an hour, then rinsed in a 
darkened room 8x5min with PBS on a rocker.  Cover slips were lightly aspirated and 
wet-mounted on glass slides using 20µL Vectashield and clear nail polish in a darkened 
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room.  Cells were imaged with bright field and the FITC/GFP filter (492 nm) using a 
Zeiss Axioskop 2 upright microscope. 
E1 LIGAND-INHIBITED 3H 2-DG TRANSPORT  
Cells were seeded and transfected as described above.  24 hr post-transfection, 
10µL/mL Geneticin was added to all wells.  40-48 hr post transfection, the medium was 
changed to medium lacking glucose and fetal bovine serum.  Cells were starved of 
glucose and serum for a minimum of two hours prior to uptake, rinsed twice with 37ºC 
PBS, and incubated in PBS ± CB for a minimum of 15 minutes at 37ºC.  PBS was 
aspirated and 400 µL of uptake solution was added to the dish.  After 6 minutes of 
incubation, the uptake solution was aspirated and the cells were rinsed twice with 1 mL 
of ice cold stop solution.  Zero-uptake was measured by adding stop solution prior to 
radiolabeled uptake solution.  After the second stop rinse, 500 µL of Triton lysis solution 
was added to the wells which were then incubated at 37ºC for 30 minutes to ensure 
complete cell lysis.  Lysed cells were subjected to centrifugation for 5 minutes at 4ºC at 
13,000 rpm.  Aliquots (200 µL each) of supernatant were placed into duplicate vials, 
suspended in scintillation fluid, and counted.  Small (10 µL) aliquots of supernatant were 
retained in duplicate and assayed for protein concentration using a Pierce BCA assay in a 
96 well plate. 
 
Sugar uptake was calculated as: 
! 
CMTP =
(AvgCounts)(WellFraction)
Totalprotein
* ( RCP
mol
)  
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CMTP is Counts Per Mol Total Protein, which were converted into units of moles 
of sugar per µg protein. AvgCounts are the average of duplicate samples for each well; 
well fraction is 500µL/200µL, RCP/Mol is radioactive mol 3H 2-DG per µL times 
DPM/µL of solution, and total protein is the BCA estimated total protein content of the 
well. 
RATIONALE FOR AND CONSTRUCTION OF MUTANT GLUT1 
All point mutants were changed to alanine, and made in a GLUT1 containing the 
Myc epitope (EQLISEEDL) in the exofacial loop between residues 55 and 56, to verify 
surface expression.  (The c-myc insertion primer ‘CGCTATGGGGAGAGCATC 
GAGCAAAAGCTTATTTCTGAAGAGGACTTG CTGCCCACCACGCTCACC’ and its 
complement were ordered.  The insertion is italicized.)  Primers were constructed such 
that point mutants were inserted via mismatched base pairs (Table 4.1). The entire 
plasmid was replicated by high-fidelity PCR (Herculase), and the product digested with 
Dpn1.  The PCR product was 
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Table 4.1 Point Mutagenesis Primers 
Primers %gc #GC Bases Sequence 
S80A 64.5 20 31.0 GGGGGCATGATTGGC*TCC*TTCTCTGTGGGCC 
Mutated : GGGGGCATGATTGGC*GCC*TTCTCTGTGGGCC 
F88A,R92A 52.4 22 42.0 CTCTGTGGGCCTTTTCGTT*AAC*CGCTTTGGC*CGG* CGGAATTC 
Mutated  : CTCTGTGGGCCTTTTCGTT*GCC*CGCTTTGGC*GCG* CGGAATTC 
W412A 48.7 19 39.0 GCAGGCTTCTCCAAC*TGG*ACCTCAAATTTCATTGTGGGC 
Mutated  : GCAGGCTTCTCCAAC*GCG*ACCTCAAATTTCATTGTGGGC 
C421A 52.6 20 38.0 GTGGGCATG*TGC*TTCCAGTATGTGGAGCAACTGTGTGG 
Mutated  : GTGGGCATG*GCC*TTCCAGTATGTGGAGCAACTGTGTGG 
R126A 54.1 20 37.0 GCTGATCCTGGGC*CGC*TTCATCATCGGTGTGTACTGC 
Mutated  : GCTGATCCTGGGC*GCC*TTCATCATCGGTGTGTACTGC 
R400A 71.9 23 32.0 CAGCCAGGGTCCA*CGT*CCAGCTGCCATTGCCG 
Mutated  : CAGCCAGGGTCCA*GCC*CCAGC*C*GCCATTGCCG 
GLUT141 
(I404M) 66.7 20 30.0 CCACGTCCAGCTGCC*ATC*GCCGTTGCAGGC 
Mutated  : CCACGTCCAGCTGCC*ATG*GCCGTTGCAGGC 
 a For R400A, a G was switched to a C as a silent mutation to reduce primer 
hairpin formation.  
 
Table 4.2 Horn Mutagenesis Primers 
‘Horn’ Primer Sequence 
GLUT1/ 
GLUT5388-412/ 
GLUT1 
Forward 
CGGCCATCTGCCTTCATGGTGGGGGGCAGTGTGCACT 
GGACCTCAAATTTCATTGTGGGC 
GLUT1/ 
GLUT5388-412/ 
GLUT1 
Reverse 
AGAGGACTGCAGGAAGATCTCAGTGATGAGCAGCGC 
TGGGATGGGGCCAGGACCC 
Italicized fragments are the 5’ extensions corresponding to the GLUT5 insertion 
sequence. 
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Figure 4.1. GLUT1 structural schematic to illustrate mutant loci.   
Structural features of GLUT1 depicted include: the exofacial loop between the 
first and second transmembrane (TM) domains has an n-linked glycosylation site, while 
the large loop between TM6 and 7 and the and N and C termini are located within the 
cytosol.  A.)   GLUT1 point mutations analyzed.  Squares indicate mutations implicated 
in clinical disease, with Arg126 in TM 4 and Cys421 in TM 11.  The hexagon is Trp412, 
which when mutated decreases CB photolabeling.  The circles are residues mapped by 
Salas-Burgos et al to bind CB: Phe88, Arg92 in the TM3-4 endofacial loop, and Arg400 
on TM11 (5).  B.)  GLUT1 chimeras.  The light gray region is Trp388-Trp412, the 
smallest fragment of GLUT1 found photo-crosslinked to CB after N-Bromosuccinamide 
digestion, and the portion of GLUT1 substituted with GLUT5 for the GLUT1/GLUT5388-
412/GLUT1 chimera.  The gray circle is GLUT1Ile404Met, the only amino acid difference 
between GLUT1 and GLUT4 in this highly conserved region. 
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 Figure 4.2.  Sequence Alignment of GLUT1 and GLUT5, as prepared by Genious. 
 Green ‘similarity’ bars indicate identical amino acids.  Each transmembrane 
domain has been boxed for ease of reference.  The 388-412 region crucial to CB 
photolabeling has been highlighted in red. 
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then transformed into Stratagene XL1Blue Supercompetent cells or Z-Competent cells, 
and amplified using plasmid extraction via Qiagen kits.  The insert was verified by 
sequencing and placed in fresh Invitrogen pcDNA 3.1+ expression plasmid via restriction 
digest.  
One endofacial photolabeling mutant (W412) and two exofacial (R126 and C421) 
point mutants that present as clinical GLUT1DS with altered CB affinity were chosen.  
Salas-Burgos et al mapped the GLUT1 sequence onto the GlpT scaffold and docked 
forskolin and cytochalasin B to GLUT1; S80, R400, N88&R92 were chosen from the 
residues that interacted at the presumed e1 interface (5) (Fig 4.1A). 
Two chimeras were constructed for the GLUT1 region between W387 and W412 
– GLUT1/GLUT4388-412/GLUT1 and GLUT1/GLUT5388-412/GLUT1 (Fig 4.1B).  Since 
this region is highly conserved between GLUT1 and GLUT4, only Ile404 had to be 
changed to Met to produce a chimera, via the point mutation.  For construction of the 
GLUT1/GLUT5388-412/GLUT1 chimera we utilized ‘Around the Horn’ PCR.  Briefly, 
primers were made that matched twenty-five base pairs of GLUT1 adjacent to the region 
of interest, with 5’extensions that matched thirty-six base pairs (half) of the desired 
GLUT5 sequence.  These primers were phosporylated using T4 phosphorylase kinase 
(PNK) in T4 ligation buffer, then used with high-fidelity PCR polymerase (Herculase) to 
produce a linear fragment.  This fragment was then circularized by T4 DNA ligase and 
the ligation product used to transform Z-Competent treated cells.  Insertion was verified 
by sequencing.  
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RESULTS 
GLUT1 Mutant Constructs 
Ten constructs were made from an untagged GLUT1 sequence in Invitrogen’s 
pcDNA3.0+ vector background.  The first construct engineered was the insertion of a 
myc epitope sequence (EQULISEEDL) into the TM1-TM2 exofacial loop of GLUT1.  
After sequence validation, all subsequent constructs were made from this Myc-GLUT1 
plasmid.  Seven point mutants were made using mismatched primers, and one chimera 
engineered from ‘around the Horn’ PCR.  A tenth construct, GLUT1-Myc-HAHis was 
made by inserting the myc epitope into a GLUT1 C-terminal HA-His background. All 
constructs displayed at least minimal overexpression of GLUT1 in HEK 293 cells at 36 
hrs post transfection.  To analyze mutant protein sensitivity to CB inhibition, three 
criteria must first be met: protein expression by Western blot, surface expression by 
immunofluorescence, and successful sugar transport to verify function. 
GLUT1 Expression in HEK cells 
IMMUNODETECTION OF OVEREXPRESSED GLUT1 
C terminal antibody immunoblot analysis of transporter expression in HEK 
membranes indicates successful overexpression of GLUT1 and various mutants.  We 
detect the presence of a 50-55 kDa C-terminal Ab reactive protein in the WT, GLUT1-
Myc, GLUT1-Myc-HaHis dual tagged, R400A, and C421A lanes, as opposed to the 
untransfected lane (Fig 4.3).  R126A shows intermediate expression by immunoblot 
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Figure 4.3  HEK293 C-AB Immunoblot Expression of GLUT1.  
Western blot using GLUT1 carboxyl-terminal antibodies (C-Ab) of GLUT1 expressed in 
HEK293 cells. Membranes were isolated by differential centrifugation, resolved by 10% 
SDS-PAGE, and transferred to nitrocellulose for Western blotting. Each lane contains 2 
µg of total membrane protein.  Strongest protein expression by construct proceeds as 
follows: WT (NoTag) GLUT1 > GLUT1-Myc ≥ C421A > R400 > Dual Tagged GLUT1 
Myc+His > R126 > S80A ≥ F88A, R92A ≥ W412A ≥ UTF. 
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Figure 4.4  Expression of c-myc GLUT1 in HEK293 cells.. 
Cells were transfected at 24 hours after splitting, and visualized 36-48 hours after 
transfection.  Cells were fixed with 4% paraformaldehyde, treated with ± 0.5% Triton, 
visualized with  mouse anti-Myc and goat anti-mouse FITC conjugate antibody, and wet 
mounted with Vectashield.  Pictures taken at room temperature, 492 nm setting, on a 
Zeiss Axioskop microscope. Surface untransfected (UTF) and untagged cells were 
indistinguishable from background fluorescence. Top row: Triton treated, untagged 
GLUT1 and UTF cells.  For the second row and all following rows, surface fluorescence 
is on the left, with Triton treated, permeable membranes on the right.  Second row, C-
myc GLUT1. Third row, S80A GLUT1. Note aggregate formation. Fourth row, R126A 
GLUT1. Fifth row, R400A GLUT1.   Bottom row, C421A GLUT1. 
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compared to WT GLUT1 and untransfected.  However, expression of S80A, W412A,  
and F88A, R92A constructs was comparable to untransfected, with S80A showing high 
molecular weight aggregates (Fig. 4.3).  The amount of immunoreactive protein in the 
WT construct-transfected HEK293 cells is comparable to that seen previously in this 
laboratory (66).  This indicates strong overexpression of GLUT1-Myc, GLUT1-Myc-His, 
R400A, and C421A. 
IMMUNOFLUORESCENCE 
Anti-Myc Ab FITC-Immunofluorescence in HEK cells of non-permeabilized (-
Triton X100) Myc-GLUT1-transfected HEK cells shows cell surface Myc-GLUT1 
expression (Fig 4.4).  Untransfected cells ± Triton treatment show fluorescence 
indistinguishable from background.  WT GLUT1 (-Myc) transfected cells display equal 
fluorescence to untransfected cellls; non-permeablized cells show fluorescence 
indistinguishable from background. For F88A-R92A, and W412A constructs, 
fluorescence is indistinguishable from fixed, non-permeablized untransfected cells. S80A 
protein, however, displays low surface expression and appears concentrated in vesicular 
aggregates.  R126A, R400A, and C421A mutants show surface expression as well as 
internal expression in HEK293 cells comparable to myc-tagged GLUT1.  Therefore, we 
conclude that the R126A, R400A, and C421A  mutants are expressed and successfully 
traffic to the plasma membrane. 
Mutant Function Verified by 3H 2 deoxy Glucose Uptake Into HEK Cells  
Functional mutant protein is characterized by successful 2 deoxy glucose (2-DG) 
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Figure 4.5. 100µM 3H 2-DG Uptake by Mutant GLUT1 into HEK293 cells. 
Ordinate: Rate of 2 DG uptake expressed as a percentage of the GLUT1-Myc protein 
uptake rate.  Abscissa lists uptake by vector, with GLUT1/GLUT4W388-W412/GLUT1 
represented as GLUT1/4/1, and GLUT1/GLUT5W388-W412/GLUT1 represented as 
GLUT1/5/1.   Uptake experiments were performed as follows: cells were seeded at 
106/well, transfected in quadruplicate after 24 hours, and assayed 48 hours after 
transfection.  Briefly, cells were starved of glucose and serum for 2 hours, rinsed, 
incubated for 6 minutes with 100µM 3H supplemented 2-DG at 37ºC, rinsed twice with 1 
mL ice cold stop solution, coated with 500µL 0.5% Triton, and incubated for 30 min at 
37ºC to facilitate lysis.  Zero time points had stop solution added before radiolabel.  
Lysed cells were centrifuged, placed in 200µL duplicate aliquots in scintillation vials and 
counted, with 10µL aliquots tested for total protein well content. Total uptake was 
normalized to each day’s mean c-myc tagged GLUT1 uptake. Each point represents a 
mean of three experiments, n=4.  Error bars were the standard deviation of the mean 
divided by the number of wells, then normalized to GLUT1 Myc uptake. 
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uptake.  2-DG is a sugar transported by GLUT1 into the cell and then phosphorylated by 
hexokinase to form 2-deoxy glucose 6-phosphate.  In the absence of significant 
intracellular glucose-6-phosphatase activity, the phosphorylated sugar is trapped in the 
cytosol.  Neither of the GLUT1 binding sites tolerate large, polar substitutions at carbon 6  
(6, 111) thus the phosphorylated sugar is trapped in the cell and does not interfere with 
sugar transport.. 2-DG therefore provides a convenient measure of sugar uptake at 
physiologic temperature and is useful in characterizing successful function of mutant 
GLUT1.   
Fig 4.5 shows uptake catalyzed by point mutant GLUT1 as a percentage of uptake 
of 2 DG catalyzed by each GLUT1 point mutant.  Each mutant assay was made in 
duplicate with n=4 transfected wells, and uptake was determined as a percentage of the 
rate of myc tagged GLUT1 uptake assayed the same day.  Constructs S80A, F88A-R92A, 
and W412A when expressed in HEK cells show total uptake activity that is not 
significantly different from that of untransfected cells.  R400A, R126A, and C421A 
mutant GLUT1 show a more intermediate phenotype, with the approximate ranking being 
R126A>MYC> R400A>C421A.   Because KiApp for 2-DG by native GLUT1 is 10mM 
(66), uptake assays at 100µM 2-DG provide an estimate of the parameter Vmax/Km. 
Uptake (V) may be described as V = [2-DG]*(Vmax/Km) where V is the maximum rate of 
2-DG uptake and Km is that 2-DG concentration where V = Vmax/2.  It therefore follows 
that π = Vmax/Km = V/[2-DG].  Our results indicate that constructs S80A, F88A-R92A, 
and W412A display extremely low π values. Although the formal possibilities remain 
that either Km has increased, resulting in loss of affinity, or that hexokinase activity has 
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been inhibited, we conclude the reduced π values are most likely the result of a 
diminished Vmax due to decreased surface protein expression or other loss of transport 
capacity. 
Cytochalasin B Dose Response 
An alteration in GLUT1 affinity for CB implies that a given mutation may affect the CB 
binding site, and therefore pinpoint specific amino acids contributing to the endofacial 
sugar binding site in the GLUT1 sequence.  Therefore, CB inhibition of 2-DG uptake was 
utilized to measure changes in protein-CB affinity. In the control experiment (Fig 4.6) 
untransfected (UTF) cells show CB sensitive, non-GLUT1, protein mediated uptake with 
an IC50 of 250 ± 60 nM. WT GLUT1 expressed in HEK 293 cells shows an IC50 = 2.7 ± 
0.5 µM for CB. To expedite mutant analysis, three concentrations (50nM, 500nM, 
5000nM) of CB were chosen to test our constructs for altered CB sensitivity. Construct 
rates are compared in two ways after  being expressed as a percentage of the GLUT1-
Myc uninhibited rate: first, by using a two-way ANOVA with a Bonferroni’s post hoc 
test for significance (Fig 4.7), and second by calculating a ratio of Kiapp for the 
concentrations of CB tested. Ratio Ki’s were calculated assuming complete inhibition at 
5000nM CB, using the following equation and presented in Table 4.3.   Bonferroni 
analysis facilitated comparison of data sets, with the values pertaining to  Myc-GLUT1  
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Figure 4.6  HEK293-expressed WT GLUT1 and UTF 6 min uptake of 2DG (0 CCB) and 
CB dose response. 
Ordinate, increasing [CB] in nM.  Abscissa, the rate of 2 DG uptake per minute, 
measured over six minutes.  The experiment was done as in Fig 4.5, with an additional 30 
minute incubation ± each CB concentration after serum starving. GLUT1 (closed 
circles,) IC50  for CB = 2.7 ± 0.5 µM.  Untransfected cells (open circles,) had an IC50 
of 250 ± 60 nM Each point represents a mean of three experiments, n=4.  Error bars were 
calculated as the standard deviation of the mean divided by the number of wells. 
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Figure 4.7   HEK-293 Mutant GLUT1 100 µM 3H 2-DG Uptake sensitivity to 50, 500, 
and 5000 nM CB, normalized to GLUT1-Myc uptake rate.  
 Each point represents a mean of three experiments, n=4. Three concentration “dose 
responses” were carried out to characterize mutant GLUT1 sensitivity to CB.  
Experiments done as seen in Fig 4.6.  Each value was normalized to the internal standard 
of that day’s GLUT1-Myc uptake rate without CB. GLUT1/4/1 on the graph corresponds 
to GLUT1/GLUT4388-412/GLUT1, or Ile404Met.  GLUT1/5/1 on the graph corresponds to 
GLUT1/GLUT5388-412/GLUT1. Statistical significance was assigned by Bonferroni 
analysis, with values significantly different from corresponding GLUT1-Myc CB 
concentrations starred. R126A uninhibited uptake is notable given weak expression by 
Western blot, and a modest stimulation of 2 DG transport by CB may be seen with the 
GLUT1/GLUT5388-412/GLUT1 vector at 50 nM CB. Error bars were the standard 
deviation of the mean divided by the number of wells, then normalized to GLUT1 Myc 
uptake.
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Figure 4.8   HEK-293 Mutant GLUT1 100 µM 3H 2-DG Uptake sensitivity to 50, 500, 
and 5000 nM CB.  
Ordinate: The rate of mutant uptake of 2 DG, expressed as a percentage of 
uninhibited uptake of that protein.  Abscissa lists uptake by vector.   Graph redrawn in 
this manner to further illustrate differences in CB inhibition by construct. Error bars were 
the standard deviation of the mean divided by the number of wells, then normalized to 0 
CCB 6 minute uptake. 
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Fig 4.8 
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reported here. 
For further visual comparison, the same uptake data was compared expressing 
CB-inhibited uptake as a percentage of each uninhibited construct rate.  (Fig 4.8) 
Chimeras of TM10-11 GLUT1/GLUT4388-412/GLUT1  and GLUT1/GLUT5388-
412/GLUT1 were also made and tested for CB sensitivity in the same fashion. 
GLUT1/GLUT4388-412/GLUT1 was significantly different at all CB concentrations from 
the GLUT1-Myc according to the Bonferroni analysis as well as the Kiapp ratio 
approximation (Table 4.3). The apparent activation of GLUT1/GLUT5388-412/GLUT1 
mediated transport by 50 nM CB warranted further investigation.  A more extensive dose 
response experiment was made with n=4 in quadruplicate. (Fig 4.9)  The inhibition of 2-
DG uptake by CB was tested for all constructs except for GLUT5, which was tested by 
measuring the inhibition of 100µM fructose uptake by CB, as GLUT5 does not 
appreciably facilitate 2-DG transport. (Fig 4.10) The data were fit using a modified 
Michaelis-Menton equation to provide initial estimates of IC50 values. Calculated by 
GraphPad Prism with α=0.05, these were 3.07 ± 0.98 µM for GLUT1, 2.91 ± .58 µM for 
GLUT1Myc, 3.04 
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Figure 4.9  HEK293 Mutant GLUT1 constructs in CB Dose Response. 
 Ordinate, increasing [CB] concentration in nM.  Abscissa, percent CB inhbition of 2 DG 
transport, normalized within each vector to uninhibited uptake.  Closed circles () 
GLUT1 WT,  Open circles () c-myc  GLUT1,  Diamonds () GLUT151, and open 
circles () UTF cells; CB inhibition was measured against 100 µM 2 DG  sugar uptake 
over 6 minutes.  Closed triangles are (▲) GLUT5 CB dose response to 100µM 14C 
fructose uptake, normalized to uninhibited uptake of fructose. Each point is a mean of 
three experiments, n=4 transfected wells.  Method used as in Fig 4.5.  Analysis made 
using Kaleidagraph and mutant KI values were determined by fitting the data to a 
modified Michaelis-Menton equation.  Overall inhibition of GLUT1 transfected protein 
Ki are statistically similar to GLUT1-Myc, indicating only subtle changes on CB affinity. 
Error bars were the standard deviation of the mean divided by the number of wells, then 
normalized to 0 CCB 6 min uptake. 
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Figure 4.10.  HEK-293 Expressed Uptake by GLUT5 of 2-DG within error of 
untransfected.uptake of 100µM 3H 2DG at 37ºC . 
Abscissa, the rate of 2 DG uptake per minute, measured over six minutes. This 
experiment performed as described in Fig 4.5, with each point the mean of three 
experiments, n=4.  Error bars were the standard deviation of the mean divided by the 
number of wells. 
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Figure 4.11  Graphical representation of cooperative inhibition of 2 DG uptake by CB 
shows moderate stimulation of sugar transport at low inhibitor concentration. 
Ordinate, increasing [CB] concentration in nM.  Abscissa, percent CB inhbition of 2 DG 
transport, normalized within each vector to uninhibited uptake.  Analysis was made using 
Kaleidagraph.  Closed circles () GLUT1 WT,  Open circles () c-myc  GLUT1,  
Diamonds () GLUT151, and open circles () UTF cells; CB inhibition was measured 
against 100 µM 2 DG  sugar uptake over 6 minutes.  Closed triangles are (▲) GLUT5 
CB dose response to 100µM 14C fructose uptake, normalized to uninhibited uptake of 
fructose. Each point is a mean of three experiments, n=4 transfected wells.  Method used 
as in Fig 4.5.  Analysis made using Kaleidagraph and mutant KI values were determined 
by fitting the data to a multisite, oligomeric fit equation as described in Appendix 1.  
While an increase in first-site CB affinity was seen for GLUT1/5/1, increasing 
concentrations of CB display reduced second-site inhibition of 2 DG uptake.  Overall 
inhibition of GLUT1 transfected construct KIs remaine statistically similar to GLUT1-
Myc, indicating W388-W412 necessary for CB binding and photolabeling of GLUT1 but 
not sufficient for CB inhibition of transport. 
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Table 4.3 Ratio KI/KCB calculations for Abbreviated Dose Responses. 
a A KIApp ratio value, based upon 2 DG uptake by vector normalized to GLUT1-Myc 
uptake, assuming complete inhibition of transport at 5000 nM CB.  Calculated from the 
following eqn: 
  
  This does not give us an exact value, but lets us approximate a KI and compare 
between vectors in a manner alternate to the Bonferroni statistical method.  Unlike the 
Bonferroni, this method is only really useful for comparing two concentrations – 
inhibition of uptake at 50nM and at 500nM vs GLUT1-Myc.  b  ΔG = 
1.987*310*LN(1/(MeanKIApp*0.000000001))/1000.  c The difference between GLUT1-
Myc ΔG and Mutant ΔG.  d The ratio of calculated KIapps, to approximate similarity 
between constructs.  Ratio values less than GLUT1Myc indicate proteins more sensitive 
to CB inhibition of 2 DG uptake, while larger values indicate less overall sensitivity. e 
Because of the stimulation of 2 DG transport by 50nM CB for GLUT1/GLUT5388-
412/GLUT1, we cannot use this method to approximate KI. 
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Vector KI/K50  
50nMa 
KI/K500 
500nMa 
Mean  
KI/KCB 
∆Gº  
(kcal)b ∆∆Gº vs. Myc
c KI 500/KI 50d 
GLUT1-Myc 28.7 158.6 93.7 9.97 0.00 5.53 
WT GLUT1 116.4 222.8 169.6 9.60 0.37 1.91 
R126A 47.9 157.3 102.6 9.91 -0.59 3.28 
R400A 81.6 1603.3 842.4 8.62 1.35 19.66 
C421A 173.5 364.4 269.0 9.32 0.65 2.10 
GLUT1/4/1 130.0 157.3 102.6 9.91 -0.59 3.28 
GLUT1/5/1e -285.1 95.0 N.D. N.D. N.D. N.D. 
UTF 71.2 38.0 54.6 10.30 -1.69 0.53 
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± 0.83 µM for GLUT1/GLUT5388-412/GLUT1 , and 0.42 ± 0.05 µM for untransfected.  
These IC50 values failed to be significantly different than that of GLUT1-Myc uptake by 
a Tukey’s multiple comparison test, arguing that the GLUT1/GLUT5388-412/GLUT1 
chimeric insertion did not effect the CB binding site. 
A multisite fit modeled after CB binding competition was also utilized to analyze 
the data (see Chapter 3 of this work, Appendix 4.1, and Fig 4.11).  Using this method we 
were able to quantify the concentration of CB at which stimulation of 2-DG transport 
occurred: 83 ± 118 nM for WT GLUT1, and 10 ± 39 nM CB for GLUT1/GLUT5388-
412/GLUT1.  When tested by one-way ANOVA with Tukey post hoc (α=0.05), these 
numbers are significantly different than results obtained with UTF and GLUT1-Myc 
constructs. 
 
DISCUSSION 
Cytochalasin B inhibition of and binding to erythrocyte GLUT1 is more complex 
than expected for a simple, alternating conformer carrier (201).  Carruthers et al refuted 
the simple carrier model of GLUT1 sugar transport by analysis of ligand modulation of 
carrier function.  (97). According to the simple carrier model, if GLUT1 behaves as a 
simple uniporter, high concentrations of e2 inhibitor should block e1 inhibitor binding by 
trapping all subunits in e2 or exofacial conformation.  This was not observed.  Rather, the 
occupancy of the e2 site by maltose allosterically modulates the affinity of the e1 site for 
cytochalasin B.  Hamill et al went on to show that low concentrations of maltose 
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stimulate 3-O-MG uptake (7), while  Cloherty et al  found that low concentrations of 
cytochalasin B (5nM) also stimulate 3MG uptake (16).  The simplest model accounting 
for inhibitor data is an obligate, functionally antiparallel tetrameric subunit arrangement 
in which two GLUT1 subunits each present a sugar uptake (e2) site and two subunits 
present sugar export (e1) sites (16).  Robichaud et al analyzed subunit/subunit 
interactions from binding CB and other CB derivative ligands to determine that substrate 
interaction with the tetramer is highly cooperative (202).  This complex behavior 
underscores the importance of the e1 sugar binding site to protein function. 
The location of the CB binding site to GLUT1 is presently unknown, though two 
endofacial locations have been proposed.  The first site was proposed by following 
analysis of limited proteolytic digests of GLUT1.  CB may be covalently cross-linked to 
GLUT1 by UV irradiation, and this in combination with N-bromosuccinamide induced 
cleavage at tryptophan residues, indicates that the smallest 3H-CB labeled GLUT1 
fragment obtained is a peptide comprising W388 through W412 (13).  This cytoplasmic 
domain connects TMs 10 and 11 of the transporter.  Mutation of either W388 or W412 to 
alanine in X. laevis oocytes decreases GLUT1 photolabeling by CB significantly, and 
mutation of both residues eliminates CB binding. (116, 117).  These data argue that the 
W388 to W412 region plays a crucial role in CB binding. 
The second CB binding site was proposed through docking of the ligand to a 
theoretical crystal structure.  Salas-Burgos et al homology modeled the GLUT1 sequence 
onto the protein backbone of GlpT, and computationally docked CB to a binding site in 
an endofacial pocket outside the presumed e1 cavity (5).  According to this in silico 
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analysis, CB interacts with L85, N88, R89, R92, K225, Q250, M251, and R400 in largely 
polar pocket.  This site is 3Å distant from the TM10-11 binding site proposed by Holman 
and Rees (13), but is plausibly close enough to the glucose-binding cavity to interfere 
with glucose docking (5).   
Other data in the literature suggests further residues are involved in CB binding to 
GLUT1.  Analysis of clinical missense GLUT1 mutations reveals sites implicated in the 
CB/GLUT1 interaction (42, 44). R126 is the most common locus for clinical GLUT1DS, 
presenting in the literature as R126H, L, C, K, & E (193).  C421 forms part of the 
putative intramolecular disulfide bridge thought to stabilize tetrameric subunit-subunit 
interactions of GLUT1(65), and mutation to alanine is expected to abrogate cooperative 
CB binding (202).  We discuss each construct analysed in turn. 
GLUT1-MYC  
The presence of the myc epitope tag on GLUT1 does affect CB affinity as 
compared to WT GLUT1.  Comparison of GLUT1-Myc 2 DG uptake to WT GLUT1 
shows significant effect of the epitope tag on CB binding at 500 and 5000 nm CB (Fig 
4.7).  We conclude this effect may be due to either 1) the polar myc epitope on the 
exofacial surface of the protein promotes a conformational change altering distal ligand 
binding, or 2) the myc tag alters subunit-subunit communication and low-concentration 
CB binding cooperativity.  With this in mind, the ability of each point mutant to transport 
2 DG in the presence of CB was compared to GLUT1-Myc rather than WT GLUT1. 
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R126A GLUT1 
The R126 locus is the most common missense mutation resulting in GLUT1 DS, 
and displays altered CB affinity.   The R126A construct 2 DG uptake rate shows mild 
stimulation over GLUT1-Myc (108 ± 6 %),  as well as less CB mediated inhibition of 2 
DG uptake at all concentrations tested.  In collaboration with Dr. Mary Jo Ondrenchen, 
the reported e1-facing GlpT homology-threaded structure of GLUT1 was docked using 
THEMATICS with CB (personal communication, 2007).  The modeling program 
predicted CB interaction with GLUT1 at Y28, R126, and C133.  In this model, R126 
rests in a highly conserved, large polar area of the sequence near the equator of GLUT1. 
It is possible CB binding fixes a GLUT1 subunit in an e1 state that is kinetically 
indistinguishable from direct competition at the same site.  Alternately, R126 may 
function as part of a glucose (or CB) sensing area of the protein, or may be a structural 
lynchpin of successful sugar transport.   Given the proximity of the R126 residue to the 
exofacial side of the membrane, it is unlikely that it participates directly in CB binding to 
the endofacial sugar binding site.  We conclude that mutations at this locus have distal 
effects upon CB binding to GLUT1. 
C421A GLUT1 
It is likely that C421A GLUT1 protein does not form correct oligomeric structures 
in the lipid bilayer, thereby displaying reduced sugar transport.  GLUT1 possesses an 
internal disulfide bond between residues C347 and C421 on the exofacial side of the 
protein. This bond is known to stabilize GLUT1 tertiary structure so that oligomers may 
be formed (65).  Mutation of C421 to alanine shows significantly reduced transport 
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capacity for 2 DG. C421A GLUT1 expression is comparable to WT GLUT1, and C412A 
GLUT1 successfully traffics to the plasma membrane.  When considering the CB 
sensitivity of C421A GLUT1, CB inhibition of 2 DG glucose uptake is significantly 
reduced compared to inhibition of GLUT1-Myc only at 5 µM CB.  The net effects of the 
C421A mutation therefore likely reflect perturbations in the quaternary associations of 
protein subunits, making it unlikely that C421A is within the e1 sugar binding site.  
R400A GLUT1 
The R400A GLUT1 protein behaves similarly to GLUT1-Myc tagged protein.  
This model showed CB interacting directly with the R400 residue of GLUT1 by Salas-
Burgos et al in a theoretical e1 crystal structure (5).  Although R400A GLUT1 protein 
has somewhat less overall expression by Western blot (Fig 4.3), it does express at the 
plasma membrane (Fig 4.4).  Uninhibited 2 DG uptake, 500nM CB & 5000 nM CB 
inhibited uptake of 2 DG are similar to GLUT1-Myc, with the 50 nM CB data point the 
only significant alteration in affinity.  We conclude that while R400A might be involved 
in CB binding, this amino acid substitution alone is not enough to abrogate CB inhibition 
of sugar transport. 
GLUT1/GLUT4388-412/GLUT1 CHIMERA, A.K.A. I404M 
 The point mutation I404M, or the GLUT1/GLUT4388-412/GLUT1 chimera, is less 
sensitive to CB than GLUT1-Myc protein.  This change was suggested because indinavir 
competitively inhibits CB binding to and sugar transport by GLUT4, with half maximal 
inhibition at 10-6M.  Indinavir, however, inhibits GLUT1 with half-maximal effects at 10-
3M, and does not compete with CB for binding to GLUT1 (203).  The GLUT1 W388-
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W412 region is highly conserved between GLUT1 and GLUT4, with I404 in GLUT1 
substituted by a methionine in GLUT4.  The GLUT1/GLUT4388-412/GLUT1 chimera 
showed significantly more transport of 2 DG in the presence of CB, making it likely that 
the I404 residue is necessary for CB affinity for GLUT1.   
GLUT1/GLUT5388-412/GLUT1 CHIMERA 
GLUT5, a group 2 transporter, is highly insensitive to CB (2).  GLUT5 TM10-11 
region shares 58% similarity with GLUT1, and lacks the photolabeling-critical residue 
W388. The GLUT1/GLUT5388-412/GLUT1 chimera transports 2 DG with less CB 
inhibition at 500 and 5000nM CB.  Moreover, the chimera showed a statistically 
significant stimulation of sugar transport at 50 nM CB, prompting us to undertake a more 
extensive dose response analysis.  While the stimulation at 50 nM for the 
GLUT1/GLUT5388-412/GLUT1 chimera was confirmed, the IC50 determined for CB 
inhibition of GLUT1/GLUT5388-412/GLUT1  is not significantly different from that for 
inhibition of  WT or myc-tagged protein.  A multisite analysis of CB inhibition based 
upon CB binding kinetics was developed, and from this KIapp values were calculated for 
the first CB binding site on the tetramer in the presence of 2 DG.  While GLUT1-Myc 
does not display stimulation of 2 DG uptake by 50 nM CB, both WT GLUT1 and 
GLUT1/GLUT5388-412/GLUT1 do.  Interestingly, the first site KIapp for the chimera (10 ± 
39 nM) was almost eightfold less than that of WT GLUT1 (83 ± 118 nM).  The multisite 
fit argues that while the chimera’s first site affinity for CB has increased, after a threshold 
the overall sensitivity of the protein to CB inhibition of sugar transport has decreased, 
likely from a decrease in affinity or cooperativity at the second CB or e1 binding site on 
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the tetramer.  It is also possible that the W388-412 photolabeling region comprises that 
part of the CB binding pocket most important for initial binding of ligand, while another 
section of GLUT1 interacts with CB to functionally inhibit sugar transport.   
CONCLUSIONS AND FUTURE IDEAS 
Overall, we conclude: 1)  CB inhibition of wild-type and myc-tagged GLUT1 
constructs is considerably less potent (Kiapp ≈ 2µM) than inhibition of erythrocyte sugar 
transport (Kiapp=460 nM, (104)).  2) R126A and C421A show altered CB affinity, but are 
not likely part of the e1 sugar binding site.  3)  R400A and GLUT1/GLUT4388-412/GLUT1 
are implicated in CB binding, but do not confer CB insensitivity to the protein. 4)  The 
GLUT1/GLUT5388-412/GLUT1 chimera sequence comprises part of the binding pocket for 
CB but may not be sufficient for CB inhibition of  2 DG transport. 5) W388 is necessary 
for photolabeling of  GLUT1 by CB but not for CB mediated inhibition of sugar uptake. 
Examining the GLUT1/GLUT5 sequence alignment suggests further 
nonconserved areas which may implicate the CB binding site, and in turn, the endofacial 
sugar binding site.  In the Salas-Burgos threaded GLUT1 structure, CB interacts with the 
sugar porter motif RFGRR at residues 88-93 (5).  While attractive, swapping in this 
GLUT5 sequence into GLUT1 is unlikely to result in altered affinity for CB because the 
equivalent GLUT5 sequence (KFGRK) has a similar charge.  Another docking site 
(Q250, M251) might produce a stronger effect upon exchanging residues 248-259 of 
GLUT1 for 254-265 of GLUT5, because the GLUT1 and GLUT5 sequence in this region 
is dissimilar in the arrangement of polar charges.  Lastly, exchanging a region near R126 
(121-139) in the GLUT1/GLUT5 alignment might also perturb binding and determine 
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whether CB inhibition of glucose transport is directly competitive for the e1 site.  GLUT5 
insensitivity to CB may suggest further loci for the endofacial sugar binding site. 
Our results demonstrate that the GLUT1 residues W388 to W412 may form the 
site of CB-GLUT1 covalent association upon UV irradiation but that this region is not the 
only determinant of GLUT1 affinity for CB.  
 
APPENDIX 4.1 
Tetrameric Analysis of GLUT1 Inhibition. 
If we assume a tetramer of GLUT1 subunits, seven configurations of oligomeric 
subunits may successfully bind sugar in the presence of an e1 inhibitor such as CB (Fig 
4.12).  Each GLUT1 tetramer is thought to exist in the membrane as a dimer of dimers; 
when an inhibitor is bound to a dimer it may not transport sugar.  Its partner dimer  in the 
tetramer, however, is unconstrained.  The total rate of sugar entry into HEK cells is the 
sum of four transport-capable conformations.  This may be mathematically represented 
using the following equation, derived from the two-site carrier model for transport(92) as 
well as two-site ligand competition binding(202).   
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α, β, and γ are cooperativity factors used to measure the interactions between 
sites.  Positive cooperativity has a value less than one, while negative has a value 
assumed greater than one.  α measures CB cooperativity for CB binding at the second 
site.  β values are the 2 DG cooperativity for 2 DG at the second site.  γ represents the 
cooperativity effects of CB on the other site for 2 DG binding, and vice versa.  When 
modeling the fit in Kaleidagraph, we made the following assumptions:  that v3 and v4 
were functionally equivalent rates retaining unique (calculated) cooperativity values, that 
Kmapp for 2 DG was 600 µM, S was 100 µM, Kd for CB was the same as Ki for CB,  α=5,  
β=0.5, and γ=1.
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Figure 4.12  Ligand Binding Conformations on Tetrameric GLUT1. 
The seven possible binding conformations in conditions of unidirectional sugar uptake.  S 
= Sugar.  CB = inhibitor, in this case cytochalasin B.   Each GLUT1 tetramer is shown as 
a dimer of dimers.  Transport through the tetramer complex may only occur when a 
bound S has no CB in the same dimer. 
 
  
189 
 
 
 
 
 
 
 
Fig 4.12 
190 
 
 
CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS  
 
 
191 
CONCLUSIONS AND FUTURE DIRECTIONS 
Nutrient importers such as GLUT1 are vital for cellular growth and life.  In this 
thesis we have discussed the effects of cellular context upon GLUT1 function, the 
structural requirements for ligand binding to the endofacial sugar binding site, and which 
regions of GLUT1 primary amino acid sequence comprise the endofacial sugar binding 
site.  Revisiting these conclusions from the previous chapters illuminates future directions 
of study. 
GLUT1 in Cellular Context 
GLUT1 may be regulated by bilayer thickness or bilayer physical state.  Connolly 
et al reconstituted erythrocyte sugar transporters in lipid vesicles with increasing amounts 
of cholesterol, and discovered that glucose transport behavior was abruptly stimulated 
when the membrane contained 15 mole % cholesterol (204).   This stimulation was 
reversible at 17.5 mole % cholesterol, with a modest increase in activity again at 30-40% 
mol cholesterol.  Membrane phase transitions from 0ºC – 65ºC in synthetic lecithin 
bilayers also affected GLUT1 transport rates (205).  These in vitro findings concerning 
GLUT1 behavior and membrane composition demonstrate that GLUT1 function is 
affected by cellular context and lipid composition.   
Erythrocytes are a readily available source of wild type GLUT1, but to facilitate 
mutational analysis of the protein we explored an alternate expression system.  RE700A 
yeast devoid of endogenous glucose transporters were successfully transformed with 
GLUT1, GLUT1 HA-HIS6, and the transport-incompetent mutant GLUT1338-A3.  RE700a 
transformed with wild-type GLUT1 and GLUT1HA-HIS showed GLUT1 specific 
  
192 
behaviors such as growth on yeast medium containing glucose, specific inhibition of 
transport by CB, and uptake of nonmetabolizeable 3-OMG.  Since these phenotypes were 
reversed by 5-fluoro-orotic acid (FOA), yeast plasmid expression of GLUT1 was 
confirmed, making available another expression system for mutant GLUT1. 
However, we soon learned that GLUT1 functions differently in each cellular 
context.  Erythrocyte GLUT1 displays transport asymmetry (Vmax and Km for net sugar 
exit are greater than the equivalent parameters for uptake(63)), intracellular sugar can 
increase the rate of sugar uptake (trans acceleration, (157)), and uptake is inhibited by 
extracellular reductant(65). Compared to erythrocytes, RE700A-GLUT1 is not inhibited 
by extracellular reductant(65), nor does it show trans-acceleration. Oocyte expression of 
GLUT1 is not inhibited by reductant (65) but may show trans-acceleration.  HEK-293 
expression of GLUT1 shows transacceleration but competition with other sugars that 
differs from that competition observed in red cells.  Thus GLUT1 behavior varies by 
expression system. 
These findings underscore the importance of the model system in experimental 
design and expression of mutant proteins, and illustrate the following caveats.  1.) 
Membrane physical state and composition strongly affect function.  The RE700A plasma 
membrane may be significantly different than that of mammalian cells thereby altering 
GLUT1 function. 2.) GLUT1 glycosylation may affect function.  For example, S. 
cerevisiae has N-linked glycosylation machinery resulting in mammalian-like 
glycosylation (206), but the few sugars added are relatively uniform as compared to the 
typical mammalian heterogeneity. This may result in proteins with altered structural and 
  
193 
functional properties.  3.) Protein density vs. ease of culture and purification may limit 
biophysical analysis. Thus, it is important that the context of expression should be 
considered in any course of study. 
EXTENDING THE YEAST EXPRESSION SYSTEM 
In spite of these reservations, questions remain that may be addressed by a 
functional yeast GLUT1 expression system.  GLUT1 immunostaining on a red blood cell 
is distinctly punctate(131), arguing for heterologous associations on the bilayer surface.  
TAT2p, a tryptophan permease native to yeast, is known to associate with detergent-
resistant lipid microdomains (206). Confocal analysis of GLUT-expressing yeast cells 
and spheroplasts may demonstrate GLUT1 inclusion or exclusion from detergent resistant 
lipid microdomains and, given the relative ease of genetic manipulation in S. cerevisiae, 
may offer a powerful model for genetic screening of determinants of GLUT1 lateral 
segregation in the plane of the membrane bilayer. 
Other attractions of a yeast expression system include plate based screening of 
new GLUT1 inhibitors.  Furthermore, yeast’s remarkable facility with homologous 
recombination and second-site mutagenesis could be combined with small molecule 
growth screens to pinpoint ligand binding sites in the GLUT1 sequence. 
Affinity and Cooperativity Determinants 
Many natural compounds inhibit GLUT1 transport. Methylxanthines and ATP act 
as mixed inhibitors of sugar exit, reducing Vmax and increasing Km, but are thought to act 
at areas distinct from sugar binding sites (98, 184, 185).  Androgens and catechins as well 
as tyrosine kinase inhibitors are competitive for sugar import, with reduced Vmax for exit 
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and increased Km for uptake (106, 186). Maltose and phloretin inhibit GLUT1 by 
interacting with the exofacial site, increasing Km for sugar uptake (97, 105).  Forskolin 
(FSK) and cytochalasins reduce Vmax for net entry, indicating noncompetitive inhibition 
of uptake and increase Km of exit, implying direct interaction with the endofacial e1 
binding site (97, 107, 194, 202).  Understanding the structural basis of GLUT1 inhibition 
may elucidate functional ligand binding domains of GLUT1. 
Comparative analysis of the ability of cytochalasin and forskolin derivatives to 
displace cytochalasin B (CB) reveal some determinants of binding at the endofacial sugar 
binding site.  We shall discuss cytochalasin binding first.  All of the cytochalasins share a 
common rigid bicyclic isoindoline moiety plus a macrocyclic ring. Dehydration of the 
macrocycle hydroxyl to form cytochalasin A decreases affinity by 6-fold.  Shortening of 
the macrocycle (e.g. comparing CB to cytochalasin C, H or J) reduces affinity by 5-8 
fold.  Comparison of cytochalasins C and D, indicates that methyl substitution at position 
5 of the isoindoline reduces affinity by 55 fold.  This indicates that the cytochalasin 
binding pocket may tolerate changes at one end of the molecule or the other, but not both.  
CB may be thought of as an ‘open book’ structure, with two planes meeting along a more 
rigid, central ‘spine’.  Altering the planar angle or the size of the ‘pages’ severely limits 
ligand binding. 
We tested the GLUT1 binding capabilities of an extensive library of forskolin 
shapes to characterize its binding pocket.  Forskolins with acetyl groups at 6 and 7 
showed the greatest affinity for GLUT1; replacement of both acetyls with hydroxyls 
results in a complete loss of binding affinity. Substitution of only the 6-acetyl with a 
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hydroxyl results in the parent molecule and a 500-fold loss of affinity as compared to 1,6 
FSK.  Acetylation of the parent at position 1 increases affinity tenfold, while removing a 
hydroxyl group at positions 1 and 9 restores affinity fifty and thirty-fold, respectively.  
Extensive, even bulky, substitution at the seven acetyl position is tolerated within the 
binding pocket.  Forskolin is planar compared to cytochalasin B, and its determinants of 
binding imply that the entire molecule is engulfed within GLUT1.  
COOPERATIVE EFFECTS OF LIGAND BINDING 
Erythrocyte inhibitor studies with GLUT1 support an oligomeric model.  Low 
concentrations of extracellular inhibitor, such as maltose, or intracellular inhibitors like 
cytochalasin B or forskolin modestly stimulate sugar transport (7).  The simplest 
explanation for this remains a homo-oligomer of GLUT1, most likely a tetramer or dimer 
of dimers, in which at any instant two subunits adopt an e1 conformation and two 
subunits adopt the e2 state.  When one inhibitor such as CB binds, a conformational 
change occurs resulting in increased activity in the opposite dimer (7, 16).  Increased 
concentrations of ligand result in occupancy of the second site and cessation of substrate 
transport.  The intermediate effects of ligand binding upon transport suggest 
communication between binding sites, supporting the oligomeric model. 
Although previous work examined inhibition of erythrocyte sugar uptake by 
cytochalasin B and forskolins (107, 121, 182, 188), this present study differs in its 
analysis of transport inhibition.  Because of our observed cooperative interactions, a 
Michaelis based kinetics analysis of inhibition is of less utility.  Unlike previous work, 
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we allow for two interacting binding sites and measure the cooperativity of these sites 
across multiple log units of inhibitor concentration.   
In competition experiments such as the ones made here, we find hetero- and 
homo- cooperative interactions in the nonlinear, non-Michaelis shapes of the [inhibitor] 
vs [CB bound]/[CB free] curves. We model these interactions mathematically as the 
cooperativity factors α ( homo- or CB.CB interactions), β (hetero- or CB.I interactions) 
and γ (homo- or I.I interactions). Values less than one represent positive cooperativity 
with apparent increases in second-site affinity for ligand.  If we consider a competition 
experiment between FSK and CB, CB displays positive homo cooperativity, with α<1.  
CB and FSK show hetero-cooperativity for one another, each with a β cooperativity 
factor of 0.44±0.05.  Functionally, this implies that the presence of a FSK in the first site 
increases the apparent affinity of the second site for CB, and vice versa. The γ value 
represents inhibitor cooperativity for itself; in this example, FSK is not significantly 
different than 1. This indicates that a given FSK binding event does not affect the affinity 
of the remaining binding site.  Each derivative displays unique values for β and  γ in 
competition with CB.  The lack of independent binding interactions for some ligands 
suggest that subunit surfaces are in direct contact to facilitate conformational change and 
hetero-cooperativity, or that the ligands themselves interact due to the proximity of their 
binding sites. 
EXTENDING AFFINITY/COOPERATIVITY DETERMINANTS 
GLUT1 is known to homooligomerize in vivo, in vitro and in culture; hetero 
oligomers of GLUTs or GLUT chimeras could display modified cooperative behavior.  
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GLUT1 normally does not oligomerize with GLUT3 (personal communication, Kara 
Levine, and (207)) or GLUT4 (65). Levine et al have created a series of GLUT1-GLUT3 
chimeras to test oligomeric association in the membrane, progressively replacing each 
GLUT1 transmembrane helix with the equivalent GLUT3 transmembrane helix.  Limited 
proteolysis with N-bromosuccinamide combined with 3H-CB photolabeling argues for 
CB association with TM’s 10 and 11.  Testing GLUT1-GLUT3 chimeras in combination 
with inhibitor modulation of cytochalasin B or forskolin binding assays may reveal 
‘GLUT1 cooperativity TMs’ and could localize the cytochalasin B or endofacial sugar 
binding site within the protein sequence.  
GLUT1 conformational changes induced by e1 ligand binding may also be 
investigated by thiol crosslinking combined with mass spectrometric analysis or 
immunofluorescence.  Blodgett et al. utilized mass spectrometric analysis of GLUT1 to 
determine that upon trypsinized GLUT1 interaction with 10 µM CB, full-length TM8 is 
released into the aqueous fraction of peptides (208). Cysteine scanning mutagenesis and 
thiol-reactive crosslinkers may illuminate the TM domains or loops required for e1 ligand 
binding. Using short sulfhydryl crosslinkers such as  bis-maleimidoethane between TM’s 
10 and 11 in a cys-less GLUT1 background, might mimic or prevent cytochalasin B 
displacement of TM8.  Since Mueckler et al have confirmed the aqueous access of TM8 
in Xenopus oocytes (80), surface immunofluorescence microscopy using endofacial loop 
8-9 antibody ± sulfhydryl crosslinking might determine if TM8 is displaced specifically 
to the exofacial side of the membrane.  A similar phenomenon is thought to occur in the 
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transport cycle of the anion transport protein AE1 (209). This analysis provides an 
opportunity to confirm tertiary conformational changes as a result of e1 site occupation. 
Mutational & Chimeric Localization of the e1 Site 
An integral membrane protein such as GLUT1 is refractory to crystallization, so 
the location of the endofacial sugar binding site within the primary sequence remains 
unknown.  Cytochalasin B reduces the Vmax for sugar entry and increases Km for sugar 
exit and is thus thought to act directly upon the e1 sugar binding site (102). HEK293 
expressed mutant GLUT1 combined with CB inhibition of 2-DG uptake provides a 
metric for GLUT1 mutant involvement in CB binding.  Three point mutants (R126A, 
C421A, and R400A) and two chimeras (GLUT141, GLUT151) were successfully 
expressed and analyzed via this technique to pinpoint the CB, and therefore endofacial 
glucose binding site. 
GLUT1 R126A expresses at the membrane, but R126 is thought to be exofacial 
and therefore not part of the e1 sugar binding site.  Arg 126 is the most common missense 
mutant locus in clinical cases of GLUT1DS, with R126L presenting the most severe 
phenotype (193).  Computer modeling has successfully docked CB to R126 in an 
exofacial vestibule (Ondrenchen, personal communication).  We find GLUT1 R126A 
moderately  increases in 2DG uptake over myc tagged GLUT1 (108.4 ± 6.5%), and 
significantly increases resistance to CB inhibition of 2DG uptake.  It is possible CB binds 
exofacially, fixing a GLUT1 subunit in the e1 orientation.  However, this would  
enhance, rather than competitively inhibit sugar binding at the endofacial site. Thus an 
exofacial cytochalasin B binding site and the endofacial sugar binding site must be 
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mutally exclusive. Alternately, R126 may function as part of a glucose (or CB) sensing 
area of the protein which does not directly participate in transport inhibition.  Since our 
assays measure inhibition and not binding, alteration of a second, lower affinity site not 
directly involved with the e1 sugar binding site would go undetected. 
Mutating GLUT1 at C421A removes one-half of the proposed intra subunit 
sulfhydryl stabilizing tetrameric association of GLUT1, and may disrupt cooperative 
action of CB on GLUT1. CB is known to bind to GLUT1 in a highly cooperative manner 
(202); the observed profile of CB inhibition of GLUT1 C421A might illuminate 
cooperative inhibition effects upon transport.  GLUT1 C421A has reduced transport 
capacity: it shows 66.3±3.5% of uninhibited myc tagged GLUT1 sugar transport. CB 
inhibition of 2 DG uptake for GLUT1 C421A was only statistically greater than myc 
tagged GLUT1 at 5000nM, showing less total uptake.  It is possible that CB binds each 
GLUT1 C421A dimer independently at lower affinity, due to lack of intra-subunit 
communications, but a direct effect of C421A upon CB binding or the e1 site is unlikely. 
A theoretical crystal structure suggests R400 as a likely participant in the e1 site.  
Salas-Burgos et al docked phloretin, cytochalasin B, and forskolin to a highly polar 
endofacial binding site in homology-modeled GLUT1 (5). The R400 site on threaded 
GLUT1 is the sole amino acid that interacts with all three inhibitors in the model 
structure.  The overall sugar transport capacity of GLUT1 R400A is 95.4 ± 11.8% of myc 
tagged GLUT1, has somewhat reduced protein expression levels, and both the 
uninhibited and the 50nM concentration of CB show significantly different values than 
myc tagged GLUT1 at the same site.  Mutation of R400A appears to alter ligand affinity, 
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supporting its role in the e1 site, but this point mutation alone does not prevent CB 
binding or concomitant inhibition of sugar uptake.   
A point mutation may be insufficient to abrogate CB binding to the e1 site, so we 
examined a larger section by swapping chimeric regions from homologous GLUTs to 
find residues that interacted with the e1 site.  Photolabeling by 3H-CB followed by N-
bromosuccinaminde digestion reveals the smallest CB interacting fragment is W388 to 
W412(13).  This GLUT1 sequence was exchanged with sequences from GLUT4 and 
GLUT5, both known to have altered e1 inhibitor affinities. 
Ironically, GLUT4 differs from GLUT1 in the 388-412 region by only one amino 
acid, I404M.  The rationale for GLUT4 selection was that Mueckler et al found GLUT4 
sugar efflux was inhibited by indinavir, a drug used in Highly Active Antiretroviral 
Therapy (HAART) Human Immunodeficiency 1 (HIV-1) antiretroviral cocktails (210).  
Indinavir acutely and reversibly inhibits GLUT4 with high affinity (26 µM), but does not 
inhibit GLUT1 uptake of substrate even at 1mM.  Furthermore, addition of increasing 
concentrations of CB to GLUT4 uptake of 2-DG in oocytes showed competitive 
inhibition vs indinavir at the e1 site(203).  GLUT1 I404M was constructed as a 
GLUT1/GLUT4388-412/GLUT1  chimera and tested for 2DOG uptake and CB sensitivity. 
GLUT1/GLUT4388-412/GLUT1showed uptake 96.3±2.1% of myc tagged GLUT1, and its 
2 DG uptake was statistically less sensitive to CB inhibition at all concentrations tested. 
Similar to GLUT1 R400A, the GLUT1/GLUT4388-412/GLUT1mutation is insufficient to 
eliminate CB binding, though its alteration of affinity supports its involvement in the e1 
binding site.  Furthermore, WT GLUT1 and GLUT1/GLUT4388-412/GLUT1 2-DG uptake 
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Figure 5.1  Mutant GLUT1 sensitivity to Indinavir inhibition, assayed by 6 minute, 2-DG 
uptake. 
Ordinate: Rate of 2 DG uptake expressed as a percentage of the GLUT1-Myc 
protein uptake rate.  Abscissa lists uptake by vector, with GLUT1/GLUT4W388-
W412/GLUT1 represented as I404M Myc.   Uptake experiments were performed as 
follows: cells were seeded at 106/well, transfected in quadruplicate after 24 hours, and 
assayed 48 hours after transfection.  Cells were starved of glucose and serum for 2 hours, 
rinsed, incubated for 30 minutes ± indinavir, incubated for 6 minutes with 100µM 3H 
supplemented 2-DG at 37ºC, rinsed twice with 1 mL ice cold stop solution, coated with 
500µL 0.5% Triton, and incubated for 30 min at 37ºC to facilitate lysis.  Zero time points 
had stop solution added before radiolabel.  Lysed cells were centrifuged, placed in 200µL 
duplicate aliquots in scintillation vials and counted, with 10µL aliquots tested for total 
protein well content. Total uptake was normalized to each day’s mean c-myc tagged 
GLUT1 uptake. Each point represents a mean of three experiments, n=4. 
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assays were performed to ascertain if I404M confers indinavir sensitivity upon GLUT1, 
but indinavir remained without significant effect on substrate uptake. (Fig 5.1)  
GLUT5 was chosen for chimeric e1 binding site analysis because cytochalasin B 
is largely without effect upon substrate transport by Group 2 sugar porters (2, 197, 211).  
GLUT5 shares approximately 58% sequence similarity at region W388-W412 with 
GLUT1, with the notable substitution of alanine for tryptophan at position 388.  A 
GLUT1/GLUT5388-412/GLUT1 chimera was constructed for this region and assayed for 
CB sensitivity.  The uninhibited transport capability of the GLUT1/GLUT5388-412/GLUT1 
construct is very similar to GLUT1 Myc at 94.4 ± 2.5%.  However, all concentrations of 
CB were significantly less effective at inhibiting 2 DG uptake, with 50 nM CB actually 
stimulating 2 DG uptake.  A more extensive dose response was made for GLUT1NT, 
Myc-GLUT1, GLUT1/GLUT5388-412/GLUT1, GLUT5, and untransfected HEK cells.  By 
traditional Michaelis-Menton analysis, the IC50 for CB inhibition of GLUT1/GLUT5388-
412/GLUT1 uptake was not statistically significant from that of the dose response 
pertaining to the WT or myc-GLUT constructs.  However, utilizing a multisite analysis 
derived from the work in Chapter 3, nM first-site KIapp constants were obtained for the 
stimulation of uptake by both GLUT1/GLUT5388-412/GLUT1 (10 ± 39 nM) and WT 
GLUT1 (83 ± 118 nM).  We conclude the chimera has increased first-site affinity for CB, 
the potential for negative second-site cooperativity, and overall decreased inhibition of 2 
DG transport by CB.     
This suggests four possibilities: 1) while CB photo-crosslinks to the W388 and 
W412 amino acids, the photoreactive moieties of CB are not involved in transport 
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inhibition, 2) the W388-W412 region is not necessary for affinity of CB binding but is 
required for CB inhibition of uptake, 3) it is possible the W388-W412 sequence 
comprises a cooperativity sensor area, resulting in altered subunit communication, or 4) 
the W388-W412 region of GLUT1 is not the major determinant of ligand binding at the 
e1 sugar binding site. 
Further GLUT1-GLUT5 chimeras should be constructed to test these hypotheses. 
Nonconserved areas of interest include region 334-351 on GLUT1, near the endofacial 
loop between TMs 7 and 8, and 121-138 on TM 4, thought to line the vestibule of the e1 
cavity (81).  Also, the Salas-Burgos model indicates that CB interacts with the sugar 
porter motif RFGRR at residues 88-93.  An equivalent GLUT5 substitution is unlikely to 
show altered affinity for CB because that sequence (KFGRK) has a similar charge.  
Another docking site (Q250, M251) might produce a stronger effect upon exchanging 
residues 248-259 of GLUT1 for 254-265 of GLUT5, because the GLUT1 and GLUT5 
sequence in this region is dissimilar in arrangement of polar charges. 
A COOPERATIVITY REGION IN GLUT1 
The existing GLUT1/GLUT5388-412/GLUT1 chimera may possess altered 
cooperativity and subunit communication patterns.  We know that CB is a highly 
cooperative inhibitor of GLUT1, it is possible that changes resulting from the chimeric 
substitution would be masked by this ligand.  To test the hypothesis that the 
GLUT1/GLUT5388-412/GLUT1 amino acid region is involved in ligand binding 
cooperativity, inhibition of 2 DG transport by a noncooperative e1 ligand such as 
forskolin should be attempted.  If the forskolin mediated inhibition pattern of the chimera 
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matches that of untagged GLUT1, the W388-W412 region is not explicitly involved in 
subunit-subunit communication.   
HELIX MAPPING OF THE CB BINDING SITE  
Dezutter et al have constructed a series of factor Xa protease site mutants in the 
exofacial loops between TM’s 7&8, 9&10, and 11&12 (in progress). A combined 
approach of photolabeling GLUT1 with CB or IAPS-FSK (both thought to bind between 
W388-W412) followed by factor Xa proteolysis and analysis by gel electrophoresis 
should confirm which TM helixes interact with CB. 
  
Final Conclusion 
This thesis has strengthened the GLUT1 structure-function relationship by 
analyzing the effect that the model system has upon protein function, by utilizing ligand 
binding to deduce multisite interactions, and by investigating the effects of directed 
mutagenesis on binding of a classic GLUT1 e1 inhibitor. The main discoveries include: 
1) A ubiquitous polypeptide of identical sequence has markedly different functional 
characteristics when expressed in erythrocytes, yeast, Xenopus oocytes, and mammalian 
tissue culture cells.  2) For some ligands, especially cytochalasin B, inhibition of the 
GLUT1 tetramer is a cooperative phenomenon involving subunit communication.  3) We 
have shown that non conserved regions of W388-W412 region of GLUT1 are not the 
primary determinats of CB binding affinity.  
We discussed future directions for investigative  anlaysis of GLUT1 and how we 
may further extend and enhance our understanding of how glucose carrier structure and 
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function are related.  Integral membrane proteins like GLUT1 comprise one-fifth of the 
proteins coded for in the human genome, each one fulfilling a vital cellular role in 
regulating cell and tissue mircroenvironment and nutrient homeostasis.  Erroneous 
expression of these proteins results in perturbed metabolic syndromes that possess many 
ramifications for cell-cell interactions, organ and tissue integrity, as well as overall 
viability of the organism.  Diseases such as GLUT1DS or diabetes mellitus illustrate well 
how integral membrane protein systems establish and sustain tissue homeostasis.   
Comprehensive understanding of the interrelationship between structure and function 
may prove the first step in providing treatments for these chronic metabolic disease 
states.  This thesis offers new methods and perspectives broadly useful when designing 
future structure-function studies. 
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